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Introduction and goals 
Data provided by the World Health Organization shows that the life expectancy is still increasing 
worldwide. For example, the life expectancy of a female at age 60 in Europe, has increased from 81.6 
years in 2000 to 84.1 years in 2016. Also the healthy life expectancy (HALE) shows a steady increase 
worldwide over the past decade. Different studies support the hypothesis that biomedical research and 
innovation is responsible for a substantial portion of recent gains in health and life expectancy. 
Innovation in pharmaceuticals not only has an effect on longevity but also on the quality of life, for 
example the ability of people to engage in daily activities.
1
  
Despite the fact that many pharmaceuticals have been developed already to treat a broad spectrum of 
medical conditions, the long list of currently incurable diseases (e.g. Alzheimer’s disease, HIV, multiple 
sclerosis, Parkinson’s disease, certain types of cancer,…) and the development of resistance by 
pathogens against existing medicines illustrate the need for new medicines. However, the 
pharmaceutical industry is challenged by increasing costs of research and development and a 
simultaneous stagnating number of new molecular entities (NMEs).
2
 Data supplied by the US Food 
and Drug Administration (FDA) show that approximately between 20 and 40 NMEs were approved by 
the FDA each year during the past decade. Approximately 70% of those NMEs were small molecules, 
while the other 30% were biologics, and this value remained relatively constant. The stagnating 
number of NMEs is not caused by the biology as many new drug targets became available the last 
decade, for example by decoding of the human genome.
3
 Medicinal chemistry proved to be the 
bottleneck in the search for new drugs.
4,5
 Indeed, the challenge is to find drug-like molecules which not 
only interact with the most druggable targets, but also possess excellent pharmacokinetic and low 
toxicological properties.  
A new drug discovery project which aims to find biologically active compounds can follow different 
approaches. For example, hits can be obtained by in silico screening methods. Very often however, 
drug discovery projects use high-throughput screening (HTS) of large commercially available 
compound libraries against the drug target. Although the combinatorial chemistry technique has 
contributed enormous amounts of new substances to these compound libraries, the number of 
identified hits did not increase proportionally.
6
 This phenomenon was mainly attributed to the poor 
drug-like properties of the compound libraries and the poor chemical diversity.
4,5
 A structural diversity 
analysis of 24 million organic compounds revealed that a small percentage of frameworks occurred in 
a large percentage of compounds and that half of the compounds could be described by only 143 
framework shapes.
7
 Similarly, an analysis of approximately 5000 drugs showed that only 32 
frameworks described the shapes of 50% of the compounds.
8
 Minimization of synthesis costs is one 
explanation for the poor diversity of compound libraries. Decorating an existing scaffold by replacing 
peripheral functional groups is much less complicated than manipulating the molecular framework.  
In order to address the problem of poor chemical diversity, pharmaceutical researchers have been 
shifting their hit finding strategy from HTS to fragment-based drug discovery (FBDD).
9,10
 One of the 
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advantages of FBDD is that even a small collection of fragments (a few thousands) covers a much 
larger proportion of all the possible compounds that could exist, termed ‘chemical space’, than large 
compound libraries (millions) for HTS. For example, the estimated number of potential fragments with 
up to twelve non-hydrogen atoms (fragment-like chemical space) is 10
7
, while for potential drug-like 
molecules with up to thirty non-hydrogen atoms, this number exceeds 10
60 
(drug-like chemical 
space).
11
 Therefore, screening a proportion of the fragment-like chemical space in FBDD is much 
more feasible than screening a proportion of the drug-like chemical space in HTS.  
Medicinal chemists have also been using compound libraries consisting of molecules based on 
privileged structures to increase hit rates in screening assays. Privileged structures are a class of 
molecules which can bind to multiple, unrelated targets with high affinity, thus providing the medicinal 
chemist with the possibility to discover biologically active compounds across a broad range of 
therapeutic areas by screening a compound library based upon one core scaffold.
12,13
 These 
structures are typically rigid, heterocyclic multiring molecules which can hold their substituent patterns 
in a well-defined three-dimensional space, which allows for high-affinity binding interactions between  
the target and either or both of the scaffold and the substituents. Well-known examples of privileged 
scaffolds are the heterobicyclic indoles, coumarines, quinolines and benzimidazoles and the 
monocyclic isoxazolidines.
14–16
 
The goal of this research is the design and synthesis of compound libraries, based on novel or highly 
underexplored scaffolds, thereby covering largely unexplored chemical space. These scaffolds should 
at the same time also possess adequate physicochemical properties. Thus, the most important issues 
are novelty and drug-likeness of the scaffolds. This approach will provide new molecules which will be 
useful for (fragment-based) screening across a broad range of therapeutic targets. 
The scaffolds were selected from the class of heterobicyclic compounds, since these are known to act 
as privileged structures. Also, the molecular weight of these scaffolds is low enough to provide the 
possibility to improve the selectivity and affinity of hit compounds by decoration of the scaffold with 
suitable substituents (which will increase the molecular weight) without losing their drug-like character. 
The concept of drug-likeness was introduced by Lipinski after an analysis of small-molecule drugs 
showed that orally administered drugs are very frequently residing in areas of chemical space which 
are defined by a limited range of molecular properties.
17
 Several descriptors and rules-of-thumb have 
been introduced to address the drug-likeness of a compound. A well-known example is Lipinski’s Rule 
of Five, which states that historically, 90% of orally absorbed drugs had no more than five hydrogen-
bond donors, no more than ten hydrogen-bond acceptors, molecular masses of less than 500 Da and 
log P values not greater than five.
18,19
 Besides oral absorption, discrimination between drugs and non-
drugs can also be based on other characteristics such as aqueous solubility and permeability, which 
can both be assessed by a range of molecular properties and descriptors.
8,20–22
 Examples of such 
molecular properties are the molecular weight, the calculated log P (CLogP), the polar surface area 
(PSA), the number of rotatable bonds and the number of hydrogen bonding groups.
23
 For the 
construction of fragment libraries, the Rule of Three can be a useful guideline, which states that both 
the number of hydrogen-bond donors and the number of hydrogen-bond acceptors should not be 
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higher than three, the molecular weight should be lower than 300 Da and the fragment-based 
predicted log P (cLogP) should not be higher than three.
24
 These guidelines will be followed whenever 
it is appropriate.  
A literature search was performed on a broad range of heterobicyclic scaffolds. Those scaffolds 
without any hits in SciFinder were not withheld, as they were considered to be synthetically intractable, 
or at least very hard to make. Only structures which have already been reported to a very limited 
extent were considered as underexplored, yet synthetically feasible scaffolds. Twenty-four scaffolds 
were selected, of which two will be covered in this PhD thesis: the furo[3,4-d]pyrimidine scaffold 1 and 
the oxazolo[4,5-d]pyrimidine scaffold 2 (Figure 1). Both scaffolds are composed of a pyrimidine ring 
fused to a 5-membered heteroaromatic ring and are related to pyrrolopyrimidine, which is a well-
known privileged scaffold.
25
 Examples of marketed drugs that contain the pyrrolopyrimidine scaffold 
are Forodesine 4 for the treatment of relapsed/refractory peripheral T-cell lymphoma and Pemetrexed 
5 for the treatment of pleural mesothelioma and non-small cell lung cancer (Figure 2). A 
straightforward synthetic route towards these scaffolds needs to be developed which allows for 
decoration of the structure with a variety of substituents, so that a library of drug-like compounds can 
be designed and synthesized.  
 
Figure 1. The furo[3,4-d]pyrimidine (1) and oxazolo[4,5-d]pyrimidine (2) scaffolds which are covered in this PhD thesis, and the 
other bicyclic scaffolds 3a-v which were selected for the medicinal project 
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Figure 2. Marketed drugs containing the pyrrolopyrimidine privileged scaffold 
Furthermore, modern medicinal chemistry is slowly abandoning the area of ‘flat’ aromatic molecules as 
an approach to improving clinical success. Lovering and coworkers demonstrated that the saturation 
of compounds correlates to their aqueous solubility, which is an important physicochemical parameter 
when it comes to success in drug discovery.
26
 Therefore, the underexplored analogues furo[3,4-
d]pyrimidine-2,4-dione 6, oxazolo[4,5-d]pyrimidine-5,7-dione 7, 5,7-dihydrofuro[3,4-d]pyrimidine-2,4-
dione 8 and tetrahydrofuro[3,4-d]pyrimidine-2,4-dione 9, characterized by a varying degree of non-
flatness, are also considered to be interesting scaffolds for medicinal chemistry (Figure 3). In addition, 
the oxazolo[5,4-d]pyrimidine-5,7-dione scaffold 10 (bearing a hydrogen atom on C-2) is virtually 
unexplored as well.  
 
Figure 3. Unexplored/underexplored analogues of the intended furo[3,4-d]pyrimidine and oxazolo[4,5-d]pyrimidine scaffold with 
a varying degree of non-flatness 
All of the molecules which are depicted in Figure 3 can be considered as analogues of uracil and 
thymine. Nucleoside analogues are a very important class of antiviral compounds, and examples of 
antiviral uridine/thymidine analogues are Idoxuridine 11, Trifluridine 12 and Zidovudine 13 (Figure 4). 
The scaffolds 6-10 will be used to synthesize a small library of nucleoside analogues, which can be 
submitted to a broad antiviral screening.  
 
Figure 4. Antiviral uridine/thymidine analogues Idoxuridine, Trifluridine and Zidovudine 
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Literature overview 
In this literature study, the synthesis of furo- and 5,7-dihydrofuro[3,4-d]pyrimidines, oxazolo[4,5-
d]pyrimidines and oxazolo[5,4-d]pyrimidines will be reviewed. Focus will lay on the construction of the 
scaffold, rather than on further modification. Nevertheless, selected examples will illustrate some of 
the most common modifications of these scaffolds. The synthetic part is complemented by an 
overview of the biological activity of these structures. The synthesis of these bioactive compounds will 
not be described in detail, but the applied synthetic methodology for the construction of the scaffold is 
always included in the overview of synthetic methodologies. This review covers literature and patents 
from 1967 until 2018. The chapters on oxazolopyrimidines have been published in the European 
Journal of Organic Chemistry.
27
 
1 Synthesis and biological activity of furo[3,4-d]pyrimidines 
1.1 Synthesis of furo[3,4-d]pyrimidines 
Furo[3,4-d]pyrimidines have been described only very scarcely in the literature. Four synthetic 
pathways have been exploited, all starting from a 3,4-difunctionalized furan ring. The scaffold was then 
constructed by pyrimidine annulation. A generic overview is given in Scheme 1. 
 
Scheme 1. Furo[3,4-d]pyrimidines by annulation of pyrimidine rings 
Babu and coworkers reported on the synthesis of nucleoside analogue 25 (Scheme 2). Only the last 
part of the synthetic pathway is described here, starting from the highly functionalized furan carboxylic 
acid 20. This carboxylic acid was transformed into the corresponding amide by a carbodiimide-
mediated coupling reaction. Then, the ester was hydrolyzed and the resulting carboxylic acid was 
6 
 
converted to a Boc-protected amine through a Curtius rearrangement. Deprotection of the amine and 
condensation with triethyl orthoformate afforded the furo[3,4-d]pyrimidinone 23. Chlorination with 
phosphorus oxychloride, subsequent substitution with ammonia and deprotection of the ribose moiety 
afforded the desired nucleoside analogue 25. Yields and detailed reaction conditions were not 
mentioned in the originating patent.
28
  
 
Scheme 2. The synthesis of nucleoside analogue 25 
Jones developed a two-step pathway towards furo[3,4-d]pyrimidine-2,4-dione 6 starting from diethyl 
ester 26 (Scheme 3). Aminolysis of the ester delivered the diamide 16 in excellent yield. In contrast, 
the subsequent Hofmann rearrangement gave the furopyrimidinone 6 only in a very low yield.
29
 
 
Scheme 3. The synthesis of furo[3,4-d]pyrimidine-2,4-dione 
A similar method, starting from the dimethyl ester, was developed by Zhan and Yao. In this case, the 
dimethyl ester was only partially aminolyzed into the mono-amide, which was then transformed into 
amine 29 via a Hofmann rearrangement in good yield (Scheme 4). Hydrolysis of the ester and 
subsequent condensation with urea delivered the desired scaffold 6.
30
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Scheme 4. The synthesis of furo[3,4-d]pyrimidine-2,4-dione 
A third pathway starting from the dialkyl ester was described by Press and coworkers (Scheme 5). 
After mono-saponification of the diethyl ester 30 with sodium hydroxide, mono-ester 31 was treated 
with hydrazine to give hydrazide 32 in excellent yield. This hydrazide was converted into the 
corresponding acyl azide upon treatment with aqueous nitrous acid. This compound appeared to be 
stable but was nevertheless converted immediately into isatoic anhydride derivative 34 by heating in 
chloroform. This anhydride is crystalline and can be stored for a long time without any special 
precautions. Ring opening with various amines, followed by ring closure with CDI, yielded a library of 
furo[3,4-d]pyrimidinones 19.
31,32
 
 
Scheme 5. Synthesis of N-3 functionalized furo[3,4-d]pyrimidine-2,4-diones 19 
Butini et al. followed the same strategy to synthesize furopyrimidinones 40 (Scheme 6). Interestingly, 
they observed that the ureid 36, which was formed after ring opening of the isatoic anhydride 
derivative 35 with an amine, was in equilibrium with its enol tautomer 37. By performing the 
subsequent ring closure in either THF or dioxane as a solvent, two different isomers 38 and 41 were 
obtained. Alkylation of 38 at N-1, followed by deprotection, eventually resulted in compounds 40.
33
 
8 
 
 
Scheme 6. Synthesis of N-1/N-3 functionalized furo[3,4-d]pyrimidine-2,4-diones 40 
1.2 Biological activity 
Nucleoside analogue 25 (Figure 5, Scheme 2) was reported in a patent on new antiviral compounds, 
more specifically against Flaviviridae. One of the members of this family of viruses is the hepatitis C 
virus. A hepatitis C virus nonstructural protein 5B (HCV NS5B) polymerase assay was described, but 
no test results were included. Therefore, it is not known if compound 25 possesses antiviral activity.
28
 
Compound 42a (Figure 5, Scheme 5) possesses antihypertensive activity in rats and is a potent α1-
adrenergic antagonist with a Ki value of 5.8 nM. One of the important functions of α1-adrenergic 
receptors is mediation of smooth muscle contraction. Remarkably, 42a is ninefold less potent than its 
corresponding thieno[3,4-d]pyrimidine-2,4-dione analogue 42b (Ki = 0.64 nM).
32
 
Furopyrimidinone 43 (Figure 5, Scheme 6) is an analogue of (S)-Willardiine 44, a heterocyclic amino 
acid which is found in the seeds of several species of Acacia and Mimosa and which is a potent α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor agonist. The AMPA, N-methyl-
D-aspartate (NMDA) and kainic acid (KA) receptors are three types of ionotropic glutamate receptors. 
These receptors play a key role in synaptic transmission in the CNS, and selective agonists could help 
in the understanding of their role in learning and memory formation and possible associations with 
neurological disorders such as Alzheimer’s, Parkinson’s and Huntington’s diseases. Compound 43 
was tested in vitro but possesses only very weak binding affinity for the AMPA and KA glutamate 
receptors.
33
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Figure 5. Biologically active furo[3,4-d]pyrimidine derivatives 
2 Synthesis and biological activity of 5,7-dihydrofuro[3,4-
d]pyrimidines 
2.1 Synthesis of 5,7-dihydrofuro[3,4-d]pyrimidines 
Dihydrofuro[3,4-d]pyrimidines have been synthesized and described in large numbers (>100 
references). Therefore, the scope in the present overview was limited to those structures without 
substituents or functionalizations on the dihydrofuran ring. All of the reported syntheses of this scaffold 
started from alkyl 4-oxotetrahydrofuran-3-carboxylate 45 (Scheme 7). The pyrimidine annulation was 
then effectuated by reaction with an appropriate ureid or amidine compound.  
 
Scheme 7. Synthesis of 5,7-dihydrofuro[3,4-d]pyrimidines by annulation of pyrimidine rings 
2.1.1 Scaffold construction by reaction of a ketoester with urea 
Reacting ethyl 2-hydroxyacetate 50 with ethyl acrylate in the presence of sodium hydride delivered 
ethyl 4-oxotetrahydrofuran-3-carboxylate 51 in low yield (Scheme 8). Condensation with urea in a 
mixture of concentrated aqueous hydrochloric acid and methanol under reflux conditions resulted in 
dihydrofuropyrimidinone 8. Chlorination with phosphorus oxychloride afforded chloropyrimidine 52. 
This compound was selectively functionalized at the 4-position by reaction with benzylamine and at 
the 2-position by reaction with 2-methyl-1H-indole under Buchwald-Hartwig conditions to afford 
compound 54.
34,35
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Scheme 8. Synthesis of 5,7-dihydrofuro[3,4-d]pyrimidine-2,4-dione and further decoration of the scaffold 
Disubstituted dihydropyrimidines 56 were synthesized from the same chloropyrimidine 52 again by 
using the difference in reactivity of the chlorines at the 2- and 4-position (Scheme 9). Both positions 
were substituted with anilines. This time, substitution at the 2-position was achieved by acid instead of 
palladium catalysis (vide supra).
36
 In a similar fashion, compounds 58 were synthesized. The chlorine 
at position 4 of 52 was substituted again with an appropriate aniline, and the 2-chlorine was then 
functionalized by a Suzuki coupling to obtain the 2,4-disubstituted structures 58 in very low yields.
37
  
 
Scheme 9. Decoration of the 2,4-dichlorofuro[3,4-d]pyrimidine scaffold via two different pathways 
Furthermore, 2,4-dichloropyrimidine 52 was converted quantitatively to the 2-chloropyrimidin-4-one 60 
by treatment with sodium hydroxide (Scheme 10). Reaction of this chloropyrimidinone with an 
appropriate pyrazole afforded 61 in low yield. The methylpyrazole-functionalized compounds 66 were 
constructed differently. First, the chlorine was substituted with hydrazine. Next, the methylpyrazole ring 
was constructed by reaction of the hydrazine substituent with enamine 63. After saponification of the 
ester and subsequent amide coupling, products 66 were obtained.
38
  
11 
 
 
Scheme 10. Decoration of the 2,4-dichlorofuro[3,4-d]pyrimidine scaffold towards the structures 66 
2.1.2 Scaffold construction by reaction of a ketoester with an amidine 
The dihydrofuropyrimidine scaffold has also been constructed directly by reaction of ketoester 51 with 
a variety of amidines. Different bases were employed for the condensation reaction, and different 
chlorinating reagents were used for the subsequent derivatization.  
Reaction of ester 67 with ammonium chloride and trimethylaluminium afforded amidine 68 in good 
yield (Scheme 11). This amidine was then condensed with the ketoester and DBU as a base to give 
the 4-hydroxydihydrofuropyrimidine 69. Chlorination was performed with phenylphosphonous 
dichloride, and the chloropyrimidine then underwent Buchwald-Hartwig coupling with various 4-
aminopyridines to give compounds 71.
39
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Scheme 11. Construction of the 5,7-dihydrofuro[3,4-d]pyrimidine scaffold and further modification towards the structures 71 
The same approach was used to construct dihydrofuropyrimidines 77 (Scheme 12). Here, sodium 
methoxide was used as a base in the coupling of the amidine (72) and ketoester (73) fragments. 
Chlorination of the resulting dihydrofuropyrimidinone 74 took place in refluxing phosphorus oxychloride 
but only proceeded in low yield. Substitution of the 4-position with morpholine and subsequent addition 
of hydrochloric acid afforded the hydrochloric acid salt 77 in acceptable yield.
40
  
 
Scheme 12. Construction of the 5,7-dihydrofuro[3,4-d]pyrimidine scaffold and further decoration 
When S-methylisothiourea was used as the amidine source, a thiomethyl substituent was obtained at 
the 2-position of the dihydrofuropyrimidine scaffold 48 (Scheme 13). This proved to be a versatile 
substituent, as it can be oxidized towards the sulfone, removed by Raney nickel-catalyzed 
hydrogenolysis or it can be retained as such. For the sulfone-containing chloropyrimidine 81, both the 
chlorine and the sulfone group were replaced by various nucleophiles affording disubstituted 
dihydrofuropyrimidines 83.
41
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Scheme 13. Different methods for the decoration of the 5,7-dihydrofuro[3,4-d]pyrimidine scaffold 
2.2 Biological activity 
Compound 54 (Figure 6, Scheme 8) is an in vitro inhibitor of protein p97 (an ATPase of the AAA 
family) with an IC50 value below 300 nM. The p97 protein is involved in a broad array of cellular 
processes including the fusion of homotypic membranes, protein degradation and activation of 
membrane-bound transcription factors. Since its function is essential for continued cellular viability, 
inhibitors of p97 have an antiproliferative effect.
42
 The possible antiproliferative activity of 54 was not 
tested in the cited study.
34
  
Compound 56a (Figure 6, Scheme 9) is an in vitro inhibitor of bromodomain 4 (BRD4) kinase with an 
IC50 value of 0.22 µM. BRD kinases are essential for the recognition of acetylated lysine residues of 
histones during transcriptional activation. Therefore, BRD4 kinase inhibitors could be useful as 
anticancer agents.
36
 Compound 84 (Figure 6, Scheme 9) is an in vitro glucose uptake inhibitor and 
inhibits glycolysis in HT1080 fibrosarcoma cells and P. falciparum-infected RBCs with IC50 values 
between 10 and 100 nM.
37
 
Compound 61 (Figure 6, Scheme 10) was shown to be a very potent in vitro inhibitor of sepiapterin 
reductase (SPR), with an IC50 value of 6 nM. SPR is a crucial enzyme in the de novo biosynthesis of 
tetrahydrobiopterin (BH4), an enzyme cofactor for various aromatic amino acid hydroxylases, nitric 
oxide synthases and alkylglycerol monooxygenase. SPR inhibitors could be used in the treatment of 
acute and chronic pain or for anti-inflammation and immune cell regulation purposes.
38
 
Compound 85 (Figure 6, Scheme 11) was found to be a very potent in vitro BUB1 kinase inhibitor with 
an IC50 value of 7 nM. BUB1 kinase is a mitotic checkpoint protein and complete inhibition of this 
checkpoint could result in induction of apoptosis. 85 showed antiproliferative activity against HeLa 
tumor cells with an IC50 value of 1.5 µM.
39
 
Compound 77 (Figure 6, Scheme 12) is an in vitro G protein-coupled receptor 119 (GPR119) agonist 
with an EC50 value of 4.1 µM. GPR119 has been reported to play a role in regulating glucose-
14 
 
dependent insulin secretion (GDIS) from pancreatic β-cells. Therefore, GPR119 agonists have 
potential for the treatment of type 2 diabetes. Interestingly, the corresponding dihydrothieno[3,4-
d]pyrimidine structure of 77 performed better as it had an EC50 value of 150 nM in the same assay.
40
  
 
Figure 6. Biologically active 5,7-dihydrofuro[3,4-d]pyrimidine derivatives 
Compound 86 (Figure 7, Scheme 13) acts as an in vitro caspase cascade activator with respective 
EC50 values of 61 nM in the human breast cancer cell line T-47D, 5.5 µM in human colon carcinoma 
cell line HCT116 and 4.7 µM in the human hepatocellular carcinoma cell line SNU398. The compound 
also inhibits cell proliferation for these cell lines in vitro. Caspases are a family of protease enzymes 
that play essential roles in programmed cell death and inflammation.
41
  
Additional activity data is also presented for a number of structures which were synthesized using the 
methodologies described in the preceding paragraphs. Compound 87 (Figure 7) is a selective inhibitor 
of Rho-associated protein kinase (ROCK2) with an IC50 value of 10 nM and could be used in the 
treatment of graft versus host disease (GVHD).
43,44
 Product 88 (Figure 7) is an inhibitor of the human 
phosphodiesterase hPDE4B. PDE4 inhibitors are expected to be promising anti-inflammatory agents 
for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory 
diseases. Compound 88 had only a low activity of 2.2 µM compared to its respective 
dihydrothieno[3,4-d]pyrimidine analogue.
45
 This exemplifies again that the substitution of oxygen by 
sulfur can have a dramatic effect on the biological activity for this scaffold. 
Compounds 89a-d (Figure 7) were tested against 14 different phytopathogenic fungi. For 9 strains, 
one or more of the structures possessed significant antifungal activity. The potency rank order 
depended on the fungal strain, but in general compound 89c performed best with significant activity 
15 
 
against 7 strains.
46
 Compounds 90 are in vitro inhibitors of mTOR kinase with Ki values between 6-10 
nM. They also inhibit cell proliferation of PC3 human prostate cancer cells in vitro with EC50 values 
between 28-331 nM.
47
 Compounds 91a-b are inhibitors of transforming growth factor-beta (TGF-β) 
with IC50 values of 3.1 and 2.25 µM, respectively. TGF-β modulates cell growth and differentiation, 
embryonic and bone development, extracellular matrix formation, hematopoiesis, immune and 
inflammatory responses. Therefore, TGF-β inhibitors could be useful in treating conditions such as 
fibrotic, pulmonary and oncologic disorders.
48
  
 
 
Figure 7. Biologically active 5,7-dihydrofuro[3,4-d]pyrimidine derivatives 
3 Synthesis and biological activity of oxazolo[4,5-d]pyrimidines 
Oxazolo[4,5-d]pyrimidines have been investigated to a limited extent only. One reason is the lack of a 
versatile building block such as 5,7-dichlorooxazolo[4,5-d]pyrimidine. Scaffold construction is generally 
achieved by oxazole ring annulation on a functionalized pyrimidine or by pyrimidine ring annulation on 
a functionalized oxazole. 
3.1 Synthesis of oxazolo[4,5-d]pyrimidines 
3.1.1 Scaffold construction starting from a functionalized pyrimidine 
Oxazolo[4,5-d]pyrimidines can be synthesized starting from a 4-amino-5-hydroxypyrimidine by 
annulation of an oxazole ring (Scheme 14). The carbon source for the C(2) of the scaffold can be an 
ester, orthoester, thioimidate, carboxylic acid or formamide.  
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Scheme 14. Oxazolo[4,5-d]pyrimidines by annulation of oxazole rings 
Kato et al. were the first to report the synthesis of oxazolo[4,5-d]pyrimidines. They discovered that the 
reaction of 2,4-diamino-5-hydroxy-6-methylpyrimidine 98 with phenyl esters delivered hemi-aminals 
99, which were isolated as stable compounds at room temperature in moderate yields (Scheme 15). 
When these hemi-aminals were heated to 110-140 °C, ring closure to the oxazolopyrimidines 101 was 
observed, but also ring opening to the ester and the amide. To reduce these side reactions, the hemi-
aminals were first methylated with iodomethane and then heated. The desired oxazolo[4,5-
d]pyrimidines 101 were still only obtained in low yields.
49,50
  
 
Scheme 15. Reaction of 2,4-diamino-5-hydroxy-6-methylpyrimidine with phenyl esters 
A more direct approach was developed by Doise and coworkers. They obtained the desired scaffold in 
one step by condensing aminopyrimidinol 94 with excess orthoester and a catalytic amount of para-
toluenesulfonic acid at high temperature (Scheme 16).
51
 In later work, a thiobenzyl imidate proved a 
suitable alternative to an orthoester. This lead to an open intermediate 102, which was ring closed by 
heating at 250 °C for two minutes (Scheme 16). No yields were reported for the latter approach.
52
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Scheme 16. Condensation of an aminopyrimidinol with excess orthoester or a thiobenzyl imidate 
Besides thioimidates and orthoesters, a carboxylic acid can also be used as a source of the C(2) 
carbon atom of the oxazolopyrimidine scaffold. When 4-aminopyrimidin-5-ol 94 was reacted with 3-
hydroxybenzoic acid under harsh reaction conditions, oxazolopyrimidine scaffold 104 was obtained in 
low yield (Scheme 17). Further reaction of the phenolic hydroxyl group with n-propylisocyanate 
afforded carbamate 105.
53
  
 
Scheme 17. Condensation of an aminopyrimidinol with a carboxylic acid 
Formamide can also be used as the source of the C(2) carbon atom. Starting from 5-hydroxyuridine 
106, a diazocoupling reaction gave diazobenzene derivative 107 in very good yield (Scheme 18). 
Raney nickel-catalyzed hydrogenolysis followed by ring closure with formamide and polyphosphate 
ester as dehydrating agent finally delivered the nucleoside analogue 109 in low yield.
54
  
 
Scheme 18. Condensation of an aminopyrimidinol with formamide 
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3.1.2 Scaffold construction starting from a functionalized oxazole 
Oxazolo[4,5-d]pyrimidines have also been synthesized starting from a functionalized oxazole by 
annulation of a pyrimidine ring (Scheme 19). 
 
Scheme 19. Oxazolo[4,5-d]pyrimidines by annulation of a pyrimidine ring 
Reaction of 1,3-oxazol-5(4H)-one 114 with various amidines gave imidazolones 115 in good yields 
(Scheme 20). These intermediates were converted to the oxazolo[4,5-d]pyrimidin-7(6H)-ones 116 by 
heating in refluxing pyridine. In the case of a phenyl or thiomethyl substituent at the 5-position of this 
scaffold, chlorination with phosphorus oxychloride was achieved in good yields. The obtained 
chloropyrimidines 117 were then reacted with thiophenol to afford final structures 118 in very good 
yields. The authors did not mention whether they also attempted to react 116c (R = NH2) with 
phosphorus oxychloride.
55
  
 
Scheme 20. Condensation of dichloromethylidene 1,3-oxazol-5(4H)-ones with amidines 
The synthesis of twenty-eight new C(2)/C(4)-functionalized oxazolo[4,5-d]pyrimidines 121 was 
reported by Cmiljanovic et al. (Scheme 21). Unfortunately, the applied synthetic methods and 
characterization of these compounds was not described in detail. The only structures of Scheme 21 
which were unambiguously reported are the final structures 121. According to the reported general 
reaction scheme, the starting material was 4-aminooxazole 112 with an ester group at the 5-position 
and optionally a substituent at the 2-position. This oxazole was cyclized to afford oxazolo[4,5-
19 
 
d]pyrimidin-5,7(4H,6H)-dione 113. Chlorination of this compound then lead to 5,7-dichloropyrimidine 
119, which was subsequently substituted at the 7- and 5-positions to obtain the final structures 121.
56
  
 
Scheme 21. Annulation of pyrimidines to 1,3-oxazol-5(4H)-ones 
3.1.3 Scaffold construction by rearrangement of isoxazolo[3,4-d]pyrimidines 
Nishigaki and coworkers investigated the photochemical behavior of 3-arylisoxazolo[3,4-d]pyrimidines 
122 and observed a photorearrangement upon irradiation with a 100W high-pressure mercury lamp 
yielding the corresponding 2-aryloxazolo[4,5-d]pyrimidines 124 in very low yields (Scheme 22). Based 
on a previous mechanistic study on the photorearrangement of isoxazoles to oxazoles, which 
proceeds via an azirine intermediate, they assumed that this ring transformation also occurs via the 
initial formation of an azirine intermediate, 123, followed by recyclization to 124.
57
  
 
Scheme 22. Photochemically induced rearrangement of 3-arylisoxazolo[3,4-d]pyrimidines 
3.2 Biological activity 
Compound 105 (Figure 8, Scheme 17) is an inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 
value of 4.5 µM and also inhibits monoglyceride lipase (MGL) by 18% at 100 µM. FAAH and MGL are 
the main enzymes responsible for the hydrolysis of the two major endogenous cannabinoids N-
arachidonoylethanolamide (AEA) and 2-arachidonoylglycerol (2-AG). These cannabinoids activate the 
cannabinoid receptors CB1 and CB2, which induces biological effects such as relief of pain and 
anxiety. Thus, inhibitors of FAAH and MGL could have anxiolytic and analgesic activity.
53
 
Compounds 121 (Figure 8, Scheme 21) were reported in a large study on protein kinase B (PKB) 
inhibitors. PKB plays a key role in multiple cellular processes such as glucose metabolism, apoptosis, 
cell proliferation, transcription and cell migration. A PKB screening assay protocol was described in the 
publication, but it is not clear whether these compounds were included in the screen, and no biological 
results are thus available for these structures.
56
 
20 
 
 
Figure 8. Oxazolo[4,5-d]pyrimidines of biological interest 
4 Synthesis and biological activity of oxazolo[5,4-d]pyrimidines 
The synthesis of oxazolo[5,4-d]pyrimidines has been described to a much larger extent than the 
aforementioned oxazolo[4,5-d]pyrimidines. Generally, this scaffold can be constructed starting from 
either a functionalized pyrimidine or oxazole.  
4.1 Synthesis of oxazolo[5,4-d]pyrimidines 
4.1.1 Scaffold construction starting from a functionalized pyrimidine 
4.1.1.1 Starting from a 5-amino-4(,6)-(di)hydroxypyrimidine 
Possible building blocks to construct oxazolo[5,4-d]pyrimidines in a single step are 5-aminopyrimidines 
with a hydroxyl group or a lactam-type carbonyl group on the 4- and/or 6-position (Scheme 23). The 
carbon source for the C(2) of the resulting oxazolopyrimidine can originate from an anhydride, nitrile or 
trifluoromethyl moiety.  
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Scheme 23. Oxazolo[5,4-d]pyrimidines by annulation of oxazole rings to 5-amino-4-hydroxypyrimidines 
Reaction of acetic, propionic or benzoic anhydride with 5-amino-4,6-dihydroxypyrimidine 125 afforded 
oxazolo[5,4-d]pyrimidinones 126 in moderate yields (Scheme 24). Subsequent chlorination with 
phosphorus oxychloride and reaction with morpholine, piperidine or various arylamines gave the final 
oxazolo[5,4-d]pyrimidines 134.
58,59
 Similarly, when diaminopyrimidinol 127 was heated in acetic 
anhydride, oxazolopyrimidinone 135 was obtained in moderate yield.
60
 When the 6-hydroxyl group of 
the substituted pyrimidine was replaced by a secondary amino group, oxazole ring annulation 
occurred between the 4-carbonyl group and the 5-amino group of the pyrimidine ring. Treatment of 
amino(glycosylamino)pyrimidinones 136 with acetic anhydride under reflux gave 
(glycosylamino)oxazolopyrimidines 137 in low yield.
61
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Scheme 24. Condensation of 5-amino-4-hydroxypyrimidines with anhydrides 
As mentioned before, a nitrile or trifluoromethyl moiety can also serve as the C(2) carbon source. 
Reaction of nitrile 138 with 5,6-diaminopyrimidin-4-ol 131 in hot polyphosphoric acid afforded 7-
aminooxazolo[5,4-d]pyrimidine 139 (Scheme 25). The yield of this reaction was not reported.
62
 Qiao 
and coworkers discovered that the trifluoromethyl group of structure 140 hydrolyzed to the 
corresponding carboxylic acid quite easily under basic conditions. This degradation pathway was used 
to replace the labile CF3-group by more stable groups. Reaction of excess of 5,6-diaminopyrimidin-4-ol 
131 with 140 under mild aqueous conditions gave the C(2)-substituted 7-aminooxazolo[5,4-
d]pyrimidine 141 in low yield. Subsequent methylation afforded 7-methylaminooxazolopyrimidine 142 
in low yield.
63
  
 
Scheme 25. Condensation of 5-amino-4-hydroxypyrimidines with nitriles and trifluoromethyl groups 
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4.1.1.2 Cyclization of a 5-acylamino-4(,6)-(di)hydroxypyrimidine 
One of the major approaches for the construction of oxazolo[5,4-d]pyrimidines is the cyclization of a 5-
acylaminopyrimidine with a hydroxyl group or lactam-type carbonyl group on the 4- and/or 6-position 
(Scheme 26). Typical dehydrating agents are phosphorus oxychloride and polyphosphoric acid, but 
other reagents or techniques may also be used.  
 
Scheme 26. Oxazolo[5,4-d]pyrimidines by cyclization of 5-acylamino-4-hydroxypyrimidines 
5-Acylaminopyrimidine 163 was treated with excess N,N-dimethylaniline in phosphorus oxychloride 
under reflux conditions to afford oxazolopyrimidine 164 (Scheme 27). The very low yield of product 
164b was attributed to side reactions such as that of phosphorus oxychloride with the free 4-amino 
group yielding phosphorochloridate compounds.
64
 Compound 163c, which also possesses a 4-amino 
group, was ring-closed to oxazolopyrimidine 164c in moderate yield.
65
 Pyrimidines 163d with a free 2-
amino group were cyclized to 5-amino-7-chlorooxazolo[5,4-d]pyrimidines 164d in moderate to very 
good yields.
66
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Scheme 27. Cyclization of 5-acylamino-4-hydroxypyrimidines utilizing excess N,N-dimethylaniline in phosphorus oxychloride 
Pyrimidine 151, lacking a free amino group, was cyclized to 7-chlorooxazolo[5,4-d]pyrimidine 152 in 
boiling phosphorus oxychloride in good yields (Scheme 28). Subsequent reaction with sodium 
thiosulfide in ethanol afforded the oxazolopyrimidine-7-thiones 165 in very good yields.
67
 Pyrimidine 
166 was cyclized to 167 in very good yield under similar reaction conditions. Subsequent substitution 
of the chlorine by ammonia afforded 7-aminooxazolopyrimidine 168.
65
 Remarkably, when 
dihydroxypyrimidine 169 was cyclized with phosphorus pentachloride, oxazolopyrimidine-7(6H)-one 
170 was obtained. The isolated yield was not mentioned so it is not clear to what extent the oxygen at 
the 7-position was substituted by a chlorine atom, if at all. Further alkylation of this compound with 1-
bromopropane afforded 7-propoxy derivative 171 in 18% yield and the 6-N-propyl regioisomer in 19% 
yield.
68
  
 
Scheme 28. Cyclization of 5-acylamino-4-hydroxypyrimidines utilizing phosphorus oxychloride or phosphorus pentachloride 
Reaction of pyrimidine 172 with furoyl chlorides afforded the 4-acylaminopyrimidines 157 in good 
yields (Scheme 29). Subsequent ring closure with phosphorus oxychloride gave 7-
chlorooxazolopyrimidine 158, which then reacted with sodium azide to get 7-azidooxazolopyrimidine 
173 in excellent yields. Reduction of the azide followed by oxidation of the sulfide afforded sulfone 
175, which was then reacted with various amines to give the final 2,5-disubstituted-7-
aminooxazolopyrimidine 176.
69
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Scheme 29. Application of the phosphorus oxychloride induced cyclization of 5-acylamino-4-hydroxypyrimidines 
In a similar example, polyphosphoric acid (PPA) was used to ring close pyrimidine 178 to 
oxazolopyrimidine 179 (Scheme 30). The oxazolopyrimidine-7-ol 179 was subsequently chlorinated by 
phosphorus oxychloride to obtain 7-chlorooxazolopyrimidine 180. Remarkably, the chlorine at the 7-
position was substituted by a bipyrrolidine moiety in DMF at high temperature, while the chlorine on 
the pyridine ring was substituted in the next step by excess dimethylamine in THF at room 
temperature to yield compound 182.
70
  
 
Scheme 30. Cyclization of 5-acylamino-4-hydroxypyrimidines utilizing polyphosphoric acid 
Besides phosphorus oxychloride or polyphosphoric acid, an acyl chloride such as benzoyl chloride can 
also effectuate ring closure. Refluxing acetyluramil 183 in benzoyl chloride delivered 2-
phenyloxazolo[5,4-d]pyrimidine-5,7-dione 184 (Scheme 31). The presence of the phenyl group 
indicates that transacylation must have occurred. The acetyl group on acetyluramil is not very stable, 
and hydrolytic cleavage followed by benzoylation probably preceded the cyclization reaction.
71
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Ring closure was also established thermally, without the use of any reagent. Pyrimidine 185, with an 
acetylated amino group at the 5-position and a hydroxyl group at the 4- and 6-positions, was ring 
closed without any condensing agent by making use of a sublimation apparatus at high temperature. 
The desired 5-amino-2-methyl-6H-oxazolo[5,4-d]pyrimidin-7-one 186 (8-methyl-9-oxoguanine) was 
obtained in very low yield.
72
  
 
 
Scheme 31. Cyclization of 5-acylamino-4-hydroxypyrimidines under forcing conditions 
4.1.1.3 Starting from a 5-(acyl)amino-4(,6)-(di)chloropyrimidine 
Another suitable building block is a 5-aminopyrimidine with a chlorine atom on the 4- and/or 6-
positions. The amino group can either be free or acylated (Scheme 32).  
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Scheme 32. Oxazolo[5,4-d]pyrimidines by annulation of oxazole rings to 5-amino-4-chloropyrimidines 
Treatment of 4-chloro-5-aminopyrimidine 187 with equimolar amounts of benzoic acid and PPA in 
phosphorus oxychloride under reflux conditions afforded oxazolopyrimidine 197 in good yield (Scheme 
33).
73
 Similarly, treatment of 5-amino-2,4-dichloropyrimidine 189 with arylcarboxylic acids in refluxing 
POCl3 gave 5-chlorooxazolo[5,4-d]pyrimidines 198 in very good yields.
74
 5-Amino-4,6-
dichloropyrimidine 191 was treated with benzoyl chloride to obtain 7-chlorooxazolo[5,4-d]pyrimidine 
199 in good yield.
75
 Cyclization of acylated 5-amino-4,6-dichloropyrimidine 200 did not require 
phosphorus oxychloride or polyphosphoric acid and treatment with a simple inorganic base such as 
cesium carbonate in acetonitrile was sufficient to get the 7-chlorooxazolo[5,4-d]pyrimidine 201 in 
acceptable yield. Subsequent substitution of the chlorine with an appropriate amine afforded the 2,7-
disubstituted oxazolopyrimidine 202.
76
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Scheme 33. Cyclizations of 5-acylamino-4-chloropyrimidines under forcing conditions 
A facile synthesis of 2,5,7-trisubstituted oxazolo[5,4-d]pyrimidines 204 was developed by Xu et al. 
(Scheme 34). A combination of copper (I) and dimethylethylenediamine as ligand was used to catalyze 
the intramolecular C-O cross-coupling of the ortho-halopyrimidine amides 203 to provide the 
oxazolopyrimidines 204 in moderate to very good yields.
77
  
 
Scheme 34. Cyclization of 5-acylamino-4-hydroxypyrimidines by means of copper catalysis 
4.1.1.4 Cyclization of a 4-hydroxy-5-thioureidopyrimidine 
Analogous to the 5-acylamino-4-hydroxypyrimidines, 4-hydroxy-5-thioureidopyrimidines can be 
cyclized to oxazolo[5,4-d]pyrimidines (Scheme 35).  
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Scheme 35. Oxazolo[5,4-d]pyrimidines by cyclization of 4-hydroxy-5-thioureidopyrimidines 
Pyrimidinone 209 was first reacted with methoxycarbonyl isothiocyanate to afford the thioureido 
intermediate 210 in moderate yield (Scheme 36). Ring closure was then effectuated by treatment with 
dicyclohexylcarbodiimide to get oxazolopyrimidines 211 in very good yields.
78
  
 
Scheme 36. DCC induced cyclization of 4-hydroxy-5-thioureidopyrimidines 
When 5-aminopyrimidin-4-ol 212 was treated with O-phenyl chlorothionoformate, an intermediate O-
thiocarbamate 213 was formed (Scheme 37). This crude product was then reacted with a highly 
functionalized pyrrolidine to get thioureidopyrimidine structure 214 in very low yield. The oxazole ring 
cyclization was effectuated by treatment with silver nitrate and aqueous ammonium hydroxide in 
ethanol to afford the intermediate 2-substituted oxazolo[5,4-d]pyrimidine 215. This crude product was 
then deprotected by stirring in a mixture of trifluoroacetic acid and dichloromethane, followed by 
stirring in a mixture of ethylenediamine and methanol to obtain 216.
79
  
 
Scheme 37. Silver nitrate induced cyclization of 4-hydroxy-5-thioureidopyrimidines 
30 
 
4.1.2 Scaffold construction starting from a functionalized oxazole 
A second synthetic pathway towards oxazolo[5,4-d]pyrimidines is the annulation of a pyrimidine ring 
on a functionalized oxazole. The oxazole usually has a free amino group at the 5-position and a nitrile, 
ester or amide group at the 4-position.  
4.1.2.1 Starting from a 5-aminooxazole-4-carbonitrile 
A C(2)-functionalized 5-aminooxazole-4-carbonitrile is a versatile building block for the construction of 
different oxazolo[5,4-d]pyrimidines (Scheme 38). 
 
Scheme 38. Oxazolo[5,4-d]pyrimidines by annulation of pyrimidine rings to 5-aminooxazole-4-carbonitriles 
Reaction of 4-cyano-5-aminooxazole 217a with formamidine acetate delivered 7-aminooxazolo[5,4-
d]pyrimidine 218a (Scheme 39). The low yield was attributed to facile ring opening and degradation of 
the 5-amino-4-cyanooxazole.
80
 Substitution of the 2-position of the oxazole with a 2-furanoyl or phenyl 
substituent improved the stability and accordingly products 218b-c were obtained in higher yields.
65,81
 
Reaction of 226 with urea at high temperature gave 7-aminooxazolopyrimidin-5-ol 227, while treatment 
with a mixture of formic acid and acetic anhydride at 80 °C afforded oxazolopyrimidin-7-one 228.
81
 
Diphosgene was also applied in the direct ring closure of 5-aminooxazole-4-carbonitrile 229, affording 
the 5,7-dichlorooxazolopyrimidine 230 in low yield. Subsequent substitution of the 7- and 5-position 
with appropriate amines resulted in compound 232.
82
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Scheme 39. One-step condensation of 4-cyano-5-aminooxazoles with a variety of one-carbon synthons 
Pyrimidine ring annulation was also achieved in two steps. Reaction of oxazole 217 with an orthoester 
in refluxing acetic anhydride afforded the intermediate N-ethoxymethylene derivatives 222 in moderate 
to excellent yields (Scheme 40). Ring closure with aqueous ammonia then afforded the desired 7-
aminooxazolo[5,4-d]pyrimidines 223.
83
 Instead of aqueous ammonia, aqueous solutions of various 
primary amines in water could also be used to obtain a substituted 7-amino group on this scaffold.
84
 
Reaction of 226 with N,N-dimethylformamide dimethyl acetal in NMP resulted in amidine 224 in very 
good yield. Subsequent cyclization by treatment with various anilines in acetic acid gave N-substituted 
oxazolopyrimidin-7-amines 233 in varying yields.
81
 
 
Scheme 40. Two-step condensation of 4-cyano-5-aminooxazoles with acetic anhydride or N,N-dimethylformamide dimethyl acetal 
4.1.2.2 Starting from various other 2,4,5-trisubstituted oxazoles 
A variety of other 2,4,5-trisubstituted oxazoles were applied as building blocks for the construction of 
oxazolo[5,4-d]pyrimidines (Scheme 41). 
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Scheme 41. Oxazolo[5,4-d]pyrimidines by annulation of pyrimidine rings to oxazoles with appropriate substituents at positions 4 and 5 
Formylated 5-aminooxazole 234 was cyclized to oxazolo[5,4-d]pyrimidine-7-ols 235 in very low yield 
by treatment with a boiling potassium bicarbonate solution (Scheme 42).
85
 When ethyl 5-
aminooxazole-4-carboxylate 245 was treated with benzoyl isothiocyanate, thiourea 236 was obtained 
in moderate yields. Direct cyclization of these thiourea structures towards the 5-aminooxazolo[5,4-
d]pyrimidin-7(6H)-ones 237 with ammonia in methanol was unsuccessful. This cyclization was 
achieved in low yields by a step-wise methylation, followed by cyclization in the presence of ammonia 
in methanol. Alternatively, thiourea 236 was ring closed to 5-mercaptooxazolo[5,4-d]pyrimidin-7(6H)-
one 238 by aqueous potassium hydroxide in ethanol in good yields.
86
 Ethyl 5-aminooxazole-4-
carboxylate 246 was also used to construct oxazolo[5,4-d]pyrimidinones 250 through a consecutive 
aza-Wittig reaction. Treatment with triphenylphosphine, hexachloroethane and triethylamine produced 
iminophosphorane 247 in good yield. Further reaction with isocyanates afforded the carbodiimide 
intermediates 248, which reacted smoothly with secondary amines to generate guanidines 249. Ring 
closure to the desired oxazolopyrimidinones 250 was effectuated by a catalytic amount of sodium 
ethoxide in good overall yields.
87
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Scheme 42. Annulation of pyrimidine rings to 4-carboxy-5-aminooxazoles using a variety of one-carbon synthons 
In the same study on protein kinase B (PKB) inhibitors as mentioned in section 3.1.2 on oxazole[4,5-
d]pyrimidines, two new C(2)/C(4)-functionalized oxazolo[5,4-d]pyrimidines 253 were synthesized 
(Scheme 43). Unfortunately, the synthesis and characterization of these compounds was not 
described in detail. The only structures of Scheme 43 which were unambiguously reported are the final 
structures 253. According to a general reaction scheme, the starting material was 5-aminooxazole 239 
with an ester group at the 4-position and optionally a substituent at the 2-position. This oxazole was 
cyclized to afford oxazolo[5,4-d]pyrimidin-5,7(4H,6H)-dione 240. Chlorination of this compound then 
lead to 5,7-dichloropyrimidine 251, which was subsequently substituted at the 7- and 5-position to 
obtain the final structures 253. No biological results were reported.
56
 
 
Scheme 43. Application of the annulation of pyrimidine rings to 4-carboxy-5-aminooxazoles 
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All of the aforementioned reactions require heating of the reaction mixture, which may be undesirable 
when fragile substituents are involved. Therefore, Kornienko and coworkers developed a method to 
construct functionalized oxazolopyrimidines under mild reaction conditions. Reacting 4-cyanooxazole-
5-sulfonyl chlorides 241 with various amidines at room temperature in THF afforded the desired 
oxazolopyrimidines 242 in moderate yields (Scheme 44).
88,89
  
 
Scheme 44. Annulation of pyrimidine rings to 4-cyanooxazole-5-sulfonyl chlorides 
The Cornforth rearrangement is a reaction which is specific for 4-acyloxazoles. This rearrangement 
was used to develop a new synthetic pathway towards oxazolo[5,4-d]pyrimidin-7-ones 258 (Scheme 
45). Reaction of 4-acyloxazole 254 with an appropriate amidine 255 delivered the intermediate 
acylamidines 256 in good yields. Thermolysis in refluxing toluene induced the Cornforth 
rearrangement reaction and gave the amidines 257 in good to excellent yields. These were 
subsequently cyclized to oxazolopyrimidin-7-ones 258 by treatment with ethanolic potassium 
hydroxide in very good yields.
90
  
 
Scheme 45. Synthesis of oxazolo[5,4-d]pyrimidin-7-ones through the Cornforth rearrangement 
4.1.3 Scaffold construction starting from violuric acid 
Violuric acid (259) can be converted to 2-substituted oxazolo[5,4-d]pyrimidine-5,7(4H,6H)-diones by 
reaction with triphenylphosphonium salts or triphenylphosphonium ylides (Scheme 46). Thus, treating 
violuric acid with various triphenylphosphonium bromides and aqueous lithium hydroxide in ethanol 
afforded the oxazolopyrimidine-5,7-diones 260 in moderate to good yields. No reaction occurred when 
ester triphenylphosphonium bromides were used, while the corresponding ester ylides 261 delivered 
the 2-carboxylated oxazolopyrimidinones 262 in low yields.
91
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Scheme 46. Synthesis of oxazolo[5,4-d]pyrimidine-5,7(4H,6H)-diones through the condensation of violuric acid and Wittig 
reagents 
4.2 Biological activity 
4.2.1 Receptor modulators 
Compound 142 (Figure 9, Scheme 25) is an in vitro P2Y1 receptor antagonist with a Ki value of 24 nM. 
The P2Y1 receptor is an important receptor for ADP in platelets. In turn, platelet activation is known to 
play a pivotal role in thrombus formation. Therefore, P2Y1 antagonists could have significant utility in 
the treatment of a variety of thrombotic disorders. Compound 142 inhibits ADP-induced platelet 
aggregation with an IC50 value of 3.9 µM.
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Compound 168 (Figure 9, Scheme 28) is an A2 adenosine receptor antagonist with an IC50 value 
below 100 nM. This receptor plays an important role in the regulation of glutamate and dopamine 
release, and could be useful in treatment of conditions such as pain, insomnia, depression, drug 
addiction and Parkinson’s disease.
65
 168 was used as a lead compound in a later study on the 
development of selective A2A adenosine receptor antagonists for positron emission tomography (PET). 
This resulted in compounds 176 (Scheme 29). Compounds 176 are antagonists of the A2A adenosine 
receptor (A2AAR) with IC50 values ranging from 14-33 nM and of the A1 adenosine receptor (A1AR) with 
IC50 values ranging from 170-1700 nM, resulting in A2A/A1 selectivity ratios ranging from 5 to 91. 
However, a high degree of unspecific binding was observed in vitro, rendering these compounds 
useless as PET ligands.
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Compound 263 (Figure 9) is an angiotensin II receptor antagonist with an IC50 value of 98 nM. This 
receptor belongs to the class of GPCRs and is responsible for the signal transduction of the 
vasoconstricting stimulus of the peptide hormone angiotensin II. Antagonists of this receptor can be 
useful in the control of hypertension and related illnesses.
93
 
Compound 202 (Figure 9, Scheme 33) is an in vitro antagonist of the human transient receptor 
potential protein vanilloid receptor 1 (TRPV1) with an IC50 value of 136 nM. TRPV1 antagonists may 
be useful in disorders or conditions mediated by TRPV1 activity, such as pain, itch, arthritis, cough, 
asthma or inflammatory bowel disease.
76
 
Compound 264 (Figure 9, Scheme 34) is an inhibitor of the vascular endothelial growth factor receptor 
2 (VEGFR-2) with an IC50 value of 0.33 µM. The vascular endothelial growth factor is a key mediator of 
36 
 
angiogenesis, which is a critical process in solid tumor progression. Compound 264 possesses 
antiproliferative activity against HepG2 and U251 cells with IC50 values of 15.5 and 15.3 µM, 
respectively, and was active against VEGF-induced human umbilical vein endothelial cell (HUVEC) 
proliferation with an IC50 value of 0.29 µM.
94
 Compound 265 (Figure 9) is an inhibitor of VEGFR-2 with 
an IC50 value of 0.3 µM. However, it was not selective and also inhibits EGFR with an IC50 value of 0.2 
µM.
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Compound 266 (Figure 9) is an agonist of the endothelial differentiation gene receptor 1 (EDG-1) and 
was three times more active than the positive control substance sphingosine 1-phosphate at 10 µM.
68
 
Further work lead to compound 267, an EDG-1 agonist which effectively reduced the severity of acute 
kidney disease (AKI) in a murine in vivo model.
96
 
 
Figure 9. Oxazolo[5,4-d]pyrimidines reported as receptor modulators 
4.2.2 Kinase inhibitors 
The 2,7-disubstituted oxazolo[5,4-d]pyrimidine 182 (Figure 10, Scheme 30) is an inhibitor of adenosine 
kinase (AK) with an IC50 value of 10 nM. AK inhibition is an attractive therapeutic approach for several 
conditions such as neurodegeneration, seizures, ischemia, pain and inflammation.
70
 Compounds 
268a-b inhibit AK with Ki values of 11.1 and 25.2 µM, respectively. The latter also showed selectivity 
for adenosine A1 over A2A receptors.
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Compounds 269 (Figure 10) are in vitro inhibitors of Aurora A kinase with IC50 values between 1 and 
50 nM. Aurora kinases belong to the serine/threonine subclass of kinases and are involved in the 
regulation of mitosis. The derivative with a 4-pyridyl substituent at the 2-position was active against 
HCT-116 cancer cells in vitro with a cytotoxicity IC50 value lower than 100 nM.
98
 
Compound 216 (Figure 10, Scheme 37) is a JAK1 inhibitor with an IC50 value between 50 and 100 nM. 
JAK1 is a tyrosine kinase and plays an important role in initiating responses to cytokine receptors. 
Expression of JAK1 in cancer cells is related to metastasis.
79
 Compound 232 (Figure 10, Scheme 39) 
is an in vitro inhibitor of JAK2 kinase with an IC50 value of 2.3 µM. Remarkably, its thiazolo[5,4-
d]pyrimidine analogue, with a sulfur atom in structure 232 instead of an oxygen atom, has an IC50 
value of 3 nM.
82
 
 
Figure 10. Oxazolo[5,4-d]pyrimidines reported as kinase inhibitors 
4.2.3 Miscellaneous biological activity 
Compound 186 (Figure 11, Scheme 31) is an effective inhibitor of ricin toxin A chain (RTA) with an 
IC50 value of 0.40 mM.
72
 It was also found to be an effective inhibitor of Shiga toxin 1 A1 (Stx1A1) with 
an IC50 value of 2 mM.
99
 Ricin is a highly toxic lectin (a carbohydrate-binding protein) which naturally 
occurs in the seeds of the castor oil plant, Ricinus communis. The Shiga toxin is produced by Shigella 
dysenteriae and shigatoxigenic serotypes of Escherichia coli. The structurally similar purine isosteres 
270 are competitive inhibitors of human erythrocytic hypoxanthine-guanine phosphoribosyl transferase 
(HGPRT) with Ki values ranging from 84 to 173 µM. HGPRT plays a central role in the generation of 
purine nucleotides through the purine salvage pathway. Inhibitors of HGPRT could be useful to treat 
schistosomiasis and malaria, diseases in which the parasites lack the de novo purine biosynthetic 
pathway.
100
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Nucleoside analogues 6-(β-D-ribofuranosyl)oxazolo[5,4-d]pyrimidin-7-ones 271 (Figure 11) were 
prepared by a standard glycosylation reaction on trimethylsilylated 2-substituted oxazolo[5,4-
d]pyrimidin-7-ones. The less bulky nucleoside analogues (R = Me, Et, n-Pr) inhibit the proliferation of 
leukemia L1210 cells with IC50 values between 7 and 50 µM while the more bulky (R = i-Pr, Ph) 
derivatives had IC50 values higher than 100 µM. They also inhibit the proliferation of E. coli K12 cells 
with IC50 values between 0.5 and 6 µM for the n-propyl and ethyl group respectively, while for methyl 
and the bulky substituents, IC50 values higher than 100 µM were observed.
101
  
Compound 272 (Figure 11) is an inhibitor of the NEDD8-activating enzyme (NAE) with an IC50 value 
below 500 nM. Activated NEDD8 is needed in two DNA repair pathways. NAE inhibition may cause 
deficient DNA repair leading to accumulation of DNA damages, eventually resulting in cell death. 
Cancer cells may be more sensitive to this effect compared to normal cells if the cancer cells are 
independently deficient in DNA repair.
75
  
Compound 273 (Figure 11) is an activator of the caspase cascade in different cancer cell lines with 
EC50 values between 58-93 nM. Caspases are a family of protease enzymes that play essential roles 
in programmed cell death and inflammation.
59
  
Compound 274 (Figure 11) is an in vitro inhibitor of plasma kallikrein (PK) with an IC50 value of 1.78 
µM. PK is the activated form of the trypsin-like serine protease plasma-prokalliokrein and is mainly 
expressed by hepatocytes in the liver. PK inhibitors are considered to be useful in the treatment of a 
wide range of disorders, in particular retinopathy or edema-associated diseases, such as hereditary 
angioedema, macular edema and brain edema.
102
  
Compound 275 (Figure 11) inhibits acetyl-CoA carboxylase 2 (ACC2) in vitro with an IC50 value of 0.34 
µM. ACC2 is one of the two isoforms of ACC in mammals, and regulates the metabolism of fatty acids. 
Inhibitors of ACC2 could be useful in the treatment of obesity and diabetes.
103
  
Compound 276 (Figure 11) is an immunosuppressing agent and inhibits the in vitro Mixed Lymphocyte 
Reaction (MLR) test with an IC50 value of 3 µM.
104
 This type of structures also possesses antiviral 
activity against poliovirus and hepatitis C genotype 1a (HCV-1a).
105
  
Compound 277 (Figure 11) inhibits human umbilical vein endothelial cell (HUVEC) proliferation in vitro 
with an IC50 value of 9.3 µM and possesses superior anti-angiogenic activity.
106
 Further research by 
the same group lead to a similar compound, 278, which also possesses anti-angiogenic activity and 
inhibits HUVEC proliferation in vitro with an IC50 value of 12.4 µM. Despite the higher IC50 value, 
compound 278 had a better dose-response curve than compound 277 and was preferred for further 
study.
107
  
Compound 279 (Figure 11) is an antiviral compound with activity against respiratory syncytial virus 
(RSV) and inhibits replication of the rgRSV224 virus in vitro.
108
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Figure 11. Oxazolo[5,4-d]pyrimidines of assorted biological interest 
5 Conclusions 
This literature overview demonstrates that the furo[3,4-d]pyrimidines are an underexplored class of 
compounds, both from a synthetic and medicinal point of view. Most likely, the lack of biological 
studies goes hand in hand with the paucity of synthetic methodologies to access this scaffold. 
Therefore, a window of opportunity exists to explore new synthetic avenues in the field of furo[3,4-
d]pyrimidines. 
Contrary to the furo[3,4-d]pyrimidines, the 5,7-dihydrofuro[3,4-d]pyrimidines (without substituents on 
the dihydrofuran ring) have been explored much more. Although the number of synthetic pathways is 
rather limited, synthetic access to a few key building blocks allowed this scaffold to be included in a 
variety of biological studies. This resulted in more than ten examples of bioactive compounds.  
The oxazolo[4,5-d]pyrimidines again form a class of underexplored compounds, both from a synthetic 
and medicinal point of view, although less dramatically than the furo[3,4-d]pyrimidines. Once again, 
this probably results from the limited synthetic access to key building blocks for this type of scaffold. 
Therefore, there is still room for exploration in the field of oxazolo[4,5-d]pyrimidines. 
40 
 
Contrary to the oxazolo[4,5-d]pyrimidines, the oxazolo[5,4-d]pyrimidines are a well-explored class of 
compounds. A broad array of synthetic pathways is available to access oxazolo[5,4-d]pyrimidines with 
a variety of substitution patterns. This scaffold has been included in many biological studies, and this 
has resulted in more than twenty examples of bioactive compounds. Depending on the substitution 
pattern, various receptor (ant)agonists, kinase inhibitors, antiproliferative compounds and other 
inhibitors were obtained.  
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Results and discussion 
1 Synthesis of furo[3,4-d]pyrimidine analogues 
The synthetic strategy to gain access to furo[3,4-d]pyrimidines was based on a literature search of 
closely related structures. Thieno[3,4-d]pyrimidines were found to be the most similar compounds, and 
they are generally synthesized via the thieno[3,4-d]pyrimidine-2,4-dione 280 (Scheme 47). 
Chlorination of this precursor gives the 2,4-dichloropyrimidine 281, which is then modified by 
replacement of the chlorine atoms by different substituents to give thieno[3,4-d]pyrimidines 282.
109,110
  
 
Scheme 47. Synthetic pathway towards thieno[3,4-d]pyrimidines 
2,4-Dichlorofuro[3,4-d]pyrimidine, the furan analogue of 281, has not been described yet in the 
literature, but its precursor furo[3,4-d]pyrimidine-2,4-dione, which is the furan analogue of 280, was 
already reported in two papers (Scheme 3, Scheme 4).
29,30
 Neither of the two reported synthetic 
pathways gave straightforward, high-yield access to the desired building block. Therefore, a more 
convenient approach was highly desired.  
1.1 Synthesis of the furo[3,4-d]pyrimidine-2,4-dione scaffold and subsequent 
reaction with phosphorus oxychloride 
The two existing routes started from dimethyl/diethyl furan-3,4-dicarboxylate because it is 
commercially available and it has functional groups at the right positions. Therefore, a new synthetic 
route starting from the same furan dicarboxylate was the first consideration. The unselective 
aminolysis step was replaced by a selective partial hydrolysis with sodium hydroxide
111
 and afforded 
the mono-acid 283 in 95% yield (Scheme 48). Then, the acid was converted to an intermediate 
isocyanate via a Curtius rearrangement by reaction of diphenyl phosphoryl azide and triethylamine as 
a base.
112
 Ammonia gas was then bubbled through the reaction for five minutes at 0 °C to form the 
ureid 284 in 86% yield. The ureid could be ring-closed to the desired furo[3,4-d]pyrimidine-2,4-dione 6 
in 82% yield by treatment with sodium methoxide in dry methanol.
113
 Attempts to speed up this ring 
closure reaction by heating of the reaction mixture resulted in a significant increase in the amount of 
side products. Overall, the desired building block 6 was obtained in three reaction steps and 67% 
yield.  
42 
 
 
Scheme 48. Three-step synthesis of furo[3,4-d]pyrimidine-2,4-dione 
The next step was the conversion of the pyrimidine-2,4-dione to the 2,4-dichloropyrimidine. In the 
literature, four procedures are reported to accomplish this conversion on thieno[3,4-d]pyrimidine-2,4-
dione, all of them make use of phosphorus oxychloride as chlorinating reagent (Table 1).  
Table 1. Reported methods to chlorinate the thieno[3,4-d]pyrimidine-2,4-dione scaffold 
Reference POCl3 (mL/mmol 280) Base (mL/mmol 280) T (°C) t (h) Yield (%) 
Okubo et al.
114
 1.7 N,N-Dimethylaniline (0.3) 100 2.5 43 
Dong et al.
115
 0.8 N,N-Dimethylaniline (0.1) 105 16 81 
Block et al.
110
 4.3 N,N-Diethylaniline (0.4) 105 16 92 
Kim et al.
116
 3.4 / 106 3 39 
 
These literature procedures were evaluated for the chlorination of furo[3,4-d]pyrimidine-2,4-dione. The 
reactions were followed by TLC analysis and in the case of a potentially successful reaction, i.e. 
conversion to a more apolar spot on TLC, the reaction was worked up and analyzed by LC-MS and 
NMR spectroscopy. The results are summarized in Table 2. The desired dichloropyrimidine was not 
detected in any of the reactions. Since the successful transformation of thieno[3,4-d]pyrimidine-2,4-
dione and 5,7-dihydrofuro[3,4-d]pyrimidine-2,4-dione to their respective 2,4-dichloropyrimidine 
counterparts by treatment with phosphorus oxychloride has been described already, it can be 
concluded that the furan ring is responsible for the failure of this reaction. A possible explanation could 
be the relatively small aromatic stabilization in furan, which enables diene chemistry and enol ether 
chemistry, leading to the formation of bicyclic adducts, ring-opened adducts and polymeric material.  
Table 2. Attempts to synthesize 2,4-dichlorofuro[3,4-d]pyrimidine using literature procedures 
Procedure Reaction time (h) Results 
Okubo et al.
114
 0.5 Starting material + apolar side products 
 1 Full conversion to apolar side products 
Dong et al.
115
 0.5 Starting material + apolar side products 
 1 Full conversion to apolar side products 
Dong et al., at 23 °C 0.5 Starting material + apolar side products 
 3 Starting material + apolar side products 
Kim et al.
116
 0.5 Starting material + polar side products 
 3 Starting material + polar side products 
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1.2 Synthesis of N-3 functionalized furo[3,4-d]pyrimidine-2,4-diones 
Without the 2,4-dichlorofuro[3,4-d]pyrimidine building block, the predetermined route towards 
functionalized furo[3,4-d]pyrimidines was blocked. Therefore, other target structures were investigated 
for valorization of the developed synthetic methodology. First of all, N-1/N-3 functionalized furo[3,4-
d]pyrimidine-2,4-diones appeared to be interesting structures. When the furo[3,4-d]pyrimidine-2,4-
dione building block is treated with a base and an electrophile, the N-1 nitrogen will react selectively 
and N-1 functionalized furo[3,4-d]pyrimidine-2,4-diones will be obtained.
33
 This impedes access to N-3 
functionalized furo[3,4-d]pyrimidine-2,4-diones by demanding a N-1 protection-deprotection sequence. 
One synthetic pathway was reported already towards N-3 functionalized furo[3,4-d]pyrimidine-2,4-
diones (Scheme 5). After six reaction steps, the overall yield was only 12-31%.
31
  
To synthesize these structures in a faster and more convenient way, appropriate amines were added 
to the intermediate isocyanate of the Curtius rearrangement reaction to form the ureids 36 (Scheme 
49). Most of the impurities were removed by silica gel column chromatography, and cyclization of the 
ureids 36 was effectuated by treatment with a base. The secondary ureids 36 were more susceptible 
towards ring closure than the primary ureid 284, and the sodium methoxide-methanol system was 
replaced by potassium tert-butoxide in tetrahydrofuran at 0 °C for 40 minutes. The N-3 functionalized 
furo[3,4-d]pyrimidine-2,4-diones 38 were obtained in 66-88% yield over two steps (Table 3).
25
  
 
Scheme 49. Straightforward synthesis of N-3 functionalized furo[3,4-d]pyrimidine-2,4-diones 
Table 3. Structures and yields of compounds 38 
Compound R Yield (%)
a 
38a n-Pr 88 
38b Bn 77 
38c 2-Picolyl 66 
38d 4-MeOC6H4CH2 76 
38e 2-MeOC6H4CH2 79 
38f 3-MeOC6H4CH2 74 
38g 2-FC6H4CH2 75 
38h 3-FC6H4CH2 71 
38i 3,4,5-(MeO)3C6H4CH2 81 
38j 2,3-(MeO)2C6H4CH2 77 
38k 4-CF3C6H4CH2 82 
38l 4-PhOC6H4CH2 80 
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38m 4-EtOC6H4CH2 76 
38n 4-MeO-3-picolyl 69 
38o 4-CNC6H4CH2 78 
a
 Yield over two steps: 283  38 (Scheme 49) 
1.3 Synthesis of N-1/N-3 functionalized furo[3,4-d]pyrimidine-2,4-diones 
Different procedures were evaluated to functionalize N-1. First, two different reductive N-alkylations 
were tested (Scheme 50). When 38a was reacted with benzaldehyde, triethylsilane and trifluoroacetic 
acid in toluene, the formation of many side products was observed, and the desired structure 285b 
was not detected.
117
 Another procedure, which makes use of 1H-benzotriazole and benzaldehyde in a 
Dean-Stark set-up and sodium borohydride as a reducing agent, resulted also in many side products 
without the formation of 285b.
118
  
 
Scheme 50. Reductive alkylation procedures to functionalize N-1 
Next, N-1 alkylation by reaction with alkyl bromides was attempted under different conditions. Reaction 
of 38a with sodium hydroxide and isopropyl bromide in water under microwave conditions only 
resulted in formation of side products (Scheme 51).
119
 When potassium carbonate was used as a 
base, and DMF as a solvent, the reaction with 38c proceeded very slowly. Heating of the reaction 
mixture at 55 °C under microwave conditions resulted in the formation of side products and only traces 
of the desired compound 285g were detected. Eventually, the use of the stronger and more soluble 
cesium carbonate in combination with tetrabutylammonium iodide in DMF gave good results for the 
alkylation reaction with isopropyl bromide.
120
 Under these conditions, the furopyrimidinones 38 reacted 
smoothly with allyl bromide and benzyl bromide as well, and a small library of compounds 285 was 
constructed (Table 4). In all of these reactions, the conversion of starting material was complete and 
the varying yields were attributed to the occurrence of side products. The isopropylation reaction 
proceeded slower than the benzylation and allylation reactions, allowing more side products to be 
formed. This resulted in lower yields for most of the isopropylations. The use of 1.1 equivalents of 
sodium hydride in DMF was also evaluated to perform these alkylation reactions but this resulted in 
more side product formation compared to the reaction with cesium carbonate. 
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Scheme 51. Reaction of N-1 with alkyl bromides under different conditions 
Table 4. Structures and yields of N-1/N-3 heterofunctionalized furo[3,4-d]pyrimidine-2,4-diones 285 
Compound R
1 
R
2
 Yield (%) 
285a n-Pr i-Pr 55 
285b n-Pr Bn 99 
285c n-Pr Allyl 51 
285d Bn i-Pr 66 
285e Bn Bn 86 
285f Bn Allyl 89 
285g 2-Picolyl i-Pr 35 
285h 2-Picolyl Bn 83 
285i 2-Picolyl Allyl 69 
285j 4-MeOC6H4CH2 i-Pr 48 
285k 4-MeOC6H4CH2 Bn 70 
285l 4-MeOC6H4CH2 Allyl 84 
 
1.4 Further exploration of the chemistry on furo[3,4-d]pyrimidine-2,4-diones 
After successful functionalization of both the N-1 and N-3 nitrogens of the furo[3,4-d]pyrimidine-2,4-
dione ring, other possibilities to explore and modify the structure were examined. While performing 
initial experiments on the Curtius rearrangement, small amounts of water were present and this 
resulted in the formation of symmetrical ureid side product 286 (Scheme 52). This compound could be 
a potential substrate for an acyloin condensation (after protection of the ureid nitrogen atoms) towards 
a 9-membered ring structure 287. When 0.5 equivalents of water were added to the isocyanate, 
symmetrical ureid 286 was obtained in 67% yield. 
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Scheme 52. Synthesis of symmetrical ureid 286 
To protect the ureid nitrogens, alkylation of 286 using cesium carbonate, TBAI and iodomethane was 
attempted (Scheme 53). However, the major reaction product turned out to be the mono-alkylated ring 
closed structure 288 and was isolated in 41% yield. The double methylated ureid and the mono-
methylated ureid were also present in the reaction mixture next to other unidentified side products, but 
isolation of these products was not successful.  
 
Scheme 53. Reaction of symmetrical ureid 286 with iodomethane 
Next, a method to protect the ureid nitrogens as a triazone moiety was evaluated. The symmetrical 
ureid 286 was reacted with aqueous formaldehyde and a primary amine in toluene with dioxane as co-
solvent (Scheme 54).
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 Unfortunately, a complex reaction mixture was obtained and the desired 
triazone 289 was not detected. No further attempts were undertaken to protect the nitrogens and 
pursue the synthesis of a 9-membered ring structure. 
 
Scheme 54. Protection of the ureid nitrogens as a triazone moiety 
In the literature, the transformation of a pyrimidine-2,4-dione moiety to a pyrimidine-2,4-dithione has 
been reported.
122
 First, 38a was reacted with Lawesson’s reagent under different conditions (Scheme 
55). In dry pyridine under reflux conditions, a complex reaction mixture was obtained without detection 
of the desired compound 290. In dry THF at room temperature, no reaction was observed. Rising the 
temperature and refluxing the reaction mixture for 12 hours still did not initiate any reaction. Addition of 
one equivalent of triethylamine and further reaction under reflux conditions only resulted in the 
formation of side products. Next, the use of phosphorus pentasulfide was evaluated. Reaction of 38a 
with 1.35 equivalents of phosphorus pentasulfide in acetonitrile or xylene under reflux conditions only 
resulted in a complex reaction mixture without detection of the target compound 290.
123,124
 
Phosphorus pentasulfide can be pre-activated by sodium carbonate to form an active thionating 
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salt.
125
 When this salt was reacted with 38c, the desired compound 291 was detected in the reaction 
mixture, but only a small fraction of the starting product was converted after 12 hours. Prolonged 
stirring did not improve the conversion. Even when the experiment was repeated with 10 equivalents 
of phosphorus pentasulfide and 5 equivalents of sodium carbonate, a significant amount of starting 
product was still present after 48 hours. Finally, Curphey’s thionation conditions, employing a 
combination of phosphorus pentasulfide and hexamethyldisiloxane, were tested.
126
 These conditions 
gave similar results as the use of phosphorus pentasulfide and sodium carbonate. Even when 10 
equivalents of phosphorus pentasulfide were used, mainly starting material was present in the reaction 
mixture after 12 hours.  
Although two reaction conditions were found in which the desired dithione compound was formed, no 
full or sufficiently clean conversion was obtained and all attempts to isolate these compounds failed.  
 
Scheme 55. Attempts to thionate the pyrimidine-2,4-dione moiety 
Although the attempts to chlorinate the furo[3,4-d]pyrimidine-2,4-dione scaffold by treatment with 
phosphorus oxychloride were unsuccessful (vide supra), chlorination of the C-2 carbonyl group of the 
N-3 functionalized scaffold by phosphorus oxychloride was still evaluated (Scheme 56). The different 
reaction conditions are given in Table 5. In all cases, a complex reaction mixture was obtained and the 
desired compound 292 or 293 was not detected. 
 
Scheme 56. Chlorination of C-2 by phosphorus oxychloride 
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Table 5. Reaction conditions of N-3 functionalized furo[3,4-d]pyrimidine-2,4-diones with phosphorus oxychloride 
R POCl3 (eq.) Base (equiv.) NuH (equiv.) T (°C) Time (h) Solvent 
n-Pr Large excess / / reflux 3 Neat 
n-Pr 3 N,N-dimethylaniline (2) / reflux 2 Toluene 
n-Pr 1.1 DIPEA (2) / reflux 2.5 Toluene 
n-Pr 1.1 Et3N (2) MeOH (10) reflux 2 Toluene 
2-picolyl 1.1 DIPEA (2) n-PrNH2 (10) reflux 1 Toluene 
 
The use of other reagents, which can accomplish the same type of transformation under milder 
conditions, were tested. The first reagent is diphenylphosphinic chloride, which works in a very similar 
way as POCl3 but under milder reaction conditions.
127
 Compound 38a was treated with sodium hydride 
in THF for 30 minutes, followed by addition of diphenylphosphinic chloride (Scheme 57). Then, an 
excess of n-propylamine was added. Unfortunately, the use of this reagent also resulted in a complex 
reaction mixture without detection of the C-2 chlorinated product or the desired compound 294.  
 
Scheme 57. Chlorination of N-3 functionalized furo[3,4-d]pyrimidine-2,4-dione using diphenylphosphinic chloride 
Another reagent which can be used for this type of transformation under mild reaction conditions is 
(benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate, better known as Castro’s 
reagent or BOP.
128
 First, furopyrimidinone 38c was activated with DBU and BOP at room temperature 
for 10 minutes (Scheme 58). Then, n-propylamine was added. LC-MS analysis of the crude reaction 
mixture after twelve hours showed full conversion to a complex reaction mixture, containing compound 
295 and a significant amount of side products. Unfortunately, compound 295 could not be isolated.  
 
Scheme 58. Functionalization of C-2 by BOP-reagent 
1.5 Synthesis of 5,7-dihydro- and tetrahydrofuro[3,4-d]pyrimidine-2,4-diones 
After exploring various methods to modify the uracil/pyrimidine moiety of the scaffold (vide supra), 
research efforts turned towards altering the furan ring. A literature search revealed that the compound 
classes of N-1/N-3 functionalized 5,7-dihydropyrimidine-2,4-diones 296 and tetrahydrofuropyrimidine-
2,4-diones 297 (Figure 12) were highly underexplored. With a straightforward pathway to the furo[3,4-
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d]pyrimidine-2,4-diones in hand, a selective hydrogenation of the furan ring to get the respective di- or 
tetrahydrofuro[3,4-d]pyrimidine-2,4-diones looked like an interesting approach to investigate.  
 
Figure 12. The unexplored compound classes of 5,7-dihydropyrimidine-2,4-diones and tetrahydrofuropyrimidine-2,4-diones 
The first hydrogenation reactions were performed on furopyrimidinone 38a (Scheme 59). Rhodium on 
alumina is generally known for its high activity for the hydrogenation of aromatic rings, while palladium 
on carbon has only a low activity for hydrogenation of aromatics.
129
 Therefore, both of these catalysts 
were evaluated. When 5 mol% of palladium (10 wt% on activated carbon) was used under an 
atmosphere of 1 bar of hydrogen pressure, full conversion of starting material was observed after four 
hours (Table 6, entry 1). The major reaction product was 5,7-dihydrofuro[3,4-d]pyrimidine-2,4-dione 
298 and was isolated in 66% yield. The minor reaction product was tetrahydrofuro[3,4-d]pyrimidine-
2,4-dione 299 (not isolated). When the hydrogen pressure was increased to 5 bar, full conversion of 
starting material was observed after one hour, and the dihydrofuropyrimidinone 298 was isolated in 
71% yield (Table 6, entry 2). When 5 mol% of rhodium (5 wt% on alumina) was used as a catalyst, full 
conversion of starting material and of the dihydrofuropyrimidinone 298 was achieved only after twelve 
hours under a hydrogen atmosphere of 5 bar (Table 6, entry 3). The tetrahydrofuropyrimidinone 299 
was isolated in 79% yield.  
 
Scheme 59. Hydrogenation of furopyrimidinone 38a 
Table 6. Reaction conditions and yields of the hydrogenation reaction of 38a. 5 mol% of catalyst was used. H2 pressure is 
expressed as overpressure relative to atmospheric pressure in bar. All reactions were carried out at room temperature in 
methanol as a solvent. 
Entry Catalyst H2 (bar) t (h) Yield of 298 or 299 (%) 
1 10 wt% Pd/C 1 4 66 (298) 
2 10 wt% Pd/C 5 1 71 (298) 
3 5 wt% Rh/Al 5 12 79 (299) 
 
Since the use of palladium on carbon resulted in full hydrogenation of the furan ring to some extent, a 
screening of different in-house hydrogenation catalysts was performed with the aim to find a catalyst 
which showed complete selectivity for the dihydrofuropyrimidinone product. Compound 38d, with a 
para-methoxybenzyl (PMB) moiety on N-3, was selected as the starting material for this screening 
(Scheme 60). This way, any undesired hydrogenolytic activity of the catalyst would be observed by the 
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occurrence of N-3 deprotected furo[3,4-d]pyrimidine-2,4-dione. The results are summarized in Table 7. 
Except for Adam’s catalyst (entry 2), all of the catalysts afforded more dihydrofuropyrimidinone 300 
than tetrahydrofuropyrimidinone 301 (entries 1, 3-6). The use of Adam’s catalyst also resulted in the 
formation of many unidentified side products, while no differences in the formation of side products 
could be detected for the other catalysts. Lindlar’s catalyst gave the best dihydro/tetrahydro ratio, but 
conversion of the starting material was very slow (entry 4). Pearlman’s catalyst (entry 5) and the 
regular palladium on activated carbon (entry 6) combined a good conversion of starting material with a 
relatively good dihydro/tetrahydro ratio. From this screening, it was concluded that 10 wt% of 
palladium on activated carbon was the most convenient catalyst for the hydrogenation of furo[3,4-
d]pyrimidine-2,4-dione 38d to 5,7-dihydro[3,4-d]pyrimidine-2,4-dione 300. No hydrogenolysis of the 
PMB group was observed in any of the reactions.  
 
Scheme 60. Catalyst screening for the hydrogenation of furopyrimidinone 38d 
Table 7. Catalyst screening for the hydrogenation reaction of 38d. 5 mol% of catalyst was used. All reactions were equipped 
with a balloon filled with pure hydrogen gas. All reactions were carried out at room temperature in methanol as a solvent.  
Entry Catalyst t (h) 38d:300:301
a 
Ratio 300/301
a 
1 3.5 wt% Pb/5 wt% Pd/CaCO3 1 57:35:8 4.4 
2 PtO2 (Adam’s catalyst) 1 56:17:27 0.6 
3 5 wt% Pd/BaSO4 1 58:37:5 7.4 
4 5 wt% Pd/CaCO3, poisoned 
(Lindlar’s catalyst) 
1 91:8:1 8 
5 20 wt% Pd(OH)2/C 1 28:59:13 4.5 
6 10 wt% Pd/C 1 25:64:11 5.8 
a
: Estimated by LC-MS analysis 
Since the screening did not result in a better catalyst for the synthesis of 5,7-dihydrofuropyrimidinones, 
compounds 300 and 301 were produced under the same reaction conditions as the n-propyl derivative 
38a and were obtained in 66% and 71% yield, respectively (Table 8).  
Table 8. Reaction conditions and yields of the hydrogenation reaction of 38d. 5 mol% of catalyst was used. H2 pressure is 
expressed as overpressure relative to atmospheric pressure in bar. All reactions were carried out at room temperature in 
methanol as a solvent. 
Entry Catalyst H2 (bar) t (h) Yield of 300 or 301 (%) 
1 10 wt% Pd/C 5 1 66 (300) 
2 5 wt% Rh/Al 5 12 71 (301) 
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The tetrahydrofuro[3,4-d]pyrimidine-2,4-dione scaffold 323 was synthesized by heterogeneous 
catalytic hydrogenation of the furo[3,4-d]pyrimidine-2,4-dione scaffold 6 (Scheme 61). Five mole 
percent of rhodium in the form of 5 wt% rhodium on alumina was used as the heterogeneous catalyst, 
and water was used as the solvent. After stirring for twenty-eight hours under a hydrogen atmosphere 
of 5 bar, complete conversion of the starting material was observed and the scaffold 323 was isolated 
in 52% yield.   
 
Scheme 61. Tetrahydrofuro[3,4-d]pyrimidine-2,4-dione was obtained via Rhodium-catalyzed hydrogenation of furo[3,4-
d]pyrimidine-2,4-dione 
X-ray analysis was performed on the crystals of 323 in order to determine the stereochemistry (Figure 
13). The crystals were composed of the two cis-isomers in a 1:1 ratio. One cis-isomer has C1 (S) and 
C4 (R) stereochemistry, the other one has C1 (R) and C4 (S).  
 
Figure 13. Structure of the C1 (S) C4 (R) stereoisomer of tetrahydrofuro[3,4-d]pyrimidine-2,4-dione 323. Thermal displacement 
ellipsoids are shown at the 50% probability level. 
The hydrogenation procedure with a palladium on carbon catalyst proved to be compatible with a PMB 
group on N-3. However, because this palladium catalyst is known for its high hydrogenolytic activity,
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the stability of a benzyl substituent on N-3 under palladium catalyzed hydrogenation reaction 
conditions was also evaluated. When compound 38b was subjected to 5 bar of hydrogen pressure for 
twenty-four hours using 5 mol% of palladium on carbon, no debenzylation was observed (Scheme 62). 
Based on LC-MS, both 302 and 303 were present in the reaction mixture in a 1:1 ratio, from which 
product 302 was isolated in 36% yield.   
 
Scheme 62. Palladium catalyzed hydrogenation of a N-3 benzylated furopyrimidinone 
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When the N-1/N-3 dibenzylated furopyrimidinone 285e was hydrogenated with rhodium on alumina, 
full conversion of the starting material was observed after twelve hours (Scheme 63). However, LC-MS 
analysis indicated that hydrogenation of the benzyl rings had occurred and that the expected product 
304a was present in the reaction mixture together with more saturated products. The predominant 
species were 305 (50%), 304a (25%) and 304b (8%), while other species -with saturation degrees 
ranging from 304a to 304b- were present in a total amount of 17%. After 60 hours of total reaction 
time, the amount of product 304a decreased to 12%, while 304b and 305 increased to 18% and 55%, 
respectively. The reaction was terminated and only compound 305 could be isolated from the reaction 
mixture in 20% yield. The structure of compound 305 was elucidated by using a combination of 1D-
NMR and 2D-NMR techniques. The apparent selectivity for the hydrogenation of the N-1 benzyl 
moiety may be due to electronic and/or steric effects. No debenzylation products were observed 
during the reaction.  
 
Scheme 63. Rhodium catalyzed hydrogenation of 285e affected the benzyl group on N-1 
One of the tetrahydrofuropyrimidinone compounds was alkylated following the same procedure as for 
the furopyrimidinones 38. When 299 was reacted with cesium carbonate, tetrabutylammonium iodide 
and allyl bromide, the desired product 306 was obtained in 60% yield (Scheme 64).  
 
Scheme 64. Alkylation of tetrahydrofuropyrimidinone 299 with allyl bromide 
1.6 Synthesis of N-1 functionalized furo[3,4-d]pyrimidine-2,4-diones 
Three different substituents were proposed for the N-1 functionalization of the furo[3,4-d]pyrimidine 
scaffolds in order to obtain nucleoside analogues 307-309 (Figure 14). The antiviral drugs Idoxuridine 
11, Trifluridine 12 and Zidovudine 13 all possess a 2-deoxyribose moiety (Figure 4), while the 
antibacterial agent Tubercidin 311a is equipped with a ribose moiety (Figure 14). The (stereoselective) 
synthesis of 2-deoxyglycosides is often more complex compared to the corresponding glycosides.
130
 
The synthesis of the proposed glycoside 307 requires only a straightforward glycosylation reaction 
with inexpensive 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose (ATBR), followed by a deprotection 
reaction. Moreover, the field of 2-deoxyribose-based nucleoside analogues has been investigated 
extensively, while a literature search on the 5-membered ring annulated uridine substructure 310 
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indicated that only seventeen such structures have been reported so far, and only four of them were 
involved in biological studies.
131–134
 Therefore, the biological evaluation of this type of uridine 
analogues would be very interesting. The acyclic nucleoside analogues 308 and 309 were proposed 
based on literature reports on the antiviral and antifungal activity of acyclouridine derivatives.
135–137
 For 
example, compound 311b inhibited the replication of the HIV-1 virus in MT-4 cells in vitro, exhibiting 
an EC50 value of 0.33 µM.
137
 In addition, Aciclovir (311c, Figure 14) is a well-known example of an 
acyclic nucleoside analogue drug.  
 
Figure 14. Proposed structures of nucleoside analogues 307-309, the SciFinder search substructure 310, the structure of 
antibacterial Tubercidin 311a and the antiviral compounds 311b-c 
Three different N-1 functionalized furo[3,4-d]pyrimidine-2,4-diones were synthesized following 
literature procedures that describe the derivatization of uracil (Scheme 65). The furo[3,4-d]pyrimidine-
2,4-dione scaffold 6 was glycosylated under Vörbruggen conditions.
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 The scaffold was first silylated 
by reaction with three equivalents of N,O-bis(trimethylsilyl)acetamide (N,O-BSA) in acetonitrile at room 
temperature for two hours, followed by addition of 0.94 equivalents of ATBR and 1.6 equivalents of 
trimethylsilyl trifluoromethanesulfonate and heating at 85 °C for 45 minutes. The benzoyl-protected 
structure 313 was subsequently deprotected by treatment with methanolic ammonia at room 
temperature for twelve hours, to afford the glycosylated furo[3,4-d]pyrimidine-2,4-dione 314 in 55% 
yield over two steps. The functionalization of N-1 with 2-(chloromethoxy)ethyl acetate was also 
initiated by silylation of the scaffold, but under slightly different reaction conditions.
139
 The silylation 
was followed by addition of a catalytic amount of tetrabutylammonium iodide at room temperature and 
1.5 equivalents of 2-(chloromethoxy)ethyl acetate at 0 °C. After stirring at 0 °C for two hours, the 
reaction was finished and the acylated structure 315 was isolated in 41% yield. Deprotection of the 
hydroxyl group was achieved by methanolic ammonia to give compound 316 in 85% yield. In a similar 
fashion, scaffold 6 reacted with chloromethyl ethyl ether to afford structure 317 in 83% yield.  
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Scheme 65. Synthesis of N-1 functionalized furo[3,4-d]pyrimidine-2,4-diones 
The 5,7-dihydrofuro[3,4-d]pyrimidine-2,4-dione scaffold 8 (Scheme 66) was synthesized following a 
literature procedure.
34
 This scaffold was then glycosylated under the Vörbruggen conditions which 
have been described earlier. However, a significant amount of side products was formed, and the 
desired glycosylated structure 319 was isolated in only 7% yield over two steps. For the synthesis of 
the 5,7-dihydro analogue of 315, another procedure was followed in an attempt to improve the yield of 
the first reaction step.
140
 Thus, after silylation of 8 with N,O-bis(trimethylsilyl)acetamide, 1.5 
equivalents of 2-(acetoxyethoxy)methyl acetate were added at room temperature, followed by 0.2 
equivalents of trimethylsilyl trifluoromethanesulfonate at 0 °C. After stirring at room temperature for 
three days, the reaction was finished and the acylated compound 320 was isolated in 26% yield. 
Deprotection of the hydroxyl group by methanolic ammonia gave derivative 321 in 92% yield. The 
reaction of 8 with chloromethyl ethyl ether was also characterized by a lower yield compared to its 
analogue 6, and compound 322 was obtained in 49% yield.  
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Scheme 66. Synthesis of N-1 functionalized 5,7-dihydrofuro[3,4-d]pyrimidine-2,4-diones 
The synthesis of the N-1 glycosylated tetrahydrofuro[3,4-d]pyrimidine-2,4-dione 325 under Vörbruggen 
reaction conditions was accompanied by the formation of many side products, and the desired 
compound 325 was obtained in only 3% yield over two steps as two diastereomers 325a and 325b in 
a 1:1 ratio (Scheme 67). Hydrogenation of the N-1 glycosylated furo[3,4-d]pyrimidine-2,4-dione 314 
using five mole percent of rhodium on alumina in methanol for two days afforded product 325 in 42% 
yield as two diastereomers 325a and 325b in a 1:1 ratio. Due to the low-pressure (up to 5 bar) 
hydrogenator being unavailable for a long time, a balloon filled with hydrogen gas was used instead. 
The two isolated diastereomers 325a and 325b were obtained as colourless viscous oils, so their 
absolute stereochemistry could not be determined via X-ray diffraction spectroscopy.  
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Scheme 67. The synthesis of N-1 glycosylated tetrahydrofuro[3,4-d]pyrimidine-2,4-dione 325 via two different pathways 
The synthesis of the N-1 functionalized tetrahydrofuro[3,4-d]pyrimidine-2,4-dione 327 was also 
achieved via hydrogenation of the furan ring (Scheme 68). This time, the acylated furo[3,4-
d]pyrimidine analogue 315 was chosen as a precursor for 327 instead of the deprotected product. This 
approach allowed for a purification step by silica gel chromatography on the relatively apolar 
compound 326. Most of the impurities, which are formed in the first reaction step, could be removed 
on silica gel and the use of preparative HPLC, which consumes high volumes of HPLC-grade solvents, 
could be avoided to isolate the polar product 327. Compound 327 was isolated in 29% yield over two 
steps. The synthesis of this compound was also attempted under the reaction conditions as described 
by Sun and coworkers,
139
 but many side products were formed and the product could not be isolated 
from the reaction mixture. The same problem was observed when the synthesis of compound 328 was 
attempted under the reaction conditions as reported by Sun et al. However, treatment of 
tetrahydrofuro[3,4-d]pyrimidine-2,4-dione 323 with sodium hydride in DMF at room temperature for 
fifteen minutes and subsequent reaction with chloromethyl ethyl ether resulted in a smaller but still 
significant amount of side products, and product 328 was obtained in 11% yield.  
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Scheme 68. The synthesis of N-1 functionalized tetrahydrofuro[3,4-d]pyrimidine-2,4-diones 327 and 328 
Compound 327 was obtained in the form of white crystals, and its absolute configuration was 
determined via X-ray diffraction spectrometry (Figure 15). The crystals contained the two cis-isomers 
in a 1:1 ratio. One cis-isomer has C1 (R) and C4 (S) stereochemistry, the other one has C1 (S) and C4 
(R).  
 
Figure 15. Structure of the C1 (R) C4 (S) stereoisomer of N-1 functionalized tetrahydrofuro[3,4-d]pyrimidine-2,4-dione 327. 
Thermal displacement ellipsoids are shown at the 50% probability level. 
1.7 Conclusions 
In summary, a straightforward synthetic route was developed to synthesize the furo[3,4-d]pyrimidine-
2,4-dione scaffold, using a Curtius rearrangement as the key step. Attempts to convert these 
furopyrimidinones into the desired furo[3,4-d]pyrimidines were not successful, due to the reactivity of 
the furan ring towards undesired side product formation upon treatment with phosphorus oxychloride. 
Instead, the furo[3,4-d]pyrimidine-2,4-diones were further explored and developed by functionalization 
of the N-3 and N-1 nitrogen atoms. Hydrogenation of the furan ring of the furo[3,4-d]pyrimidine-2,4-
diones gave access to the 5,7-dihydrofuro[3,4-d]pyrimidine-2,4-diones and the tetrahydrofuro[3,4-
d]pyrimidine-2,4-diones. This resulted in the construction of a library of 45 compounds.  
Parts of this chapter have been published in the journal Synthesis.
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2 Synthesis of oxazolo[4,5-d]pyrimidines and oxazolo[5,4-
d]pyrimidines 
The proposed pathway for the synthesis of oxazolo[4,5-d]pyrimidine and oxazolo[5,4-d]pyrimidine 
analogues was based on the successfully developed pathway towards furo[3,4-d]pyrimidine 
analogues. Synthesis of the furo[3,4-d]pyrimidine pathway started from commercially available dialkyl 
furan-3,4-dicarboxylate and was followed by the hydrolysis of one of the two ester groups to give the 
monocarboxylic acid. This hydrolysis step did not need to be selective for the C-3 methyl ester over 
the C-4 methyl ester due to the symmetry of the starting material. However, dialkyl oxazole-4,5-
dicarboxylates are asymmetric and conversion of one of the ester groups to a monocarboxylic acid 
should be selective for either position 4 or 5 to avoid the formation of isomers. Thus, starting from 
dialkyl ester 329, a chemoselective transformation step should give the mono-acid 330 or 334 
(Scheme 69). A Curtius rearrangement on the carboxylic acid would then give the corresponding 
isocyanate, which would afford ureid compounds 332 or 336 upon reaction with an appropriate amine. 
Ring closure of the ureid structures would then result in the oxazolo[4,5-d]pyrimidine-5,7-diones 333 or 
oxazolo[5,4-d]pyrimidine-5,7-diones 337, respectively. Chlorination of these scaffolds by phosphorus 
oxychloride and further modification could then give synthetic access to the C2/C4-substituted 
oxazolo[4,5-d]pyrimidines and oxazolo[5,4-d]pyrimidines.
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Scheme 69. Proposed synthetic pathways towards oxazolo[4,5-d]pyrimidine analogues (top) and oxazolo[5,4-d]pyrimidine 
analogues (bottom) 
2.1 Synthesis of the monocarboxylic acid precursors for the Curtius 
rearrangement reaction 
In order to accomplish the chemoselective conversion of either the C-4 or C-5 ester group to a 
carboxylic acid, R
1
 should be different from R
2
 in structure 329. In the literature, the synthesis of 
dimethyl- and diethyl oxazole-4,5-dicarboxylate was already described, and one of the reported 
methods seemed likely to be able to deliver the desired esters (with R
1 
≠ R
2
) after appropriate 
adjustments.
142–145
 Indeed, following the reported protocol of Henneke et al., reaction of commercially 
available ethyl 2-chloro-2-oxoacetate 339a, imidazole, triethylamine and commercially available methyl 
isocyanoacetate 338a afforded 5-ethyl 4-methyl oxazole-4,5-dicarboxylate 340a in 79% yield (Scheme 
70).
145
 Isopropyl 2-chloro-2-oxoacetate 339b and tert-butyl 2-chloro-2-oxoacetate 339c were easily 
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prepared by reacting oxalyl chloride with isopropanol and tert-butanol, respectively.
146,147
 Reaction of 
these alkyl 2-chloro-2-oxoacetate products with methyl isocyanoacetate gave 5-isopropyl 4-methyl 
oxazole-4,5-dicarboxylate 340b and 4-methyl 5-tert-butyl oxazole-4,5-dicarboxylate 340c in very good 
yields. Reaction of both commercially available methyl 2-chloro-2-oxoacetate 339d and tert-butyl 
isocyanoacetate 338d afforded 5-methyl 4-tert-butyl oxazole-4,5-dicarboxylate 340d in 87% yield.  
 
Scheme 70. Synthesis of dialkyl oxazole-4,5-dicarboxylates 
First, the chemoselective conversion of compound 340a, bearing a methyl and ethyl ester group, was 
investigated. The use of this compound would be cheaper and more atom-economical than the use of 
the respective isopropyl or tert-butyl ester molecules 340b-c. When compound 340a was reacted with 
one equivalent of lithium hydroxide in THF-H2O, no full selectivity was observed but the methyl ester 
342 was formed predominantly (Scheme 71, Table 9, entry 1). Attempts to separate compound 342 
from 341 were not successful. A selective system, using cyanide in hexamethylphosphoric triamide 
(HMPT) as a solvent, was reported by Müller and Siegfried.
148
 Under these reaction conditions, no full 
selectivity was observed either, but this time the ethyl ester turned out to be the major reaction product 
(entry 2). In a last experiment, HMPT was replaced by DMF for two reasons. First of all, HMPT is 
suspected of being carcinogenic, and secondly it is more difficult to remove during work-up than 
DMF.
149
 In DMF, the reaction proceeded more slowly and less selectively compared to HMPT. 
Unfortunately, monocarboxylic acid 341 could not be separated from 342 in any of the experiments. In 
order to obtain either compound 341 or 342 in its pure form, a conversion method with complete 
chemoselectivity was required.  
 
Scheme 71. Conversion of diester 340a into a monocarboxylic acid 
Table 9. Reaction conditions of the conversion of diester 340a into a monocarboxylic acid 
Entry Reagent Solvent T (°C) t (h) Ratio 340a:341:342
a 
1 LiOH (1 eq.) THF:H2O (7:4) 0 °C to r.t. 1 5:19:76 
2 KCN (1.4 eq.) HMPT 75 62 7:90:3 
3 KCN (2.1 eq.) DMF 75 64 15:80:5 
a
: Product ratios were estimated by LC-MS 
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No complete discrimination between the ethyl and methyl ester group could be achieved and 
therefore, the next experiment was carried out on the tert-butyl ester 340c (Scheme 72). The 
chemoselective base-catalyzed hydrolysis of a methyl ester function in the presence of a tert-butyl 
ester group has already been described by White et al.
150
 When these reaction conditions were 
applied to the hydrolysis of 340c, a complete and fully selective conversion towards lithium salt 343 
was observed after one hour. Unfortunately, all attempts to isolate compound 343 in its free acid form 
were unsuccessful due to a very high instability of the tert-butyl ester group by acidification. Therefore, 
the subsequent Curtius rearrangement was attempted on the lithium carboxylate salt 343 (vide infra), 
which was isolated in 86% yield. To anticipate on solubility problems of this lithium salt, the synthesis 
of the cesium salt was also considered in order to improve its solubility.
151
 Reaction of 340c with one 
equivalent of cesium hydroxide in THF:H2O gave a complete and full conversion to cesium 5-(tert-
butoxycarbonyl)oxazole-4-carboxylate after one hour. However, the extreme hygroscopic nature of the 
obtained cesium salt made it very difficult to isolate the salt as a water-free compound, and the 
presence of water during the Curtius rearrangement would be problematic.   
 
Scheme 72. Chemoselective hydrolysis of diester 340c using lithium hydroxide 
The lithium 5-(tert-butoxycarbonyl)oxazole-4-carboxylate 343 was used to perform a Curtius 
rearrangement towards ureid compound 344 (Scheme 73). The reaction conditions for the Curtius 
rearrangement, which were previously used for the synthesis of furo[3,4-d]pyrimidine-2,4-diones, were 
slightly adjusted. Due to the limited solubility of the lithium salt 343 in the reaction mixture, the reaction 
time of the first step was extended to twelve hours. Molecular sieves were added to the reaction 
mixture to capture any water originating from the hygroscopic lithium salt. Then, the mixture was 
heated at 75 °C for three hours. A successful Curtius rearrangement is characterized by the evolution 
of gas bubbles in this step, but no clear formation of gas bubbles was observed during this stage. Two 
equivalents of 4-methoxybenzylamine were added, and after stirring for two hours at room 
temperature, LC-MS analysis showed that no conversion of starting material had occurred. One 
possible explanation for this observation could be the very poor solubility of the lithium salt in the 
reaction mixture. Therefore, toluene was replaced by DMF as a solvent in a next attempt. In DMF, the 
solubility of the lithium salt was much better, and the reaction time of the first step was reduced again 
to its usual value of one hour (Scheme 73). During the heating step, no evolution of gas bubbles was 
observed again. After addition of the amine and stirring at room temperature, LC-MS analysis showed 
that a complex reaction mixture had formed in which no starting material was present anymore. Based 
on these results, the lithium salt was considered as an inappropriate starting material for the Curtius 
rearrangement, and the focus turned again towards acquiring the monocarboxylic acid.  
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Scheme 73. Attempts to perform a Curtius rearrangement on lithium salt 343 
A possible solution to obtain the monocarboxylic acid could be the replacement of the tert-butyl ester 
group by an isopropyl ester function, as the latter is expected to be more stable against acidification. 
When isopropyl ester 340b was reacted with one equivalent of lithium hydroxide, complete 
chemoselectivity was observed again and lithium 5-isopropyloxazole-4-carboxylate 345 was obtained 
in 90% yield (Scheme 74). Unfortunately, all attempts to isolate compound 345 in its free acid form 
were unsuccessful, due to the instability of the isopropyl ester group during acidification.  
 
Scheme 74. Chemoselective hydrolysis of diester 340b using lithium hydroxide 
The observed instability of the tert-butyl group against acidification forms the basis for the well-known 
acidic deprotection of the BOC protecting group.
152
 Therefore, the acid mediated deprotection of the 
tert-butyl ester group was attempted. Reaction of the tert-butyl ester 340c or 340d with an excess of 
trifluoroacetic acid and 2.5 equivalents of triethylsilane afforded the corresponding monocarboxylic 
acid 342 or 341, respectively, in nearly quantitative yields (Scheme 75).
153
  
 
Scheme 75. TFA-mediated deprotection of tert-butyl esters 340c and 340d 
2.2 Evaluation of the Curtius rearrangement reaction 
With the free monocarboxylic acids 342 and 341 in hand, the Curtius rearrangement was attempted 
again. Following the usual protocol, 342 and 341 were first reacted with diphenyl phosphoryl azide and 
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triethylamine at room temperature for one hour and then heated at 75 °C for three hours to affect the 
rearrangement (Scheme 76). No evolution of gas bubbles was observed during the heating step. 
Twenty minutes after addition of the amine to the reaction mixture, LC-MS analysis showed the 
presence of the starting materials 342 or 341, unreacted DPPA and unidentified side products. In both 
reactions, formation of the desired ureids 346 or 347 could not be detected. Therefore, the course of 
this reaction was studied in more detail.  
 
Scheme 76. The Curtius on monocarboxylic acids 342 and 341 was unsuccessful 
In dichloromethane instead of toluene, 4-(methoxycarbonyl)oxazole-5-carboxylic acid did not react 
with diphenyl phosphoryl azide after one hour at room temperature and after one hour at 50 °C (Table 
10, entry 1). Heating of the reaction mixture at 75 °C for twelve hours resulted in formation of a 
complex reaction mixture. The carboxylic acid was consumed, and only a trace of DPPA was still 
present. After addition of 4-methoxybenzylamine, the desired ureid could not be detected in the 
reaction mixture. Replacing the combination of triethylamine and dichloromethane by pyridine gave a 
very similar course of the reaction (entry 2). At room temperature and 50 °C, no reaction was 
observed. Heating at 75 °C for  twelve hours resulted in consumption of the carboxylic acid and the 
majority of DPPA, and formation of a complex reaction mixture. After addition of the amine, formation 
of the desired ureid was not observed. This was in contrast to the reference reaction of 4-
(methoxycarbonyl)furan-3-carboxylic acid in toluene, which reacted smoothly with DPPA at room 
temperature (entry 3). After heating at 75 °C for twelve hours and addition of the amine, a successful 
formation of the desired ureid was observed. The reaction of the furan starting material with DPPA 
also proceeded very well in acetonitrile as a solvent at room temperature (entry 4), while 4-
(methoxycarbonyl)oxazole-5-carboxylic acid failed to react under these conditions (entry 5). Thus, no 
reaction occurred at room temperature or at 50 °C, while heating of the reaction mixture at 75 °C lead 
to undesired reactions (entries 1, 2 and 5). The onset temperature of the thermal degradation of neat 
DPPA is reported to be around 270 °C.
154
 Therefore, thermal degradation of DPPA is not expected to 
cause the undesired reactions at 75 °C. However, the thermal ring-opening of certain oxazoles has 
been reported in the literature at 95 °C.
155
 This could be a possible explanation for the occurrence of 
side reactions at elevated temperature. Besides thermal ring-opening, base-induced ring-opening of 
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the oxazole could also take place. Vedejs and Monahan reported a method to prevent base-induced 
ring opening of oxazoles by treatment with a Lewis acid.
156
 Thus, one equivalent of borane-THF 
complex was added to the reaction at room temperature, and the temperature was then raised to 75 
°C for two hours (entry 5). Unfortunately, these reaction conditions also lead to formation of a complex 
mixture, and after addition of the amine, the desired ureid could not be detected.  
Table 10. Study on the reaction of monocarboxylic acid starting materials with DPPA and the subsequent Curtius 
rearrangement. The reactions were monitored by TLC and LC-MS analysis. 
Entry Starting 
material 
Reagents Solvent T 
(°C) 
t (h) Results 
1 
 
DPPA (1 eq.) 
Et3N (1.4 eq.) 
CH2Cl2 r.t. 1 No reaction
 
    50 1 No reaction
 
    75 12 Starting materials consumed, 
formation of complex RM
 
  PMB-NH2 (2 eq.)  r.t. 1 No target detected, complex RM 
2  DPPA (1 eq.) Pyridine r.t. 1 No reaction
 
    50 1 No reaction
 
    75 12 Starting materials consumed, 
formation of complex RM
 
  PMB-NH2 (2 eq.)  r.t. 1 No target detected, complex RM 
3 
 
DPPA (1 eq.) 
Et3N (1.4 eq.) 
Toluene r.t. 1 Full conversion of starting 
materials 
    75 12  
  PMB-NH2 (2 eq.)  r.t. 1 Successful reaction 
4  DPPA (1 eq.) 
Et3N (1.4 eq.) 
CH3CN r.t. 1 Full conversion of starting 
materials 
5 
 
DPPA (1 eq.) 
Et3N (1.4 eq.) 
CH3CN r.t. 1 No reaction 
     4 No reaction 
  BH3-THF (1 eq.)  75 2 Starting materials consumed, 
formation of complex RM
 
  PMB-NH2 (2 eq.)  r.t. 12 No target detected, complex RM 
 
From the experiments which have been described in Table 10, it was not clear if 4-
(methoxycarbonyl)oxazole-5-carboxylic acid reacted with diphenyl phosphoryl azide at 75 °C to give 
the intermediate acyl azide or not. Therefore, the synthesis of the acyl azide was attempted via the 
classic two-step pathway, i.e. conversion of the carboxylic acid to the acyl chloride, followed by 
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substitution of the chloride by reaction with sodium azide.
157
 When oxazole 342 was treated with a 
small excess of oxalyl chloride and a catalytic amount of DMF at room temperature for one hour, the 
acyl chloride 348 was obtained (Scheme 77). TLC and 
1
H- and 
13
C-NMR analysis proved a successful 
reaction, and the crude acyl chloride was used for the next step. The crude acyl chloride 348 was then 
reacted with aqueous sodium azide in acetone at 0 °C for one hour, giving the crude acyl azide 349 in 
86% yield after aqueous work-up. Again, the crude product was used for the next step, after TLC and 
1
H- and 
13
C-NMR analysis showed that the acyl azide was formed in high purity. The crude acyl azide 
was dissolved in dry toluene and heated at 75 °C. TLC analysis showed full conversion of the azide 
after two hours. Several new spots were observed on TLC, but this could be due to reaction with 
atmospheric moisture or instability of the azide on silica. The reaction was cooled down and two 
equivalents of either 3,4,5-trimethoxybenzylamine or 2,4,5-trimethoxybenzylamine were added to the 
reaction. LC-MS analysis showed formation of a complex reaction mixture in both cases. Only a trace 
of the desired ureids 350 could be detected.  
 
Scheme 77. The Curtius rearrangement of 4-(methoxycarbonyl)oxazole-5-carboxylic acid was not successful 
2.3 Synthesis of the monocarboxamide precursors for the Hofmann 
rearrangement reaction 
A Hofmann rearrangement, induced by a hypervalent iodine reagent, was chosen to replace the 
unsuccessful Curtius rearrangement for two reasons. First, this type of Hofmann rearrangement can 
be performed at room temperature. Secondly, the reaction typically does not require addition of a 
base.
158–160
 These mild conditions could avoid the occurrence of the undesired side reactions which 
were observed during the Curtius rearrangement. However, the Hofmann rearrangement converts a 
primary amide and not a carboxylic acid group to an isocyanate. Therefore, the primary amides had to 
be synthesized first. Aminolysis of 5-(tert-butyl) 4-methyl oxazole-4,5-dicarboxylate 340c with 
ammonia in methanol at 0 °C resulted in formation of both amides 351 and 352 and the diamide 353, 
as expected (Scheme 78). Using one equivalent of ammonia, no reaction was observed after one hour 
at 0 °C. Then, a large excess (approximately 30 equivalents) of ammonia was added. After 40 minutes 
at 0 °C, mainly starting material was present, next to both mono-amides and the diamide.  
65 
 
 
Scheme 78. Aminolysis of 5-(tert-butyl) 4-methyl oxazole-4,5-dicarboxylate did not proceed chemoselectively 
Reaction of the acyl chloride 348 with ammonia in dichloromethane gave the desired amide 351 in 
37% yield over two steps, next to unidentified side products (Scheme 79). Formation of the diamide 
was not observed. Pellegata and coworkers reported a mild method to convert acyl chlorides to 
primary carboxamides by using hexamethyldisilazane as a synthetic equivalent of ammonia.
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Treatment of the acyl chloride 348 with three equivalents of hexamethyldisilazane in dichloromethane 
gave the crude mono-trimethylsilyl protected amide 354, which was subsequently fully deprotected by 
treatment with trifluoroacetic acid in dichloromethane. The primary amide 351 was obtained in 88% 
yield over three steps.  
 
Scheme 79. Synthesis of methyl 5-carbamoyloxazole-4-carboxylate 351 
The synthesis of methyl 4-carbamoyloxazole-5-carboxylate was attempted following the same method 
as described above. Remarkably, hexamethyldisilazane failed to react with the acyl chloride. 
Theodorou and coworkers described a method to prepare primary amides from acyl chlorides by 
reaction with tritylamine as a synthetic equivalent of ammonia.
162
 Treatment of 5-
(methoxycarbonyl)oxazole-4-carboxylic acid 341 with an excess of oxalyl chloride and a catalytic 
amount of DMF afforded the crude acyl chloride 355 (Scheme 80). Reaction of this acyl chloride with 
one equivalent of tritylamine and an excess of triethylamine afforded the trityl-protected amide 356 in 
79% yield over two steps. Deprotection of the amide using triethylsilane as a cation scavenger in a 
mixture of TFA and dichloromethane gave methyl 4-carbamoyloxazole-5-carboxylate 357 in 81% yield.  
 
Scheme 80. Synthesis of methyl 4-carbamoyloxazole-5-carboxylate 357 
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2.4 Evaluation of the Hofmann rearrangement reaction towards oxazolo[5,4-
d]pyrimidines 
With the primary amides in hand, the hypervalent iodine-mediated Hofmann rearrangement could now 
be investigated. The most commonly employed hypervalent iodine reagents are the organoiodine(III) 
compounds (diacetoxyiodo)benzene [PhI(OAc)2] 358, [bis(trifluoroacetoxy)iodo]benzene 
[PhI(OCOCF3)2] 359, iodosylbenzene (PhIO) 360 and (tosylimino)phenyl-λ
3
-iodane (PhINTs) 361 
(Figure 16).
160
 The proposed reaction mechanism is depicted in Scheme 81. The primary carboxamide 
351 first substitutes one of the ligands of the hypervalent iodine reagent, to give the intermediate N-
(phenyl-λ
3
-iodanyl)carboxamide 363. The following step is a reductive elimination of iodobenzene, 
resulting in the nitrenium species 364. This reactive intermediate then undergoes a 1,2-aryl shift to 
afford the isocyanate 365, which can be treated with an appropriate amine to give the final ureids 350. 
Whether the nitrenium species is actually formed or the reductive elimination and 1,2-aryl shift proceed 
in a concerted fashion remains a matter of debate.
158,163–167
 
 
 
Figure 16. Typical hypervalent iodine reagents used in the Hofmann rearrangement 
 
Scheme 81. Proposed mechanism of the transformation of primary carboxamide 351 to its corresponding N-3 substituted ureid 
350 
An initial qualitative screening was performed, using different amines and hypervalent iodine reagents 
(Scheme 82, Table 11). Reaction of carboxamide 351 with 1.5 equivalents of propylamine and 1.5 
equivalents of iodosylbenzene for two hours at room temperature gave a relatively clean conversion to 
the desired ureid 350 (entry 1). Under the same reaction conditions, the more sterically hindered 
cyclohexylamine gave nearly identical results (entry 2). When benzylamine was used under these 
conditions, unreacted starting material 351 was present next to the ureid 350 in a one-to-one ratio 
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(entry 3). One of the observed side products was imine 366, resulting from oxidation of benzylamine 
(Figure 17). The oxidation of amines with hypervalent iodine reagents has been described in the 
literature.
168–170
 However, the release of water by iodosylbenzene during the Hofmann rearrangement 
requires the concurrent presence of the iodine reagent and the amine to avoid addition of water to the 
isocyanate. When 3,4,5-trimethoxybenzylamine was used (entry 4), a large peak of imine 367 (Figure 
17) was detected, and formation of the desired ureid was not observed. The use of PhINTs was 
reported by Yoshimura and coworkers as a mild reagent which allowed the transformation of 
substituted benzamides to their respective isocyanates.
171
 Unfortunately, the use of this iodine reagent 
resulted only in the formation of many side products, and the desired ureid could not be detected 
(entry 5). When (diacetoxyiodo)benzene was reacted with carboxamide for two hours, followed by 
addition of benzylamine, a minor amount of starting material was observed in the reaction mixture after 
one hour, next to a major amount of the desired ureid and different side products (entry 6). Stirring the 
reaction further overnight did not result in any significant changes of the reaction mixture. When 
[bis(trifluoroacetoxy)iodo]benzene was used under the same reaction conditions, a large amount of 
unreacted starting material remained in the reaction mixture, next to different side products (entry 7). 
Formation of ureid 350 was not observed.  
Based on this initial screening, iodosylbenzene proved a suitable reagent for the Hofmann 
rearrangement in the presence of amines that are relatively inactive towards oxidation. The use of 
(tosylimino)phenyl-λ
3
-iodane or [bis(trifluoroacetoxy)iodo]benzene did not give the desired ureid and 
these reagents were abandoned from further study. The use of (diacetoxyiodo)benzene looked 
promising but still required reaction optimization. 
 
Scheme 82. Transformation of carboxamide 351 to ureid 350 via a Hofmann rearrangement 
Table 11. Initial screening of the hypervalent iodine-mediated Hofmann rearrangement 
Entry Reagent (eq.) Amine (eq.) t (h) Results 
1 PhIO (1.5) n-Pr-NH2 (1.5) 2 350 (major) + side products (minor) 
2 PhIO (1.5) c-Hex-NH2 (1.5) 2 350 (major) + side products (minor) 
3 PhIO (1.5) Bn-NH2 (1.5) 2 351:350 (1:1) + side products 
4 PhIO (1.5) 3,4,5-(MeO)3-
C6H2CH2NH2 (1.5) 
2 Conversion to side products, no 350 
detected 
5 PhINTs (1.2) n-Pr-NH2 (1.5)
a 
0.5 351 (minor) + side products (major), 
no 350 detected 
6 PhI(OAc)2 (1.5) Bn-NH2 (1.5)
b
 1 351 (minor) + 350 (major) + side 
products (major) 
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7 PhI(OCOCF3)2 
(1.5) 
Bn-NH2 (1.5)
b
 1 351 (major) + side products (minor), 
no 350 detected 
a/b
: amine was added after 1.5 h
a
 or 2 h
b
 of reaction time between the carboxamide and the iodine 
reagent. 
 
Figure 17. Side products observed during the Hofmann rearrangement experiments 
Next, iodosylbenzene and (diacetoxyiodo)benzene were used to construct a small series of ureids 350 
(Scheme 83). For (diacetoxyiodo)benzene, a small optimization study was done with isopropylamine 
and the following reaction conditions were found to give the most satisfactory results: reacting 
carboxamide 351 with three equivalents of (diacetoxyiodo)benzene in dichloromethane for two hours 
at room temperature, followed by addition of six equivalents of isopropylamine and continued stirring 
for twelve hours. For n-propyl, n-butyl and isopropyl, the use of (diacetoxyiodo)benzene gave similar 
results as the use of iodosylbenzene, and the desired ureids 350a-c were obtained in 52-65% yield 
(Table 12, entry 1-6). For benzyl derivative 350d, the amount of both iodosylbenzene and benzylamine 
was increased to three equivalents, in an attempt to increase the conversion of the carboxamide 351 
(entry 7). Unfortunately, the conversion of starting material was incomplete and 351 was still present in 
a 3:7 ratio to the ureid 350d, next to various side products. This resulted in a low isolated yield of 18%. 
The reaction with (diacetoxyiodo)benzene was adjusted as well (entry 8). First, the carboxamide 351 
was refluxed with six equivalents of (diacetoxyiodo)benzene for two and a half hours to convert all of 
the carboxamide to the isocyanate. Then, the mixture was cooled down to 0 °C and six equivalents of 
benzylamine were added. The reaction was allowed to warm up to room temperature and continued 
stirring for twelve hours. After purification, the ureid 350d was obtained in 15% yield. The low yield 
could be explained by (oxidative) side reactions. Based on these reactions, the use of iodosylbenzene 
did not give a clear advantage over the use of (diacetoxyiodo)benzene, and since it is a potentially 
explosive compound, (diacetoxyiodo)benzene was preferred for further reactions.
172
 The isobutyl and 
cyclohexyl derivatives 350e and 350f were synthesized using (diacetoxyiodo)benzene and were 
obtained in 51 and 63% yield, respectively (entry 9-10). The cyclopropyl ureid 350g was isolated in 
only 19% yield after a difficult purification (entry 11). When tert-butylamine or tritylamine were used 
under the typical reaction conditions for (diacetoxyiodo)benzene (cfr. entry 2), oxidative degradation of 
the ureid product by the excess amount of oxidant was observed. This degradation process could be 
halted by adding a quenching agent or a sacrificial agent such as isopropylamine to the reaction. For 
tritylamine, the same reaction conditions were used as for benzylamine, except that the reaction was 
kept at 0 °C after addition of tritylamine and quenched by aqueous sodium thiosulfate after half an 
hour (entry 12). Despite these efforts, a significant amount of side products were formed and the 
desired ureid 350h was isolated in 31% yield. Compound 350h could be deprotected by treatment with 
trifluoroacetic acid and triethylsilane, affording ureid 350i in 82% yield.  
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Scheme 83. Synthesis of ureids 350 via a Hofmann rearrangement on carboxamides 351, and deprotection of 350h into 350i 
Table 12. Synthesis of ureid compounds 350 via a Hofmann rearrangement on carboxamide 351. All reactions were conducted 
in dichloromethane and at room temperature, unless mentioned otherwise 
Entry Reagent (eq.)  Amine  (eq.) Addition of amine t (h) Yield (%) 
1 PhIO 1.5 n-Pr-NH2 1.5 At start 2 63 
2 PhI(OAc)2 3 n-Pr-NH2 6 After 2 h, at r.t. 12 58 
3 PhIO 1.5 n-Bu-NH2 1.5 At start 12 56 
4 PhI(OAc)2 3 n-Bu-NH2 6 After 2 h, at r.t. 12 56 
5 PhIO 1.5 i-Pr-NH2 1.5 At start 12 52 
6 PhI(OAc)2 3 i-Pr-NH2 6 After 2 h, at r.t. 1 65 
7 PhIO 3 Bn-NH2 3 At start 12 18 
8 PhI(OAc)2 6 Bn-NH2 6 After 2.5h reflux, at 0 °C 12 15 
9 PhI(OAc)2 3 i-Bu-NH2 6 After 2 h, at r.t. 12 51 
10 PhI(OAc)2 3 c-Hexyl-NH2 6 After 2 h, at r.t. 12 63 
11 PhI(OAc)2 3 c-Pr-NH2 6 After 2 h, at r.t. 12 19 
12 PhI(OAc)2 6 (Ph)3CNH2 6 After 2.5h reflux, at 0 °C 0.5
a 
31 
  a
: Reaction at 0 °C, followed by sat. aq. NaHSO3 quench. 
2.5 Synthesis of oxazolo[5,4-d]pyrimidines via ring closure of the ureid 
precursors 
The final step, ring closure of the ureids 350 to the oxazolo[5,4-d]pyrimidine-5,7-diones 337, was 
effectuated by reaction with 2.9 equivalents of sodium methoxide in methanol at room temperature 
(Scheme 84). The reaction proceeded very slowly, and full conversion was observed after fifteen 
(337e) or twenty-seven (337a-d) days of stirring at room temperature. The oxazolo[5,4-d]pyrimidine-
5,7-diones were isolated in 33-53% yield. The low to moderate yields can be explained by formation of 
side products, and losses during isolation of the products. The ureids bearing an isopropyl, cyclohexyl, 
cyclopropyl or trityl group failed to ring-close under these reaction conditions, most likely due to steric 
hindrance. When the temperature of this reaction was raised to 50 °C, more side products were 
formed in general, and no ring closure was observed for the sterically hindered derivatives.  
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Scheme 84. Ring closure of ureid structures 350 afforded oxazolo[5,4-d]pyrimidine-5,7-diones 337 
Other reaction conditions were screened in order to improve the ring closure reaction of ureids 350 
(Table 13). The use of lithium hexamethyldisilazide resulted in the formation of side products, and the 
desired ring structure was not detected (entry 1). The use of potassium tert-butoxide could not induce 
the ring closure either (entry 2). Next to the remaining starting material, only side products were 
formed. Sodium hydride did not give any conversion in tetrahydrofuran as a solvent (entry 3). When 
N,N-dimethylformamide was added to the reaction, the ureid started to convert only to side products. 
When the ureid was heated in the microwave reactor in acetonitrile at 100 °C for twelve hours, no 
conversion was observed (entry 4). Heating the ureid in DMF at 160 °C for fifteen minutes in the 
microwave reactor resulted in side product formation (entry 5). Treatment with two and a half 
equivalents of lithium diisopropylamide at – 78 °C did not give any conversion at first, but when the 
reaction was allowed to warm up to room temperature, full conversion to side products occurred (entry 
6). An attempt was made to achieve ring closure with a catalytic amount of sodium methoxide in 
methanol (entry 7). After two hours at 70 °C in the microwave reactor, mainly starting material was 
present, next to the desired ring structure and side products. The experiment was not continued due to 
the increased formation of side products compared to the reaction at room temperature. Next, the 
sodium methoxide-methanol system was evaluated for ring closure of the sterically hindered 
isopropylureid 350c. Treatment with one, two or four equivalents of sodium methoxide in methanol at 
70 °C for one hour and fifteen minutes resulted in an incomplete conversion to side products and a 
trace amount of the desired ring structure 337 (entry 8-10). The use of potassium tert-butoxide in tert-
butanol gave inferior results compared to the sodium methoxide-methanol system, as no formation of 
the ring structure was observed (entry 11). In DMSO as a solvent, a large amount of side products 
was formed after half an hour at 85 °C in the microwave reactor, without formation of the ring structure 
(entry 12). In DMF as a solvent, not much conversion was observed under these reaction conditions 
(entry 13). Finally, some acid-catalyzed reaction conditions were tested.
173,174
  Heating of the ureid in 
concentrated hydrochloric acid at 100 °C for two minutes gave full conversion to (chlorine-containing) 
side products (entry 14). In a mixture of ethanol and aqueous concentrated hydrochloric acid, 
complete conversion to (chlorine-containing) side products was seen after half an hour at 100 °C in a 
microwave reactor (entry 15).  
Table 13. Reaction conditions screening for the ring closure of ureids 350 
Entry Ureid Reagent (eq.) Solvent T (°C) t (h) Results 
1 350a  
(R = n-Pr) 
LiHMDS (1.1) THF 0 1 Starting material + 
side products 
  (+ 1.1)  r.t. 1.5 Full conversion to side 
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products 
2  KOt-Bu (1.1) THF 0 1 Starting material + 
side products 
  (+ 1.1)  r.t. 12 Starting material + 
side products 
3  NaH (1.1) THF 0 1 No conversion 
  (+ 1.1)  r.t. 12 No conversion 
   + DMF 
(THF:DMF, 1:2) 
r.t. 12 Starting material + 
side products 
4  No reagent CH3CN 100 (µW) 12 No conversion 
5  No reagent DMF 160 0.25 Starting material + 
side products 
6  LDA (2.5) THF -78 0.5 No conversion 
    r.t. 1 Full conversion to side 
products 
7 350d  
(R = Bn) 
NaOMe (0.1) MeOH 70 (µW) 2 350d (major) + 337d 
(minor) + side 
products (minor) 
8 350c 
(R = i-Pr) 
NaOMe (1) MeOH 70 1.25 Starting material 
(major) + side 
products (minor) + 
337 (trace) 
9  NaOMe (2) MeOH 70 1.25 Starting material 
(major) + side 
products (minor) + 
337 (trace) 
10  NaOMe (4) MeOH 70 1.25 Starting material 
(major) + side 
products (minor) + 
337 (trace) 
11  KOt-Bu (1) tert-BuOH 70 1.25 Starting material + 
side products 
12  NaOMe (1) DMSO 85 (µW) 0.5 Starting material + 
side products 
13  NaOMe DMF 85 (µW) 0.5 No conversion 
  (+ 1)  85 (µW) 1 No conversion 
14  Conc. HCl (15) Neat 100 2 min.  Conversion to side 
products 
15  Conc. HCl (15) EtOH 100 (µW) 0.5 Conversion to side 
products 
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Based on this screening of reaction conditions and on the preceding ring closure experiments, it was 
concluded that the use of sodium methoxide in methanol at room temperature was the best system to 
ring-close the ureids 350 to the oxazolo[5,4-d]pyrimidine-5,7-diones 337, although it was characterized 
by very long reaction times. Heating of the reaction mixture could increase the reaction speed, but also 
gave rise to the formation of side products which greatly impeded the purification of the final ring 
closed compounds.  
When side products were formed during the ring closure attempts of n-propylureid 350a and 
isopropylureid 350c, very frequently an LC-MS peak with the same m/z value as the ureid starting 
material was detected among the side product peaks. Intrigued by this particular side product, it was 
isolated from one of the experiments and characterized by 
1
H- and 
13
C-NMR spectrometry. The NMR 
data suggested the isoureid structure 368 (Figure 18, left): one of the N-H proton signals has 
disappeared, while the remaining N-H proton couples with the C-H proton of the isopropyl group. 
Normally, the isoureid tautomer is less stable than the ureid form, but the possibility of intramolecular 
hydrogen bonding between the oxazole oxygen atom and the isoureid hydroxyl group could explain 
the stability of the isoureid (Figure 18, right).
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Figure 18. Suggested structure of an isolated side product after the attempted ring closure of isopropylureid (left) and possible 
intramolecular hydrogen bonding of this structure (right) 
An attempt was made to protect the nitrogen atom which is directly connected to the oxazole ring with 
a BOC protecting group. After BOC protection, the effect on the ring closure could then be 
investigated. However, treatment of the ureid 350a with 1.3 equivalents of both triethylamine and di-
tert-butyldicarbonate and a catalytic amount of DMAP unexpectedly afforded the BOC protected amine 
369 in 81% yield (Scheme 85).
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Scheme 85. DMAP-catalyzed reaction of ureid 350a with di-tert-butyldicarbonate afforded BOC-protected amine 369 
2.6 Evaluation of the Hofmann and Curtius rearrangement reaction towards 
oxazolo[4,5-d]pyrimidines 
The Hofmann rearrangement was also performed on methyl 4-carbamoyloxazole-5-carboxylate 357 in 
pursuit of the oxazolo[4,5-d]pyrimidine-5,7-dione isomers (Scheme 86, Table 14). Only the n-
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propylureid 370a was constructed due to time restraints. In this case, iodosylbenzene performed better 
than (diacetoxyiodo)benzene, and the ureid 370a was obtained in 85% yield and 61% yield, 
respectively. When the Hofmann rearrangement reaction was performed in a solution of 7M ammonia 
in methanol instead of dichloromethane, formation of the diamide was observed next to other minor 
side products (Table 14, entry 3 and 4). The desired ureid 370b was not formed in these reactions. 
Addition of another 1.5 equivalents of (diacetoxyiodo)benzene to the reaction (entry 4, after five hours) 
in an attempt to cyclize the diamide, did not result in formation of the ring-closed product.  
 
Scheme 86. Synthesis of ureid 370 via a Hofmann rearrangement on methyl 5-carbamoyloxazole-4-carboxylate 
Table 14. Reaction conditions and yields for the Hofmann rearrangement on carboxamide 357 
Entry Reagent (eq.)  RNH2 (eq.) Addition of amine t (h) Yield (%) 
1
a 
PhIO 1.5 n-PrNH2 (1.5) At start 2 85 
2
a 
PhI(OAc)2 3 n-PrNH2 (6) After 2 h, at r.t. 0.5 61 
3
b 
PhIO 1.5 NH3 (60) At start 5 / 
4
b 
PhI(OAc)2 1.5 NH3 (60) At start 5 / 
 
a
: Reaction in dichloromethane. 
b
: Reaction in methanol.  
The Curtius rearrangement was unsuccessful on 4-(methoxycarbonyl)oxazole-5-carboxylic acid (vide 
supra), but was still evaluated for its isomer 5-(methoxycarbonyl)oxazole-4-carboxylic acid, following 
the same synthetic protocol. Thus, carboxylic acid 341 was treated with a small excess of oxalyl 
chloride and a catalytic amount of DMF in dichloromethane at room temperature for one hour, 
affording the acyl chloride 371 (Scheme 87). The crude acyl chloride was then substituted by reaction 
with sodium azide, giving the acyl azide 372 in 92% yield over two steps. When this acyl azide was 
heated at 70 °C for one hour and fifteen minutes, TLC analysis showed complete conversion of the 
starting material. The reaction was cooled down to room temperature, and two equivalents of 3-
methoxybenzylamine were added. After twelve hours, LC-MS analysis of the reaction mixture showed 
that the desired ureid 370c was formed -next to a significant amount of side products- and was 
isolated in 35% yield. For the synthesis of ureid 370b, another approach was used in an attempt to 
increase the yield of the reaction. Carboxylic acid 341 and 1.1 equivalents of 1H-benzotriazole were 
suspended in dry toluene and heated to 70 °C. After a few minutes, the suspension turned into a clear 
solution and gas formation was observed. After 1.5 hours, the formation of gas had ceased and the 
solvent was evaporated to afford the crude ureid 370d as an off-white solid. The crude material was 
dissolved in a solution of 7M of ammonia in methanol (large excess of ammonia) and stirred at room 
temperature for fifteen minutes. Full conversion of 370d was observed, but product 370b could not be 
isolated and still contained residual 1H-benzotriazole a small amount of side products. The crude 
product was used for further reaction.  
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Scheme 87. Synthesis of ureids 370c and 370b via a Curtius rearrangement 
Different attempts were made to ring-close the ureids to their corresponding oxazolo[4,5-d]pyrimidine-
5,7-dione counterparts (Scheme 88). Ring closure of the ureids was attempted using the sodium 
methoxide-methanol system (Table 15, entry 1-2). Unfortunately, the reaction of 370 with 2.9 
equivalents of sodium methoxide in methanol afforded only side products after twelve hours of stirring 
(R = n-Pr) or sixty hours of stirring (R = 3-methoxybenzyl). When 1.1 equivalents of potassium tert-
butoxide were used as a base in tetrahydrofuran, no reaction occurred (entry 3). After an additional 1.1 
equivalents of potassium tert-butoxide were added and stirring continued for three days, small 
amounts of side products started to appear next to the unreacted starting material. Only traces of the 
desired ring-closed product could be detected. Subsequently, 1.1 equivalents of potassium 
hexamethyldisilazide (KHMDS) were added and stirring continued for one hour at room temperature. 
This resulted in an increase of the amount of side products, while unreacted starting material was still 
present. Finally, the use of one equivalent of sodium hydroxide (1M in H2O) in ethanol at 80 °C for two 
hours gave the desired ring closed product 333a in 6% yield (over three steps, from 372 to 333a).
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Significant improvements of the yield of this reaction may be possible on a larger scale and after 
optimization of the reaction conditions and the work-up protocol. Ureids 370a and 370c could not be 
obtained anymore with this method due to time constraints, but a trial with ureid 370a showed a large 
peak of the desired ring closed product in LC-MS, indicating that this ring closure protocol also works 
for this n-propylureid.  
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Scheme 88. Ring closure of ureids 370 towards the oxazolo[4,5-d]pyrimidine-5,7-diones 333 
Table 15. Attempts to ring-close the ureids 370 to the oxazolo[4,5-d]pyrimidine-5,7-diones 333 
Entry Ureid Reagent (eq.) Solvent T (°C) t (h) Results 
1 370a  
(R = n-Pr) 
NaOMe (2.9) MeOH r.t. 12 Full conversion to side products 
2 370c  
(R = 3-MeO-
C6H4CH2) 
NaOMe (2.9) MeOH r.t. 12 Starting material + side products 
     60 Full conversion to side products 
3 370a KOt-Bu (1.1) THF 0 °C 0.25 No conversion 
    0 °C 2 No conversion 
    r.t. 2.5 No conversion 
  (+1.1)  r.t. 72 Starting material + side products 
  + KHMDS (1.1)  r.t. 1 Starting material + side products 
4 370b NaOH (1M in 
H2O, 1 eq.) 
EtOH 80 2 333a, 6% isolated yield (from 
372 to 333a) 
2.7 Conclusions 
In conclusion, an efficient two-step pathway was developed towards 4-(methoxycarbonyl)oxazole-5-
carboxylic acid and 5-(methoxycarbonyl)oxazole-4-carboxylic acid. The conversion of these carboxylic 
acids to their corresponding ureids via a Curtius rearrangement was only achieved in the case of 5-
(methoxycarbonyl)oxazole-4-carboxylic acid, although in low yield. Both carboxylic acids were further 
transformed to their corresponding primary amides, methyl 5-carbamoyloxazole-4-carboxylate and 
methyl 4-carbamoyloxazole-5-carboxylate, via the intermediate acyl chlorides. A hypervalent iodine-
mediated Hofmann rearrangement on the primary amides then afforded the corresponding N-3 
substituted ureids in varying yields. The combination of oxidation-sensitive amines and the hypervalent 
iodine oxidant proved problematic, limiting the scope of this reaction. The oxazolo[5,4-d]pyrimidine-
5,7-dione scaffold and a handful of N-3 substituted derivatives could be obtained in low to moderate 
yields via ring closure of the corresponding ureids by treatment with sodium methoxide in methanol, 
except for sterically hindered ureids. The oxazolo[4,5-d]pyrimidine-5,7-dione scaffold could be 
obtained via ring closure of the corresponding ureid by treatment with aqueous sodium hydroxide in 
ethanol at elevated temperature, although in very low yield.  
  
76 
 
3 Synthesis of 2-amino-(5-tert-butyl)furan-3-carboxamide 
A pharmaceutical company requested the synthesis of a specific molecule to include it in one of their 
lead optimization campaigns. This molecule was 2-amino-(5-tert-butyl)furan-3-carboxamide 375 
(Figure 19). A literature search revealed that this compound had not been reported yet. A similarity 
search in the literature then gave the 3-carbonitrile analogue 376 as a closely related structure and 
possible precursor for the synthesis of 375.
178–182
 Unfortunately, none of the literature references 
described the synthesis of compound 376. The similarity search was extended and structures 377 and 
378, equipped with a phenyl and methyl substituent at the 5-position respectively, were found.
183,184
  
 
Figure 19. Target structure 375 and related molecules which were found in the literature 
According to Jun, reaction of α-chloroketone 379 with a slight excess of malononitrile and one 
equivalent of triethylamine in methanol afforded the 5-substituted-2-aminofuran-3-carbonitriles 380 in 
61-65% yield (Scheme 89, top).
183
 Bakavoli and coworkers used solvent-free conditions to synthesize 
the same structures. According to their work, grinding a mixture of α-chloroketone 379, one equivalent 
of malononitrile, three equivalents of diethylamine and an excess of silica in a mortar for 15 minutes 
afforded the desired products 380 in 60-80% yield (Scheme 89, bottom).
184
  
 
Scheme 89. Synthesis of 5-substituted-2-aminofuran-3-carbonitriles according to Jun (top) and Bakavoli and coworkers (bottom) 
3.1 Synthesis of 2-amino-5-(tert-butyl)furan-3-carbonitrile 
When 1-chloropinacolone was reacted with malononitrile under the reaction conditions of Jun, 
complete conversion of starting material was observed after two hours, and LC-MS analysis indicated 
that a new product with the correct target mass was formed. However, after isolation of this product in 
86% yield, NMR analysis showed that the substitution product 382 was formed and that it had not ring 
closed to the desired 2-amino-5-(tert-butyl)furan-3-carbonitrile 376, which is an isomer of 382 (Scheme 
90). The reaction conditions of Bakavoli et al. were also evaluated for the reaction of 1-
chloropinacolone with malononitrile. Under these conditions, different side products were formed and 
the substitution product 382 was isolated in only 7% yield. Formation of the desired 2-amino-5-(tert-
butyl)furan-3-carbonitrile 376 could not be detected. When 1-chloropinacolone was reacted with one 
equivalent of malononitrile and one equivalent of diethylamine in tetrahydrofuran as a solvent, most of 
the 1-chloropinacolone was attacked by diethylamine instead of malononitrile, resulting in a huge 
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amount of undesired side product. Hence, the use of diethylamine should be avoided for this reaction 
and it should be replaced by the non-nucleophilic base triethylamine.  
 
Scheme 90. Reaction of 1-chloropinacolone with malononitrile 
The next step was a screening of reaction conditions for the ring closure of 382 to 376 (Table 16). 
Treatment with potassium tert-butoxide or sodium hydride in THF resulted in complex reaction 
mixtures (entries 1-4). Nakano et al. have reported acidic reaction conditions to affect a similar ring 
closure with success.
185
 When three equivalents of aqueous hydrochloric acid in acetic acid were used 
(entry 5), different side products were formed. The proposed structure of the major side product (383) 
is depicted in Figure 20. Bakavoli et al. reported the use of neat TFA to accomplish a similar ring 
closure.
184
 Unfortunately, the use of neat TFA lead to a complex reaction mixture (entry 6). The 
reaction conditions of Matsuda et al.,
186
 using piperidine in ethanol at reflux temperature (entry 7), and 
the conditions reported by Nakano et al.,
185
 using piperazine in ethanol at room temperature (entry 9) 
both resulted in complex reaction mixtures. Switching to triethylamine as a base in ethanol (entry 8) or 
water (entry 10) or diethylamine in water (entry 11) still resulted in complex reaction mixtures. When 
triethylamine was used in methanol at 90 °C under microwave irradiation (entry 12), a complex 
reaction mixture was obtained again, and methoxypyrrole structure 384 (Figure 20) was proposed as a 
major side product. Based on the suspected formation of the undesired pyrroles 383 and 384 during 
this reaction screening, it was proposed that the presence of nucleophiles should be avoided during 
the ring closure reaction. Changing the solvent to toluene and heating of the reaction mixture for 10 
minutes at 110 °C under microwave irradiation lead to a complex reaction mixture again (entry 13). 
The use of THF as a solvent and triethylamine as a base at 65 °C under microwave irradiation for 
thirty minutes gave 15% conversion of the starting material to the desired product 376 (entry 14). The 
amount of triethylamine was increased to a 1:3 v/v ratio to THF and the reaction temperature was 
raised to 90 °C in order to speed up the reaction (entry 15). After one hour, full conversion was 
observed and 2-amino-5-(tert-butyl)furan-3-carbonitrile 376 was isolated in 85% yield.  
Table 16. Screening of reaction conditions for the ring closure of 382. 1.06 equivalents of malononitrile were used in all 
experiments. 
Entry Solvent Reagent T (°C) t (h) Results 
1 THF KOtBu (1 eq.) r.t. 0.5 Complex RM 
2 THF NaH (1 eq.) r.t. 0.5 Complex RM 
3 THF KOtBu (2 eq.) r.t. 0.5 Complex RM 
4 THF NaH (2 eq.) r.t. 0.5 Complex RM 
5 CH3COOH Aq. HCl (3 eq.) r.t. 4 Complex RM 
6 TFA / r.t. 1 Complex RM 
7 EtOH Piperidine (2.5 eq.) Reflux 1 Complex RM 
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8 EtOH Et3N (1:3 v/v to EtOH) Reflux 1 Complex RM 
9 EtOH Piperazine (2.5 eq.) r.t. 1 Complex RM 
10 H2O Et3N (1:2 v/v to H2O) r.t. 1 Complex RM 
11 H2O Et2NH (1:2 v/v to H2O) r.t. 1 Complex RM 
12 MeOH Et3N (3 eq.) 90, µW  0.5 Complex RM 
13 Toluene Et3N (3 eq.) 110, µW 0.17 Complex RM 
14 THF Et3N (3 eq.) 65, µW 0.5 15% conversion to 376 
15 THF Et3N (1:3 v/v to THF) 90, µW 1 85% isolated yield of 376 
 
 
Figure 20. Proposed structures of side products which were observed during the ring closure reaction screening 
The reaction of 1-chloropinacolone with malononitrile and the subsequent ring closure reaction could 
be merged into a one-pot procedure (Scheme 91). Reaction of 1-chloropinacolone with malononitrile in 
a mixture of triethylamine and THF at 90 °C under microwave irradiation for one hour resulted in 49% 
yield of the desired aminofuran 376. However, the yield of this one-pot reaction is lower than the 
combined yields of the separate reactions.  
 
Scheme 91. One-pot procedure for the synthesis of 2-amino-5-(tert-butyl)furan-3-carbonitrile 
3.2 Synthesis of 2-amino-5-(tert-butyl)furan-3-carboxamide 
The last step in the synthetic pathway to obtain the requested 2-amino-5-(tert-butyl)furan-3-
carboxamide 375 consisted of the transformation of the nitrile group to an amide functionality. First, a 
mild, selective and efficient method reported by Lakouraj and coworkers was investigated.
187
 The 
nitrile 376 was reacted with Amberlyst-supported hydroperoxide in methanol, but no conversion of 
starting material was observed after three hours at room temperature (Scheme 92). The reaction 
mixture was then heated at 65 °C for half an hour, but this resulted only in the formation of side 
products and the desired amide 375 was not detected. Katritzky and coworkers reported on the 
efficient conversion of nitriles to amides using aqueous hydrogen peroxide and potassium carbonate 
in DMSO at room temperature.
188
 When these reaction conditions were applied to nitrile 376, no 
conversion was observed after half an hour. Addition of extra aqueous hydrogen peroxide and up to 
twelve hours of prolonged stirring still did not result in any conversion. After heating of the reaction 
mixture at 50 °C for three hours, side products were formed and the desired amide 375 was not 
detected in the reaction mixture. Finally, a classic acid catalyzed hydrolysis was used to convert the 
nitrile into the amide.
189
 Compound 376 was added to concentrated sulfuric acid, heated at 60 °C for 
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half an hour to protonate the nitrile group, and then cooled down to 0 °C. Subsequently, crushed ice 
was added carefully to affect the hydrolysis. Following this procedure, the amide 375 was obtained in 
77% yield. This product appeared to be quite unstable, and during the development of the reaction 
work-up and purification protocol, the product was lost many times. This is in agreement with literature, 
which reports that 2-aminofurans are much less stable in the absence of an electron withdrawing 
group.
190
   
 
Scheme 92. Conversion of nitrile 376 to amide 375 
3.3 Conclusions 
In conclusion, an efficient and straightforward synthetic route towards 2-amino-(5-tert-butyl)furan-3-
carbonitrile was developed. Starting from commercially available 1-chloropinacolone, a substitution 
with malononitrile afforded the dinitrile 382 in 86% yield. Ring closure of this product under microwave 
irradiation gave the 2-aminofuran 376 in 85% yield. Acid catalyzed hydrolysis of the nitrile group to an 
amide functionality delivered the end product 375 in 77% yield (56% yield over three steps).  
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4 Drug-likeness of the synthesized compounds 
As mentioned in the introduction, the synthesized compounds should preferentially be in agreement 
with the Lipinski rules for drug-likeness. A selection of relevant compounds was assessed on drug-like 
properties as defined by the Lipinski Rule of Three (Ro3) and Rule of Five (Ro5) and the results are 
summarized in Table 17. As can be seen, 25 out of 71 compounds were not in agreement with the 
Rule of Three. The most frequent property that was not in agreement with the Ro3 was the number of 
hydrogen bond acceptors (15 out of 25 compounds), followed by the molecular weight (13 out of 25 
compounds), the partition coefficient (4 out of 25 compounds) and the number of hydrogen bond 
donors (3 out of 25 compounds). All of the compounds were in agreement with the Ro5.  
Table 17. Assessment of the drug-like properties of the synthesized compounds according to the Lipinski rules. ‘Y’ = in 
agreement, ‘N’ = not in agreement. 
Compound Ro3 Ro5 Compound Ro3 Ro5 
6 Y Y 298 Y Y 
8 Y Y 300 N Y 
284 Y Y 299 Y Y 
36a Y Y 301 Y Y 
36b Y Y 302 Y Y 
36c Y Y 305 N Y 
36d N Y 306 Y Y 
38a Y Y 314 N Y 
38b Y Y 316 N Y 
38c Y Y 317 Y Y 
38d Y Y 319 N Y 
38e Y Y 321 N Y 
38f Y Y 322 N Y 
38g Y Y 323 Y Y 
38h Y Y 325 N Y 
38i N Y 327 N Y 
38j N Y 328 N Y 
38k N Y 341 N Y 
38l N Y 342 N Y 
38m Y Y 351 Y Y 
38n N Y 357 Y Y 
38o Y Y 350a Y Y 
285a Y Y 350b Y Y 
285b Y Y 350c Y Y 
285c Y Y 350d Y Y 
285d Y Y 350e Y Y 
285e N Y 350f Y Y 
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285f Y Y 350g Y Y 
285g Y Y 337a Y Y 
285h N Y 337b Y Y 
285i Y Y 337c Y Y 
285j N Y 337d Y Y 
285k N Y 369 Y Y 
285l N Y 370 Y Y 
286 N Y 373 N Y 
288 Y Y    
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5 Biological evaluation 
The synthesized compounds were evaluated for biological activity in collaboration with research 
institutions and companies. There was no clear rationale for the performed biological screenings; 
whenever there was a call for compounds by a research institution or company, a representative 
selection of available compounds was submitted for biotesting.  
5.1 Inhibition of NPP1 
NPP1, or ectonucleotide pyrophosphatase/phosphodiesterase-1, is a membrane glycoprotein that 
hydrolyzes pyrophosphate and phosphodiester bonds of nucleotides such as ATP. It has a Zn(II)-
binding extracellular catalytic site. Hydrolysis of ATP mainly results in the release of AMP and 
pyrophosphate and also ADP and inorganic phosphate.
191–193
 Animal studies suggest that a disrupted 
NPP1 function is associated with significant changes in skeletal and soft tissue mineralization, the 
calcium/phosphate balance and glucose homeostasis.
194
 In calcific aortic valve disease (CAVD), the 
most frequent heart valve disorder, an abnormally high level of NPP1 is found,
191,195
 and elevated 
pyrophosphate levels are observed in calcium pyrophosphate deposition disease (CPPD), which is a 
joint pathology. Both health disorders are lacking disease-modifying therapies. Therefore, new drugs 
that slow down or stop CAVD/CPPD progression are needed, and selective NPP1 inhibitors could be 
suitable candidates to treat these diseases.
196–199
  The screening of NPP1 inhibition was performed by 
the research group of Prof. Müller (PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical 
Chemistry I, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany). The inhibition was 
determined by assessing the phosphodiesterase activity of NPP1, using p-nitrophenyl 5’-thymidine 
monophosphate (p-Nph-5’-TMP) as an artificial substrate. Only compounds which display more than 
70% inhibition in this first screening are allowed to proceed to the next screening, which uses the 
natural substrate ATP. Thirty-four compounds were screened, but none of them were active (Table 
18). 
Table 18. First screening of NPP1 inhibition. Assay conditions: 400 µM p-nitro-5’-TMP, 10 µM compound concentration, 20 ng of 
human recombinant NPP1, reaction buffer (1 mM CaCl2, 200 µM ZnCl2, 50 mM Tris, pH 9.0), spectrophotometric detection at 
400 nm and n = 1 
Compound Structure Inhibition of NPP1 (p-Nph-5’-TMP)
a 
38a 
 
NA 
38b 
 
NA 
38c 
 
NA 
38d 
 
NA 
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38e 
 
NA 
38f 
 
NA 
38g 
 
NA 
38h 
 
NA 
38i 
 
NA 
38j 
 
NA 
38k 
 
NA 
38l 
 
NA 
38m 
 
NA 
38n 
 
NA 
38o 
 
NA 
285a 
 
NA 
285b 
 
NA 
285c 
 
NA 
285d 
 
NA 
285e 
 
NA 
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285f 
 
NA 
285g 
 
NA 
285h 
 
NA 
285i 
 
NA 
285j 
 
NA 
285k 
 
NA 
285l 
 
NA 
286 
 
NA 
288 
 
NA 
298 
 
NA 
302 
 
NA 
300 
 
NA 
299 
 
NA 
301 
 
NA 
a
: NA = no activity 
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5.2 Antibacterial activity 
Five compounds were submitted to an antibacterial screening campaign of the Laboratory for 
Microbiology at the University of Ghent (K.L. Ledeganckstraat 35, 9000 Gent, Belgium) in collaboration 
with the Belgian Co-ordinated Collections of Micro-organisms (BCCM). The growth inhibition was 
tested on a panel of four internationally used test- and control strains based on clinical relevance. The 
four strains were the Gram-negative Escherichia coli LMG 8063 and Klebsiella pneumoniae LMG 2095 
and the Gram-positive Staphylococcus aureus LMG 8064 and Bacillus subtilis LMG 13579. The initial 
screening used a single ‘high’ concentration (C, Table 19) against the test panel and was based on 
visual assessment of bacterial growth compared to negative and positive controls. None of the 
compounds was active against the Gram-negative strains (Table 19). Compounds 299, 298 and 285i 
showed a very slight growth inhibition of both of the Gram-positive strains.  
Table 19. First screening of antibacterial activity 
   Growth inhibition
a 
Compound Structure C (µg/mL) EC 
LMG 8063 
KP 
LMG 2095 
SA 
LMG 8064 
BS 
LMG 13579 
299 
 
508 NA NA Very slight Very slight 
298 
 
194 NA NA Very slight Very slight 
38d 
 
490 NA NA NA NA 
285i 
 
520 NA NA Very slight Very slight 
288 
 
502 NA NA NA NA 
a
: NA = no activity 
Compounds 299 and 285i were selected to proceed to a follow-up assay to determine their MIC 
values against four clinically relevant Gram-positive strains: Enterococcus faecium LMG 11397, 
Streptococcus pneumoniae LMG 16738, Staphylococcus aureus LMG 8064 and Bacillus subtilis LMG 
13579. Both compounds exhibited MIC values of >1000 µg/mL for all four bacterial strains (Table 20). 
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Table 20. Determination of MIC values for selected compounds against four Gram-positive strains 
  MIC (µg/mL)
 
Compound Structure EF 
LMG 11397 
SP 
LMG 16738 
SA 
LMG 8064 
BS 
LMG 13579 
Positive control gentamicin 5 5 25 10 
299 
 
>1000 >1000 >1000 >1000 
285i 
 
>1000 >1000 >1000 >1000 
 
Seven compounds were submitted to a screening campaign of the Laboratory of Pharmaceutical 
Microbiology (Prof. Coenye, Ghent University). The purpose of the campaign was the identification of 
new agents with activity against bacterial biofilms. Bacteria usually don’t exist as individual organisms 
in a ‘planktonic state’, but can form monolayers, multilayer colonies and finally a mature biofilm. The 
extracellular matrix or ‘slime’ which forms the basis for the biofilm consists of extracellular 
polysaccharides, cell debris, nucleic acids and structural proteins, also called extracellular polymeric 
substances (EPS). Bacterial biofilms are much more resistant to antibiotics, components of both the 
innate and adaptive immune response  and phagocytosis. Hence, they are very hard to treat with 
antibiotics.
200
 Before the compounds were allowed to proceed to the antibacterial biofilm assay, a first 
screening assessed their antibacterial activity against the Gram-negative bacterial strains Escherichia 
coli LMG 8063, Klebsiella pneumoniae LMG 2095 and Pseudomonas aeruginosa PAO1, and the 
Gram-positive strains Staphylococcus aureus ATCC 6538 and Staphylococcus aureus Mu50, which is 
a multi-resistant strain. The screening assay was carried out in 96-well plates in a concentration range 
of 2500 to 1.22 µg/mL of test compound. None of the compounds exhibited antibacterial activity at the 
tested concentrations (Table 21). 
Table 21. Screening for antibacterial activity 
  Growth inhibition
a 
Compound Structure EC 
LMG 8063 
KP 
LMG 2095 
PA 
PAO1 
SA 
ATCC 6538 
SA 
Mu50 
317 
 
NA NA NA NA NA 
316 
 
NA NA NA NA NA 
314 
 
NA NA NA NA NA 
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350a 
 
NA NA NA NA NA 
350c 
 
NA NA NA NA NA 
350b 
 
NA NA NA NA NA 
350e 
 
NA NA NA NA NA 
a
: NA = no activity 
5.3 Antiviral activity 
The feline parvovirus (FPV) is a single-stranded DNA virus which causes panleukopenia in both 
domestic and wild feline species. It is also known as ‘cat plague’ and is a highly contagious and often 
lethal disease.
201
 The activity against FPV was tested on CrFK infected cell cultures by Okapi 
Sciences, Leuven, Belgium. Five compounds were screened at concentrations of 50, 10, 2 and 0.4 µM 
and none of them were active against FPV (Table 22). The screening campaign was terminated by 
Okapi Sciences and no more compounds were tested. 
Table 22. Screening for activity against Feline Parvovirus 
Compound Structure Activity against FPV
 
38a 
 
NA 
38b 
 
NA 
38c 
 
NA 
285a 
 
NA 
285d 
 
NA 
a
: NA = no activity 
A collection of 44 compounds was screened for antiviral activity against a broad panel of viruses in 
different cell cultures (Tables 23-27). This screening was performed by prof. Naesens of the Rega 
Institute for Medical Research (KU Leuven). The activity against vesicular stomatitis virus, coxsackie 
virus B4 and RSV was determined in either HeLa cell cultures (Table 23) or Hep-2 cell cultures (Table 
24). In the HeLa cell culture assay, compounds 321 and 327 exhibited a slight activity against 
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coxsackie virus B4, with EC50 values of 97 and 67 µM, respectively. Both structures are characterized 
by a (2-hydroxyethoxy)methyl substituent on N-1. Compound 316, also equipped with this substituent, 
showed no activity. Compound 38k was slightly cytotoxic in Hep-2 cell cultures with a CC50 of 89 µM. 
The activity against HIV-1 and HIV-2 was determined in MT4 cell cultures (Table 25). Only compound 
305 was slightly active against HIV-1 strain IIIB with an EC50 value of 104 µM. Compounds 38k and 
38l were slightly cytotoxic with CC50 values of 64 and 69 µM, respectively. The activity against herpes 
simplex virus-1 strain KOS, herpes simplex virus-2 strain G, thymidine kinase negative and acyclovir-
resistant herpes simplex virus-1 strain KOS, vaccinia virus, adenovirus-2 and human coronavirus 
strain 229E was determined in HEL cell cultures (Table 26). None of the compounds showed antiviral 
activity in this assay. The activity against reovirus-1, sindbis virus, coxsackie virus B4, punta toro virus 
and zika virus was determined in Vero cell cultures (Table 27). In this assay, none of the compounds 
showed antiviral activity. Compounds 321 and 327, which exhibited slight activity against coxsackie 
virus B4 in HeLa cell cultures, did not possess activity against this virus in Vero cell cultures.  
Table 23. Cytotoxicity and antiviral activity in HeLa cell cultures 
Compound Structure CC50
a 
(µM) 
Antiviral EC50
b
 (µM) 
Vesicular 
stomatitis virus 
Coxsackie virus 
B4 
Respiratory 
syncytial virus
 
316 
 
> 100 > 100 > 100 > 100 
321 
 
> 100 > 100 97 > 100 
327 
 
> 100 > 100 67 > 100 
317 
 
> 100 > 100 > 100 > 100 
322 
 
> 100 > 100 > 100 > 100 
314 
 
> 100 > 100 > 100 > 100 
DS-10.000 > 100
c 
0.3
c 
> 100
c 
0.2
c 
Ribavirin > 250 87 126 5 
a
:50% Cytotoxic concentration, as determined by measuring the cell viability with the colorimetric formazan-based MTS assay. 
b
:50% Effective concentration, or concentration producing 50% inhibition of virus-induced cytopathic effect, as determined by 
measuring the cell viability with the colorimetric formazan-based MTS assay. 
c
: in µg/mL.  
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Table 24. Cytotoxicity and antiviral activity in Hep-2 cell cultures 
Compound Structure CC50
a 
(µM) 
Antiviral EC50
b
 (µM) 
Vesicular 
stomatitis virus 
Coxsackie virus 
B4 
Respiratory 
syncytial virus
 
319 
 
>100 >100 >100 >100 
6 
 
>100 >100 >100 >100 
8 
 
>100 >100 >100 >100 
323 
 
>100 >100 >100 >100 
286 
 
>100 >100 >100 >100 
284 
 
>100 >100 >100 >100 
36d 
 
>100 >100 >100 >100 
38a 
 
>100 >100 >100 >100 
38b 
 
>100 >100 >100 >100 
38c 
 
>100 >100 >100 >100 
38d 
 
>100 >100 >100 >100 
38g 
 
>100 >100 >100 >100 
38h 
 
>100 >100 >100 >100 
38i 
 
>100 >100 >100 >100 
38j 
 
>100 >100 >100 >100 
38k 
 
89 >100 >100 >100 
38l 
 
>100 >100 >100 >100 
90 
 
38m 
 
>100 >100 >100 >100 
38n 
 
>100 >100 >100 >100 
38o 
 
>100 >100 >100 >100 
285h 
 
>100 >100 >100 >100 
298 
 
>100 >100 >100 >100 
300 
 
>100 >100 >100 >100 
299 
 
>100 >100 >100 >100 
301 
 
>100 >100 >100 >100 
305 
 
>100 >100 >100 >100 
306 
 
>100 >100 >100 >100 
341 
 
>100 >100 >100 >100 
342 
 
>100 >100 >100 >100 
351 
 
>100 >100 >100 >100 
357 
 
>100 >100 >100 >100 
369 
 
>100 >100 >100 >100 
350a 
 
>100 >100 >100 >100 
350c 
 
>100 >100 >100 >100 
91 
 
350f 
 
>100 >100 >100 >100 
350g 
 
>100 >100 >100 >100 
337a 
 
>100 >100 >100 >100 
337c 
 
>100 >100 >100 >100 
DS-10.000 > 100
c 
0.07
c 
> 100
c 
0.05
c 
Ribavirin > 250 22 112 4.5 
a
:50% Cytotoxic concentration, as determined by measuring the cell viability with the colorimetric formazan-based MTS assay. 
b
:50% Effective concentration, or concentration producing 50% inhibition of virus-induced cytopathic effect, as determined by 
measuring the cell viability with the colorimetric formazan-based MTS assay. 
c
: in µg/mL.  
Table 25. Anti-HIV activity and cytotoxicity in MT4 cells 
Compound Structure CC50
a 
(µM) 
Antiviral EC50
b
 (µM) 
HIV-1 (strain IIIB) HIV-2 (strain ROD) 
316 
 
> 125 > 125 > 125 
321 
 
> 125 > 125 > 125 
327 
 
> 125 > 125 > 125 
317 
 
> 125 > 125 > 125 
322 
 
> 125 > 125 > 125 
314 
 
> 125 > 125 > 125 
319 
 
> 125 > 125 > 125 
6 
 
> 125 > 125 > 125 
92 
 
8 
 
> 125 > 125 > 125 
323 
 
> 125 > 125 > 125 
286 
 
> 125 > 125 > 125 
284 
 
> 125 > 125 > 125 
36d 
 
> 125 > 125 > 125 
38a 
 
> 125 > 125 > 125 
38b 
 
> 125 > 125 > 125 
38c 
 
> 125 > 125 > 125 
38d 
 
> 125 > 125 > 125 
38g 
 
> 125 > 125 > 125 
38h 
 
> 125 > 125 > 125 
38i 
 
> 125 > 125 > 125 
38j 
 
> 125 > 125 > 125 
38k 
 
64 > 64 > 64 
38l 
 
69 > 69 > 69 
38m 
 
> 125 > 125 > 125 
38n 
 
> 125 > 125 > 125 
38o 
 
> 125 > 125 > 125 
285h 
 
> 125 > 125 > 125 
93 
 
298 
 
> 125 > 125 > 125 
300 
 
> 125 > 125 > 125 
299 
 
> 125 > 125 > 125 
301 
 
> 125 > 125 > 125 
305 
 
> 125 104 > 125 
306 
 
> 125 > 125 > 125 
341 
 
> 125 > 125 > 125 
342 
 
> 125 > 125 > 125 
351 
 
> 125 > 125 > 125 
357 
 
> 125 > 125 > 125 
369 
 
> 125 > 125 > 125 
350a 
 
> 125 > 125 > 125 
350c 
 
> 125 > 125 > 125 
350f 
 
> 125 > 125 > 125 
350g 
 
> 125 > 125 > 125 
337a 
 
> 125 > 125 > 125 
337c 
 
> 125 > 125 > 125 
94 
 
Nevirapine >4
a 
0.075
a
 >4
a
 
Zidovudine >2
a
 0.0020
a
 0.0022
a
 
Lamivudine >20
a
 0.58
a
 2.3
a
 
Didanosine >50
a
 18
a
 19
a
 
Antiviral activity and cytotoxicity were determined by the colorimetric MTT cell viability assay. The antiviral EC50 represents the 
compound concentration producing 50% inhibition of virus-induced cytopathicity. The CC50 represents the compound 
concentration causing 50% reduction of cell viability. 
a
: in µg/mL.  
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Table 26. Cytotoxicity and antiviral activity in HEL cell cultures 
Compound Structure CC50
a 
(µM) 
 Antiviral EC50
b
 (µM) 
Herpes 
simplex 
virus-1 
(KOS) 
Herpes 
simplex 
virus-2 (G) 
Herpes 
simplex 
virus-1 TK
-
 
KOS ACV
r 
Vaccinia 
virus 
Adenovirus-2 
Human 
coronavirus 
(229E) 
316 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
321 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
327 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
317 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
322 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
314 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
319 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
96 
 
6 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
8 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
323 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
286 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
284 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
36d 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
38a 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
38b 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
38c 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
38d 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
38g 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
38h 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
97 
 
38i 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
38j 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
38k 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
38l 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
38m 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
38n 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
38o 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
285h 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
298 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
300 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
299 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
301 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
98 
 
305 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
306 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
341 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
342 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
351 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
357 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
369 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
350a 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
350c 
 
ND > 100 > 100 > 100 > 100 > 100 > 100 
350f 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
99 
 
350g 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
337a 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
337c 
 
> 100 > 100 > 100 > 100 > 100 > 100 > 100 
Brivudin > 250 0.1 96 >250 13   
Cidofovir > 250 32 7.5 21 8.7 11  
Acyclovir > 250 2.9 0.1 >250 >250   
Ganciclovir > 100 0.7 0.7 4.8 >100   
Zalcitabine >250     17  
Alovudine >250     9.3  
UDA > 100
c 
     3.9
c 
a
:50% Cytotoxic concentration, as determined by measuring the cell viability with the colorimetric formazan-based MTS assay. 
b
:50% Effective concentration, or concentration producing 50% 
inhibition of virus-induced cytopathic effect, as determined by measuring the cell viability with the colorimetric formazan-based MTS assay. 
c
: in µg/mL. ND = not determined 
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Table 27. Cytotoxicity and antiviral activity in Vero cell cultures 
Compound Structure CC50
a 
(µM) 
Antiviral EC50
b
 (µM) 
Reovirus-1 Sindbis virus 
Coxsackie 
virus B4
 
Punta Toro 
virus 
Zika virus 
316 
 
> 100 > 100 > 100 > 100 > 100 > 100 
321 
 
> 100 > 100 > 100 > 100 > 100 > 100 
327 
 
> 100 > 100 > 100 > 100 > 100 > 100 
317 
 
> 100 > 100 > 100 > 100 > 100 > 100 
322 
 
> 100 > 100 > 100 > 100 > 100 > 100 
314 
 
> 100 > 100 > 100 > 100 > 100 > 100 
319 
 
> 100 > 100 > 100 > 100 > 100 > 100 
6 
 
> 100 > 100 > 100 > 100 > 100 > 100 
101 
 
8 
 
> 100 > 100 > 100 > 100 > 100 > 100 
323 
 
> 100 > 100 > 100 > 100 > 100 > 100 
286 
 
> 100 > 100 > 100 > 100 > 100 > 100 
284 
 
> 100 > 100 > 100 > 100 > 100 > 100 
36d 
 
> 100 > 100 > 100 > 100 > 100 > 100 
38a 
 
> 100 > 100 > 100 > 100 > 100 > 100 
38b 
 
> 100 > 100 > 100 > 100 > 100 > 100 
38c 
 
> 100 > 100 > 100 > 100 > 100 > 100 
38d 
 
> 100 > 100 > 100 > 100 > 100 > 100 
38g 
 
> 100 > 100 > 100 > 100 > 100 > 100 
38h 
 
> 100 > 100 > 100 > 100 > 100 > 100 
38i 
 
> 100 > 100 > 100 > 100 > 100 > 100 
102 
 
38j 
 
> 100 > 100 > 100 > 100 > 100 > 100 
38k 
 
> 100 > 100 > 100 > 100 > 100 > 100 
38l 
 
> 100 > 100 > 100 > 100 > 100 > 100 
38m 
 
> 100 > 100 > 100 > 100 > 100 > 100 
38n 
 
> 100 > 100 > 100 > 100 > 100 > 100 
38o 
 
> 100 > 100 > 100 > 100 > 100 > 100 
285h 
 
> 100 > 100 > 100 > 100 > 100 > 100 
298 
 
> 100 > 100 > 100 > 100 > 100 > 100 
300 
 
> 100 > 100 > 100 > 100 > 100 > 100 
299 
 
> 100 > 100 > 100 > 100 > 100 > 100 
301 
 
> 100 > 100 > 100 > 100 > 100 > 100 
305 
 
> 100 > 100 > 100 > 100 > 100 > 100 
103 
 
306 
 
> 100 > 100 > 100 > 100 > 100 > 100 
341 
 
> 100 > 100 > 100 > 100 > 100 > 100 
342 
 
> 100 > 100 > 100 > 100 > 100 > 100 
351 
 
> 100 > 100 > 100 > 100 > 100 > 100 
357 
 
> 100 > 100 > 100 > 100 > 100 > 100 
369 
 
> 100 > 100 > 100 > 100 > 100 > 100 
350a 
 
> 100 > 100 > 100 > 100 > 100 > 100 
350c 
 
> 100 > 100 > 100 > 100 > 100 > 100 
350f 
 
> 100 > 100 > 100 > 100 > 100 > 100 
350g 
 
> 100 > 100 > 100 > 100 > 100 > 100 
104 
 
337a 
 
> 100 > 100 > 100 > 100 > 100 > 100 
337c 
 
> 100 > 100 > 100 > 100 > 100 > 100 
DS-10,000 >100
c 
1.2
c 
14.0
c 
26.2
c 
5.4
c 
24.1
c 
Mycophenolic acid >100 >100 21.5 >100 10.6 10.1 
a
:50% Cytotoxic concentration, as determined by measuring the cell viability with the colorimetric formazan-based MTS assay. 
b
:50% Effective concentration, or concentration producing 50% 
inhibition of virus-induced cytopathic effect, as determined by measuring the cell viability with the colorimetric formazan-based MTS assay. 
c
: in µg/mL. 
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5.4 Conclusions 
A variety of compounds which were synthesized during this PhD research were screened for 
antibacterial and antiviral activity, and inhibition of NPP1. No significant activity was found in these 
screenings. A slight antibacterial activity was observed for three compounds, but determination of the 
MIC values for two of these compounds resulted in values higher than 1000 µg/mL. A slight antiviral 
activity was observed for two acyclic nucleoside analogues against coxsackie virus B4 in HeLa cell 
cultures, but these compounds did not exhibit this activity in Vero cell cultures. One compound was 
slightly active against HIV-1 strain IIIB. The activity of these hits was not good enough to start a hit 
optimization campaign. Thus, it can be concluded that the biological screening of the compound 
libraries did not return any significant hits.  
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Perspectives 
The proposed furo[3,4-d]pyrimidines were not obtained because the transformation of the furo[3,4-
d]pyrimidine-2,4-dione precursors by treatment with phosphorus oxychloride was not successful. Other 
reagents might be able to accomplish the transformation to furo[3,4-d]pyrimidines, and a more 
thorough screening of reagents could be performed. However, it is possible that this approach is 
chemically intractable, and that the furo[3,4-d]pyrimidines should be constructed via ring annulation of 
appropriate pyrimidine precursors instead.  
A handful of oxazolo[5,4-d]pyrimidine-5,7-diones was synthesized, but the scope of the Hofmann 
reaction was limited to amines that were not very sensitive to oxidation by the hypervalent iodine 
reagent. This problem could be tackled by introducing an extra step in the reaction pathway and 
applying the Hofmann rearrangement reaction for the synthesis of an appropriate precursor for the 
ureids. The (oxidation-sensitive) amines could then be allowed to react with this precursor under non-
oxidative conditions to afford the ureids. A possible precursor could be the benzotriazole carboxamide 
385 (Scheme 93). The successful in situ trapping of isocyanates (obtained via Curtius rearrangement) 
with 1H-benzotriazole to form this type of benzotriazole carboxamides, and the subsequent reaction 
with amines to afford ureid compounds, has been described already.
202
 This approach should allow 
the use of a much broader range of amines, so that a diverse compound library of oxazolo[5,4-
d]pyrimidine-5,7-diones can be designed and synthesized.  
 
Scheme 93. Transformation of carboxamide 351 to ureid 350 via a benzotriazole ureid precursor 
Patent literature strongly suggests that the transformation of oxazolo[5,4-d]pyrimidine-5,7-dione 337e. 
to the 5,7-dichlorooxazolo[5,4-d]pyrimidine scaffold 388 by treatment with phosphorus oxychloride is 
synthetically feasible, as well as further modification towards the functionalized oxazolo[5,4-
d]pyrimidines 389 (Scheme 94).
56
 
 
Scheme 94. Proposed synthetic pathway towards the C-5/C-7 functionalized oxazolo[5,4-d]pyrimidines 389 
The oxazolo[4,5-d]pyrimidine-5,7-dione 333a was obtained only in a very low yield. The ring closure 
protocol for the ureids 370 to oxazolo[4,5-d]pyrimidinones 333 could be optimized to improve the yield, 
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or another approach could be followed. A possible new approach could be the selective hydrolysis of 
the ester bond of ureid 370 to obtain the carboxylic acid 390 (Scheme 95). Ring closure could then be 
accomplished under peptide coupling conditions, for example with PyBOP reagent, as reported by 
Drewe and coworkers.
203
  
 
Scheme 95. Proposed synthetic strategy to ring-close ureids 370 towards the oxazolo[4,5-d]pyrimidine-5,7-diones 333 
Patent literature strongly suggests that oxazolo[4,5-d]pyrimidine-5,7-dione 333a could be converted to 
the 5,7-dichlorooxazolo[4,5-d]pyrimidine scaffold 393 by treatment with phosphorus oxychloride, and 
subsequent modification would then afford the functionalized oxazolo[4,5-d]pyrimidines 394 (Scheme 
96).
56
  
 
Scheme 96. Proposed synthetic pathway towards the oxazolo[4,5-d]pyrimidines 394 
None of the screened compounds possessed a significant biological activity which would justify further 
medicinal optimization. However, the library of new compounds can be used for further biological 
screening in the future.   
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Experimental part 
1 Materials and methods 
All of the reagents and solvents were commercially available and used as such, unless mentioned 
otherwise.  
1.1 Relevant safety data sheet information 
1.1.1 Methanol 
Hazard statements: 
H225 Highly flammable liquid and vapour. 
H301 + H311 + H331 Toxic if swallowed, in contact with skin or if inhaled. 
H370 Causes damage to organs. 
Precautionary statements: 
P210 Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No 
smoking. 
P280 Wear protective gloves/ protective clothing. 
P302 + P352 + P312 IF ON SKIN: Wash with plenty of water. Call a POISON CENTER/doctor if you 
feel unwell. 
P304 + P340 + P311 IF INHALED: Remove person to fresh air and keep comfortable for breathing. 
Call a POISON CENTER/doctor. 
P370 + P378 In case of fire: Use dry powder or dry sand to extinguish. 
P403 + P235 Store in a well-ventilated place. Keep cool. 
1.1.2 Sodium hydroxide 
Hazard statements: 
H290 May be corrosive to metals. 
H314 Causes severe skin burns and eye damage.  
Precautionary statements: 
P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray. 
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. 
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P303 + P361 + P353 IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin 
with water/shower. 
P304 + P340 + P310 IF INHALED: Remove person to fresh air and keep comfortable for breathing. 
Immediately call a POISON CENTER/doctor. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact 
lenses, if present and easy to do. Continue rinsing. 
1.1.3 Diphenyl phosphoryl azide 
Hazard statements: 
H301 + H311 + H331 Toxic if swallowed, in contact with skin or if inhaled. 
H315 Causes skin irritation. 
H319 Causes serious eye irritation. 
H335 May cause respiratory irritation.  
Precautionary statements: 
P261 Avoid breathing vapours.  
P280 Wear protective gloves/ protective clothing. 
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER/doctor. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact 
lenses, if present and easy to do. Continue rinsing. 
P311 Call a POISON CENTER /doctor. 
1.1.4 Triethylamine 
Hazard statements: 
H225 Highly flammable liquid and vapour. 
H302 Harmful if swallowed. 
H311 + H331 Toxic in contact with skin or if inhaled. 
H314 Causes severe skin burns and eye damage. 
H335 May cause respiratory irritation.  
Precautionary statements: 
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P210 Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No 
smoking. 
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. 
P303 + P361 + P353 IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin 
with water/shower. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact 
lenses, if present and easy to do. Continue rinsing. 
P370 + P378 In case of fire: Use dry sand, dry chemical or alcohol-resistant foam to extinguish. 
1.1.5 Sodium methoxide 
Hazard statements: 
H251 Self-heating: may catch fire. 
H302 Harmful if swallowed. 
H314 Causes severe skin burns and eye damage. 
Precautionary statements: 
P235 + P410 Keep cool. Protect from sunlight. 
P280Wear protective gloves/ protective clothing/ eye protection/ face protection. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact 
lenses, if present and easy to do. Continue rinsing. 
P310 Immediately call a POISON CENTER/doctor.  
Supplemental Hazard information (EU): 
EUH014 Reacts violently with water. 
Other hazards: 
This substance/mixture contains no components considered to be either persistent, bioaccumulative 
and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher. 
Reacts violently with water. 
1.1.6 Phosphorus(V) oxychloride 
Hazard statements:  
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H300 + H330 Fatal if swallowed or if inhaled 
H314 Causes severe skin burns and eye damage. 
H372 Causes damage to organs through prolonged or repeated exposure.  
Precautionary statements:  
P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. 
P301 + P310 + P330 IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. 
P303 + P361 + P353 IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin 
with water/shower. 
P304 + P340 + P310 IF INHALED: Remove person to fresh air and keep comfortable for breathing. 
Immediately call a POISON CENTER/doctor. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact 
lenses, if present and easy to do. Continue rinsing. 
P403 + P233 Store in a well-ventilated place. Keep container tightly closed.  
Supplemental Hazard information (EU): 
EUH014 Reacts violently with water.  
EUH029Contact with water liberates toxic gas. 
Other hazards: 
This substance/mixture contains no components considered to be either persistent, bioaccumulative 
and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher. 
Reacts violently with water. Contact with water liberates toxic gas. Lachrymator. 
1.1.7 Triethylsilane 
Hazard statements: 
H225 Highly flammable liquid and vapour. 
H412 Harmful to aquatic life with long lasting effects.  
Precautionary statements: 
P210 Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No 
smoking. 
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P273 Avoid release to the environment 
1.1.8 Trifluoroacetic acid 
Hazard statements: 
H314 Causes severe skin burns and eye damage. 
H332 Harmful if inhaled. 
H412 Harmful to aquatic life with long lasting effects.  
Precautionary statements: 
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray. 
P271 Use only outdoors or in a well-ventilated area. 
P273 Avoid release to the environment.  
P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. 
Call a POISON CENTER/doctor if you feel unwell. 
P501 Dispose of contents/ container to an approved waste disposal plant. 
1.1.9 N,N-Dimethylformamide 
Hazard statements: 
H226 Flammable liquid and vapour. 
H312 + H332 Harmful in contact with skin or if inhaled. 
H319 Causes serious eye irritation. 
H360D May damage the unborn child. 
Precautionary statements: 
P201 Obtain special instructions before use. 
P280 Wear protective gloves/ protective clothing. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact 
lenses, if present and easy to do. Continue rinsing. 
P308 + P313 IF exposed or concerned: Get medical advice/ attention. 
1.1.10 Trimethylsilyl trifluoromethanesulfonate 
Hazard statements: 
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H226 Flammable liquid and vapour. 
H314 Causes severe skin burns and eye damage.  
Precautionary statements:  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact 
lenses, if present and easy to do. Continue rinsing. 
P310 Immediately call a POISON CENTER/doctor. 
Supplemental Hazard information (EU): 
EUH014 Reacts violently with water. 
1.1.11 N,O-Bis(trimethylsilyl)acetamide 
Hazard statements: 
H226 Flammable liquid and vapour. 
H302 Harmful if swallowed. 
H314 Causes severe skin burns and eye damage. 
Precautionary statements: 
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact 
lenses, if present and easy to do. Continue rinsing. 
P310 Immediately call a POISON CENTER/doctor. 
Supplemental Hazard information (EU): 
EUH014 Reacts violently with water. 
1.1.12 Oxalyl chloride 
Hazard statements: 
H314 Causes severe skin burns and eye damage. 
H331 Toxic if inhaled. 
H335 May cause respiratory irritation. 
Precautionary statements: 
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P261 Avoid breathing vapours. 
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact 
lenses, if present and easy to do. Continue rinsing. 
P310 Immediately call a POISON CENTER/doctor. 
Supplemental Hazard information (EU): 
EUH014 Reacts violently with water. 
EUH029 Contact with water liberates toxic gas 
1.1.13 Sodium azide 
Hazard statements: 
H300 + H310 Fatal if swallowed or in contact with skin. 
H373 May cause damage to organs (Brain) through prolonged or repeated exposure if swallowed. 
H410 Very toxic to aquatic life with long lasting effects. 
Precautionary statements: 
P273 Avoid release to the environment. 
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. 
P301 + P310 + P330 IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth.  
P302 + P352 + P310 IF ON SKIN: Wash with plenty of water. Immediately call a POISON 
CENTER/doctor. 
P391 Collect spillage. 
P501 Dispose of contents/ container to an approved waste disposal plant. 
Supplemental Hazard information (EU): 
EUH032 Contact with acids liberates very toxic gas. 
This substance/mixture contains no components considered to be either persistent, bioaccumulative 
and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher. 
Contact with acids liberates very toxic gas. Sodium Azide may react with lead and copper plumbing to 
form highly explosive metal azides. Rapidly absorbed through skin. 
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1.1.14 Malononitrile 
Hazard statements: 
H301 + H311 + H331 Toxic if swallowed, in contact with skin or if inhaled. 
H410 Very toxic to aquatic life with long lasting effects. 
Precautionary statements: 
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray. 
P273 Avoid release to the environment. 
P280 Wear protective gloves/ protective clothing. 
P301 + P310 + P330 IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. 
P391 Collect spillage. 
P403 + P233 Store in a well-ventilated place. Keep container tightly closed. 
1.2 Solvents 
Dry diethyl ether, dry tetrahydrofuran and dry toluene were freshly distilled over sodium wire and 
benzophenone. Dry dichloromethane was freshly distilled over calcium hydride. Dry N,N-
dimethylformamide was distilled over calcium hydride under vacuum and stored over activated 
molecular sieves (4 Å). Dry DMSO and dry acetonitrile were obtained by drying over activated 
molecular sieves (4 Å) for one day prior to use. Dry triethylamine was distilled over calcium hydride 
and stored over activated molecular sieves (4 Å) under an atmosphere of argon and in the dark. Dry 
diethyl ether, dry tetrahydrofuran, dry dichloromethane, dry toluene and dry acetonitrile were also 
provided by a MBraun MB-SPS-5 solvent system, equipped with columns packed with activated 
alumina to remove moisture and activated copper to remove oxygen (column packing depending on 
the solvent). Dry methanol was purchased from Acros Organics.  
1.3 Thin layer chromatography 
TLC analysis was carried out on glass plates coated with silica gel (Merck TLC silica gel 60 F254). 
Visualization was performed by means of fluorescence in a UV cabinet (254 or 366 nm) or by 
treatment with a potassium permanganate stain solution. Preparative TLC was carried out on glass 
plates coated with silica gel (Analtech Uniplate silica gel GF UV254, 20 x 20 cm, layer thickness 2000 
µm).  
1.4 Column chromatography 
Column chromatography was performed in glass columns packed with amorphous silica as solid 
support (70-200 µm particle size, 60 Å pore size). Rf values were determined by TLC using 
appropriate solvent mixtures. Automated column chromatography was performed on a Grace 
Reveleris flash chromatography system or Büchi Reveleris X2 flash system using Grace Reveleris 
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silica cartridges (for normal phase chromatography) or Grace Reveleris C18 reversed-phase flash 
cartridges (for reverse phase chromatography). Detection of the eluting compounds was performed via 
online UV detection at appropriate wavelengths or via online evaporative light-scattering detection 
(ELSD).  
1.5 Microwave reactor 
Microwave reactions were performed in a CEM Discover microwave reactor, using capped glass tubes 
of 10 mL.  
1.6 Hydrogenator 
Hydrogenation reactions were either performed by equipping the reaction flask with a balloon filled 
with hydrogen gas or by pressurizing the reaction flask with hydrogen gas by a Parker Balston 
hydrogen generator, model 75-32-220. The reported pressure (bar) is relative to the atmospheric 
pressure, i.e. 0 bar is equal to atmospheric pressure.  
1.7 Elemental analysis 
Elemental analysis was performed on a PerkinElmer 2400 Series II CHNS/O analyzer.  
1.8 Infrared spectroscopy 
Infrared spectra were recorded on a PerkinElmer Spectrum BX FTIR spectrometer equipped with an 
ATR (attenuated total reflectance) accessory on a ZnSe crystal, or on a Shimadzu IRAffinity-1S FTIR 
spectrophotometer. Compounds were analyzed in neat form and selected absorbances νmax are 
reported in cm
-1
.  
1.9 Melting points 
The melting points of solid compounds were determined on a Wagner & Munz Heizbank System 
Kofler (Type WME). Reference materials were used for calibration of the apparatus in the operating 
temperature range (50 to 260 °C).  
1.10 LC-MS analysis 
LC-MS analysis was performed on an Agilent 1200 series high performance liquid chromatograph 
equipped with a Supelco Ascentis Express C18 column (L 3 cm x ID 4.6 mm) packed with 2.7 µm 
fused-core particles (90 Å pore size) and a DAD-UV/VIS detector operating at 221, 255 and 281 nm. 
Mass spectra were recorded on an Agilent 1100 series LC/MSD VL mass spectrometer with 
Electrospray Ionization Geometry (ESI 70 eV) using a quadrupole detector.  
1.11 Mass spectrometry 
Low-resolution mass spectra were recorded using a direct inlet system on an Agilent 1100 series 
LC/MSD VL mass spectrometer with Electrospray Ionization Geometry (ESI 70 eV) using a 
quadrupole detector. Depending on the analyte, the mass spectrometer was set for detection of 
positive or negative ions. High resolution mass spectrometry (HRMS) was performed on an Agilent 
6220 TOF mass spectrometer equipped with an ESI/APCI-multimode source.  
117 
 
1.12 Preparative HPLC 
Compounds were purified on an Agilent 1100 series high performance liquid chromatograph equipped 
with a Supelco Ascentis C18 column (L 15 cm x ID 21.2 mm, 5 µm particle size), a UV VWD detector 
and a fully automatic fraction collector. The flow rate was set at 6 mL/min and a solvent mixture of 
HPLC-grade water and acetonitrile was used to elute the compounds.  
1.13 NMR spectroscopy 
1
H- and 
13
C-NMR spectra were recorded on a Jeol Eclipse 300+ FT-NMR spectrometer (300 MHz and 
75 MHz, respectively) or on a Bruker Avance III HD spectrometer (400 MHz and 100 MHz, 
respectively) at 21 °C. 
19
F-NMR spectra were recorded at 21 °C on a Bruker Avance III HD 
spectrometer (376 MHz). The compounds were dissolved in deuterated solvents, using 
tetramethylsilane (TMS) as an internal standard or using the residual solvent peak as an internal 
reference for 
1
H-NMR, and CFCl3 was used as an internal standard for 
19
F-NMR. The assignment of 
the different peaks was based on 1D-NMR spectra (
1
H, 
13
C, 
19
F, DEPT) and 2D-NMR spectra (
1
H-
1
H 
COSY, HSQC, H2BC, HMBC). δ values are reported in ppm and J values in Hz. Peak multiplicities are 
reported by the following abbreviations: s = singlet, d = doublet, t = triplet, q = quadruplet, m = 
multiplet, br = broad.  
1.14 X-ray diffraction spectroscopy 
For the structures of 323 and 327, X-ray intensity data were collected at 100 K on a Rigaku Oxford 
Diffraction Supernova Dual Source (Cu at zero) diffractometer equipped with an Atlas CCD detector 
using  scans and CuK ( = 1.54184 Å) radiation. The images were interpreted and integrated with 
the program CrysAlisPro
204
. Using Olex2,
205
 the structure was solved by direct methods using the 
ShelXS structure solution program and refined by full-matrix least-squares on F
2
 using the ShelXL 
program package.
206,207
 Non-hydrogen atoms were anisotropically refined and the hydrogen atoms in 
the riding mode and isotropic temperature factors fixed at 1.2 times U(eq) of the parent atoms (1.5 
times for hydroxyl groups). For both structures, the N-H hydrogen atoms were located from a 
difference Fourier electron density map. 
 
For 323 and 327, the asymmetric unit has chirality at C1 (S), C4 (R) and C1 (R), C4 (S), for 323 and 
327, respectively. But obviously, because of the centro-symmetric space groups of both 323 and 327, 
also the inverse configurations are present in the crystal structures.  
 
Crystal data for compound 323. C6H8N2O3, M = 156.14, monoclinic, space group P21/c (No. 14), a 
= 11.5884(6) Å, b = 4.9484(2) Å, c = 12.3181(6) Å, β = 113.997(6)˚, V = 645.32(6) Å
3
, Z = 4, T = 100 
K, calc = 1.607 g cm
-3
, μ(Cu-Kα) = 1.117 mm
-1
, F(000) = 328, 6184 reflections measured, 1277 unique 
(Rint = 0.0468) which were used in all calculations. The final R1 was 0.0417 (I >2 (I)) and wR2 
was 0.1068 (all data). 
 
Crystal data for compound 327. C9H14N2O5, M = 230.22, triclinic, space group P-1 (No. 2), a 
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= 8.6171(3) Å, b = 8.7300(4) Å, c = 8.7325(3) Å, α = 115.865(4)˚, β = 94.524(3)˚, γ = 117.071(4)˚, V 
= 493.80(5) Å
3
, Z = 2, T = 100 K, calc = 1.548 g cm
-3
, μ(Cu-Kα) = 1.087 mm
-1
, F(000) = 244, 17583 
reflections measured, 2000 unique (Rint = 0.0331) which were used in all calculations. The final R1 
was 0.0336 (I >2 (I)) and wR2 was 0.0912 (all data). 
 
CCDC numbers 1900567 and 1900568 contain the supplementary crystallographic data for these 
compounds and can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from 
the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44-
1223-336033; or deposit@ccdc.cam.ac.uk). 
2 Synthetic procedures and characterization 
2.1 Furo[3,4-d]pyrimidine derivatives 
4-(Methoxycarbonyl)furan-3-carboxylic acid (283) 
This compound was synthesized in 95% yield according to the method of Hawker and Silverman.
208
 All 
spectra were in accordance with reported data. 
Methyl 4-ureidofuran-3-carboxylate (284) 
A two-necked, round-bottomed flask of 250 mL is flame dried and equipped with an air cooler and 
calcium chloride tube. To this flask, 2.409 g of 4-(methoxycarbonyl)furan-3-carboxylic acid 283 (14.2 
mmol; 1 eq.), 100 mL of dry toluene and 2.8 mL of triethylamine (1.4 eq.) are added. The reaction is 
stirred at room temperature until a clear solution is obtained. Then, a solution of 3.2 mL DPPA (1.05 
eq.) in 40 mL of dry toluene is added to the reaction and stirred for one hour at room temperature. 
Then, the temperature is increased to 75 °C and the reaction is stirred for three hours at this 
temperature. The reaction is cooled down to 0 °C with an ice bath, and a gentle flow of pure ammonia 
gas is bubbled through the reaction for 5 minutes at 0 °C. The solvent is removed in vacuo, and the 
residue is suspended in 100 mL of water. The pH of this suspension was measured and was around 
pH = 6. In case the pH is higher than pH = 6, adjust with dilute aqueous hydrochloric acid to pH = 6. 
The suspension is extracted with 100 mL of ethyl acetate (5x), which turns the suspension into a clear 
aqueous layer upon extraction of the product by ethyl acetate. The organic layers are combined, dried 
over magnesium sulfate and filtered. After rotary evaporation of the solvent, 3.43 g of pale yellow 
product is obtained. The crude product is purified by column chromatography over silica gel, eluting 
with 20% methanol in ethyl acetate. A pale yellow product is obtained, which is triturated in 10 mL of 
ethyl acetate. The solvent is removed by filtration and 2.245 g of a white powder is obtained (Y = 
86%).  
1
H NMR (400 MHz, DMSO-d6): δ = 3.82 (s, 3H, OCH3), 6.51 (br. s, 2H, NH2), 7.95 (d, J = 
1.8 Hz, 1H, CHar), 8.10 (s, 1H, NH), 8.24 (d, J = 1.8 Hz, 1H, CHar). 
13
C NMR (100 MHz, 
DMSO-d6): δ = 52.0 (OCH3), 110.3 (CqC(O)OMe), 125.8 (CqNHC(O)), 131.4 (OCHCqNH), 
147.5 (OCHCqC(O)), 155.8 (NHC(O)NH2), 164.0 (C(O)OMe). IR: 3442, 3214, 1716, 1678, 
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1550, 1511, 1349, 1250, 1153, 1118, 1038, 767 cm
–1
. MS (ESI, 70 eV): m/z (%) = 185.0 (100, [M + 
H]
+
). HRMS: m/z [M + H]
+
 calcd for C7H9N2O4: 185.0557; found: 185.0557. Mp 239-240 °C (degrad.). 
 
Furo[3,4-d]pyrimidine-2,4(1H,3H)-dione (6) 
To a suspension of 1.147 g of sodium methoxide (2.9 eq.) in 26 mL of dry methanol is added 1.348 g 
of methyl 4-ureidofuran-3-carboxylate 284 (7.3 mmol; 1 eq.). The reaction is stirred at room 
temperature for three days. After removal of the solvent in vacuo, the residue is taken up in 25 mL of 
water, cooled down to 0 °C and acidified to pH = 5~6 by dropwise addition of 4N aqueous HCl. The 
white precipitate is filtered off, washed with water (2 x 5 mL) and dried under vacuum to obtain 911 mg 
of a white powder (Y = 82%). All spectra were in accordance with reported data.
33
  
Representative procedure for the synthesis of compounds 36: 
Methyl 4-(3-propylureido)furan-3-carboxylate (36a) 
In a flame-dried round-bottomed two-neck flask equipped with an air cooler and CaCl2-tube, DPPA 
(2.27 ml, 10.5 mmol, 1.05 eq.) was dissolved in dry toluene (100 mL). In another flame-dried round-
bottomed flask, 4-(methoxycarbonyl)furan-3-carboxylic acid 283 (1.7 g, 10 mmol, 1 eq.) and dry Et3N 
(2 mL, 14 mmol, 1.4 eq.) were dissolved in dry toluene (50 mL). This solution was added to the 
reaction mixture and stirring was continued at room temperature for 1 hour. Next, the reaction mixture 
was heated at 75 °C for 3 hours. After cooling to room temperature, n-propylamine (1.65 mL, 20 mmol, 
2 eq.) was added and the reaction mixture was stirred at room temperature overnight. After 
evaporation of the solvent, the residue was taken up in EtOAc (100 mL) and was added in a 
separation funnel together with water (100 mL). While frequently shaking, the aqueous layer was 
neutralized with dilute HCl (3N). After separation, the aqueous layer was extracted again with EtOAc 
(100 mL). The combined organic extracts were washed with brine (100 mL), dried over magnesium 
sulfate and evaporated in vacuo. After column chromatography over silica (100% ethyl acetate), 2.26 g 
of partially purified 36a was obtained (95% purity, HPLC). For characterization purposes, 500 mg of 
this compound was used for recrystallization from ethyl acetate to give the title compound 36a (350 
mg, 70%) as white crystals.  
1
H NMR (300 MHz, CDCl3):  = 0.95 (t, J = 7.3 Hz, 3H), 1.57 (sextet, J = 7.3 Hz, 2H), 
3.15-3.27 (m, 2H), 3.84 (s, 3H), 5.33 (br. s, 1H), 7.83 (s, 1H), 8.01 (br. s, 2H). 
13
C NMR 
(75 MHz, CDCl3):  = 11.4, 23.3, 42.6, 51.7, 109.9, 125.5, 131.7, 146.2, 155.0, 165.1. 
IR: 1725, 1648, 1552, 1253, 1154, 766 cm
-1
. MS (ESI, 70 eV): m/z (%) = 227 (100) [M 
+ H]
+
. HRMS: m/z [M + H]
+
 calcd for C10H14N2O4: 227.1032; found: 227.1029. Mp 141-
142 °C; Rf = 0.6 (EtOAc).  
Methyl 4-(3-benzylureido)furan-3-carboxylate (36b) 
DPPA (1.34 mL, 6.2 mmol, 1.05 eq.) in dry toluene (60 mL) and a solution of 4-
(methoxycarbonyl)furan-3-carboxylic acid 283 (1.0 g, 5.9 mmol, 1 eq.) and dry Et3N (1.17 mL, 8.4 
mmol, 1.4 eq.) in dry toluene (30 mL) and benzylamine (1.3 mL, 11.9 mmol, 2 eq.) were used following 
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the representative procedure. After work-up and chromatography, 1.37 g of partially purified 36b was 
obtained (95% purity, HPLC). For characterization purposes, 500 mg of this compound was used for 
recrystallization from EtOH/H2O (1:1) to give the title compound 36b (365 mg, 62%) as white crystals. 
1
H NMR (300 MHz, CDCl3):  = 3.80 (s, 3H), 4.44 (d, J = 5.5 Hz, 2H), 5.25 (br. s, 
1H), 7.22-7.38 (m, 5H), 7.81 (s, 1H), 7.98 (s, 1H), 8.00 (s, 1H). 
13
C NMR (75 MHz, 
CDCl3):  = 44.8, 51.7, 109.9, 125.4, 127.6, 127.7, 128.8, 131.8, 138.6, 146.2, 
154.6, 165.1. IR: 1722, 1646, 1568, 1557, 1304, 1272, 1150, 1086, 766, 696, 679 
cm
-1
. MS (ESI, 70 eV): m/z (%) = 275 (100) [M + H]
+
. HRMS: m/z [M + H]
+
 calcd for 
C14H14N2O4: 275.1032; found: 275.1032. Mp 113-114 °C; Rf = 0.3 (hexanes-EtOAc, 3:1).  
 
Methyl 4-[3-(pyridin-2-ylmethyl)ureido]furan-3-carboxylate (36c) 
DPPA (1.34 mL, 6.2 mmol, 1.05 eq.) in dry toluene (60 mL) and a solution of 4-
(methoxycarbonyl)furan-3-carboxylic acid 283 (1.0 g, 5.9 mmol, 1 eq.) and dry Et3N (1.17 mL, 8.4 
mmol, 1.4 eq.) in dry toluene (30 mL) and 2-picolylamine (1.22 mL, 11.8 mmol, 2 eq.) were used 
following the representative procedure. After work-up and chromatography, 1.29 g of partially purified 
36c was obtained (85% purity, HPLC). For characterization purposes, 500 mg of this compound was 
used for recrystallization from EtOH to give the title compound 36c (364 mg, 58%) as off-white 
crystals. 
1
H NMR (300 MHz, CDCl3):  = 3.81 (s, 3H), 4.59 (d, J = 5.0 Hz, 2H), 6.32 (br. s, 
1H), 7.16-7.24 (m, 1H), 7.31 (d, J = 7.7 Hz, 1H), 7.62-7.72 (m, 1H), 7.82 (s, 1H), 
8.02 (s, 1H), 8.07 (s, 1H), 8.55 (d, J = 3.9 Hz, 1H).
 13
C NMR (75 MHz, CDCl3):  = 
45.45, 51.7, 109.95, 122.0, 122.5, 125.5, 131.7, 136.9, 146.2, 149.1, 154.7, 157.1, 
164.95. IR: 1726, 1649, 1552, 1508, 1250, 1151, 1096, 1085, 1048, 761, 657 cm
-1
. 
MS (ESI, 70 eV): m/z (%) = 276 (100) [M + H]
+
. HRMS: m/z [M + H]
+
 calcd for C13H13N3O4: 276.0984; 
found: 276.0984. Mp 133-134 °C; Rf = 0.22 (hexanes-EtOAc, 1:2). 
Methyl 4-[3-(4-methoxybenzyl)ureido]furan-3-carboxylate (36d) 
DPPA (1.34 mL, 6.2 mmol, 1.05 eq.) in dry toluene (60 mL) and a solution of 4-
(methoxycarbonyl)furan-3-carboxylic acid 283 (1.0 g, 5.9 mmol, 1 eq.) and dry Et3N (1.17 mL, 8.4 
mmol, 1.4 eq.) in dry toluene (30 mL) and 4-methoxybenzylamine (1.54 mL, 11.8 mmol, 2 eq.) were 
used following the representative procedure. After work-up and chromatography, 1.60 g of partially 
purified 36d was obtained (95% purity, HPLC). For characterization purposes, 500 mg of this 
compound could be recrystallized from EtOH to give the title compound 36d (358 mg, 64%) as white 
crystals. 
1
H NMR (300 MHz, CDCl3):  = 3.79 (s, 6H), 4.36 (d, J = 5.5 Hz, 2H), 5.28-5.38 (m, 1H), 6.85 (d, J = 
8.6 Hz, 2H), 7.23 (d, J = 8.6 Hz, 2H), 7.81 (s, 1H), 7.97 (s, 1H), 8.00 (s, 1H). 
13
C NMR (75 MHz, 
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CDCl3):  = 44.2, 51.7, 55.4, 109.9, 114.1, 125.4, 129.0, 130.7, 131.8, 146.2, 
154.6, 159.1, 165.1. IR: 1715, 1644, 1566, 1513, 1242, 1152, 1083, 1034, 768 
cm
-1
. MS (ESI, 70 eV): m/z (%) = 305 (100) [M + H]
+
. HRMS: m/z [M + H]
+
 calcd 
for C15H16N2O5: 305.1138; found: 305.1139. Mp 139-140 °C; Rf = 0.27 
(hexanes-EtOAc, 2:1). 
Representative procedure for the synthesis of compounds 38: 
3-Propylfuro[3,4-d]pyrimidine-2,4(1H,3H)-dione (38a) 
A solution of 36a (1.76 g, 7.8 mmol, 1 eq.) in dry THF (40 mL) was cooled down to 0 °C with an ice 
bath. Next, potassium tert-butoxide (960 mg, 8.6 mmol, 1.1 eq.) was added in one portion and stirring 
continued at 0 °C for 40 minutes. After quenching the reaction with water (1 mL), the reaction mixture 
was brought into a separation funnel and EtOAc (100 mL) and water (100 mL) were added. While 
shaking frequently, the aqueous layer was neutralized with dilute HCl (3N). After separation, the 
aqueous layer was extracted again with EtOAc (100 mL). The combined organic layers were washed 
with brine (100 mL), dried over magnesium sulfate and evaporated in vacuo. The crude product was 
recrystallized from MeOH to give the title compound 38a (1.33 g, 88% over two steps) as white 
crystals.  
1
H NMR (300 MHz, DMSO-d6):  = 0.84 (t, J = 7.5 Hz, 3H, CH3), 1.52 (sextet, J = 
7.5 Hz, 2H, CH2CH3), 3.74 (t, J = 7.5 Hz, 2H, NCH2), 7.61 (s, 1H, OCHCqNH), 8.43 
(s, 1H, OCHCqC(O)), 10.87 (s, 1H, NH). 
13
C NMR (75 MHz, DMSO-d6):  = 11.7 
(CH3), 21.5 (CH2CH3), 41.7 (NCH2), 110.9 (CqC(O)), 125.5 (CqNHC(O)), 125.9 
(OCHCqNH), 145.0 (OCHCqC(O)), 151.2 (NHC(O)N), 159.0 (CqC(O)N). IR: 1723, 1652, 1345, 1241, 
746, 698 cm
-1
. MS (ESI, 70 eV): m/z (%) = 193 (100) [M-H]
-
. HRMS: m/z [M - H]
-
 calcd for C9H10N2O3: 
193.0613; found: 193.0623. Mp 163-164 °C (degrad.). 
3-Benzylfuro[3,4-d]pyrimidine-2,4(1H,3H)-dione (38b) 
36b (0.87 g, 3.2 mmol, 1 eq.) in dry THF (20 mL) and potassium tert-butoxide (392 mg, 3.5 mmol, 1.1 
eq.) were used following the representative procedure. The crude product was recrystallized from 
MeOH to give the title compound 38b (696 mg, 77% over two steps) as white crystals. 
1
H NMR (300 MHz, DMSO-d6):  = 4.99 (s, 2H), 7.18-7.34 (m, 5H), 7.66 (s, 1H), 
8.49 (s, 1H), 11.01 (s, 1H). 
13
C NMR (75 MHz, DMSO-d6):  = 43.3, 110.8, 125.5, 
126.2, 127.6, 127.9, 128.9, 138.2, 145.3, 151.3, 159.1. IR: 1725, 1652, 1345, 1240, 
751, 699, 683 cm
-1
. MS (ESI, 70 eV): m/z (%) = 241 (100) [M-H]
-
. HRMS: m/z [M - 
H]
-
 calcd for C13H10N2O3: 241.0613; found: 241.0623. Mp 241-242 °C (degrad.).  
3-(Pyridin-2-ylmethyl)furo[3,4-d]pyrimidine-2,4(1H,3H)-dione (38c) 
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36c (0.79 g, 2.9 mmol, 1 eq.) in dry THF (20 mL) and potassium tert-butoxide (354 mg, 3.2 mmol, 1.1 
eq.) were used following the representative procedure. The crude product was recrystallized from 
EtOH to give the title compound 38c (578 mg, 66% over two steps) as white crystals. 
1
H NMR (300 MHz, DMSO-d6):  = 5.11 (s, 2H), 7.18-7.29 (m, 2H), 7.66-7.76 (m, 
2H), 8.42 (d, J = 4.5 Hz, 1H), 8.49 (s, 1H), 10.99 (s, 1H). 
13
C NMR (75 MHz, DMSO-
d6):  = 44.7, 110.8, 121.2, 122.6, 125.6, 126.2, 137.2, 145.3, 149.4, 151.3, 156.8, 
159.1. IR: 1713, 1668, 1648, 1386, 1329, 1244, 765, 694 cm
-1
. MS (ESI, 70 eV): m/z 
(%) = 244 (100) [M+H]
+
. HRMS: m/z [M + H]
+
 calcd for C12H9N3O3: 244.0722; found: 244.0718. Mp 
228-229 °C (degrad.).  
3-(4-Methoxybenzyl)furo[3,4-d]pyrimidine-2,4(1H,3H)-dione (38d) 
36d (1.10 g, 3.6 mmol, 1 eq.) in dry THF (20 mL) and potassium tert-butoxide (446 mg, 4.0 mmol, 1.1 
eq.) were used following the representative procedure. The crude product was recrystallized from 
MeOH to give the title compound 38d (836 mg, 76% over two steps) as white crystals. 
1
H NMR (300 MHz, DMSO-d6):  = 3.69 (s, 3H), 4.91 (s, 2H), 6.84 (d, J = 8.4 
Hz, 2H), 7.23 (d, J = 8.4 Hz, 2H), 7.64 (s, 1H), 8.47 (s, 1H), 10.97 (s, 1H). 
13
C 
NMR (75 MHz, DMSO-d6):  = 42.7, 55.6, 110.8, 114.2, 125.4, 126.1, 129.7, 
130.3, 145.2, 151.3, 158.9, 159.0. IR: 1721, 1661, 1652, 1242, 1028, 766, 750, 
721 cm
-1
. MS (ESI, 70 eV): m/z (%) = 271 (100) [M-H]
-
. HRMS: m/z [M - H]
-
 calcd for C14H12N2O4: 
271.0719; found: 271.0731. Mp 217-218 °C (degrad).  
3-(2-Methoxybenzyl)furo[3,4-d]pyrimidine-2,4(1H,3H)-dione (38e) 
DPPA (0.13 mL, 0.62 mmol, 1.05 eq.) in dry toluene (6 mL) and a solution of 4-
(methoxycarbonyl)furan-3-carboxylic acid 283 (100 mg, 0.59 mmol, 1 eq.) and dry Et3N (0.12 mL, 0.84 
mmol, 1.4 eq.) in dry toluene (3 mL) and 2-methoxybenzylamine (0.16 mL, 1.18 mmol, 2 eq.) were 
used following the representative procedure for compound 36. After work-up and chromatography 
(hexanes-EtOAc, 4:1, Rf = 0.17), 163 mg of 36e was obtained. Next, 36e (163 mg, 0.54 mmol, 1 eq.) 
in dry THF (2 mL) and potassium tert-butoxide (66 mg, 0.59 mmol, 1.1 eq.) were used following the 
representative procedure for compound 38. The crude product was recrystallized from MeOH to give 
the title compound 38e (126 mg, 79% over two steps) as white crystals. 
1
H NMR (400 MHz, DMSO-d6):  = 3.85 (s, 3H), 4.96 (s, 2H), 6.78 (d, J = 7.6 Hz, 
1H), 6.85 (t, J = 7.6 Hz, 1H), 7.01 (d, J = 7.6 Hz, 1H), 7.22 (t, J = 7.6 Hz, 1H), 7.70 
(s, 1H), 8.51 (s, 1H), 11.03 (br. s, 1H). 
13
C NMR (100 MHz, DMSO-d6):  = 38.9, 
55.8, 110.7, 110.9, 120.65, 125.3, 125.4, 125.5, 126.1, 128.15, 145.2, 151.1, 156.8, 
159.0. IR: 1724, 1660, 1240, 1027, 743 cm
-1
. MS (ESI, 70 eV): m/z (%) = 273 (100) [M+H]
+
. HRMS: 
m/z [M + H]
+
 calcd for C14H12N2O4: 273.0870; found: 273.0882. Mp 209-210 °C (degrad.).  
3-(3-Methoxybenzyl)furo[3,4-d]pyrimidine-2,4(1H,3H)-dione (38f) 
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DPPA (0.13 mL, 0.62 mmol, 1.05 eq.) in dry toluene (6 mL) and a solution of 283 (100 mg, 0.59 mmol, 
1 eq.) and dry Et3N (0.12 mL, 0.84 mmol, 1.4 eq.) in dry toluene (3 mL) and 3-methoxybenzylamine 
(0.15 mL, 1.18 mmol, 2 eq.) were used following the representative procedure for compound 36. After 
work-up and chromatography (hexanes-EtOAc, 3:1, Rf = 0.22), 152 mg of 36f was obtained. Next, 36f 
(152 mg, 0.50 mmol, 1 eq.) in dry THF (2 mL) and potassium tert-butoxide (62 mg, 0.55 mmol, 1.1 eq.) 
were used following the representative procedure for compound 38. The crude product was 
recrystallized from MeOH to give the title compound 38f (118 mg, 74% over two steps) as white 
crystals. 
1
H NMR (400 MHz, DMSO-d6):  = 3.72 (s, 3H), 4.98 (s, 2H), 6.79-6.86 (m, 
3H), 7.22 (t, J = 8.0 Hz, 1H), 7.67 (d, J = 1.3 Hz, 1H), 8.50 (d, J = 1.3 Hz, 1H), 
11.00 (br. s, 1H). 
13
C NMR (100 MHz, DMSO-d6):  = 43.1, 55.4, 110.6, 112.7, 
113.7, 119.8, 125.35, 126.1, 129.9, 139.7, 145.2, 151.2, 159.0, 159.7. IR: 
1731, 1664, 1652, 1389, 1239, 760, 709 cm
-1
. MS (ESI, 70 eV): m/z (%) = 273 (100) [M+H]
+
. HRMS: 
m/z [M + H]
+
 calcd for C14H12N2O4: 273.0870; found: 273.0859. Mp 187-188 °C (degrad.).  
3-(2-Fluorobenzyl)furo[3,4-d]pyrimidine-2,4(1H,3H)-dione (38g) 
DPPA (0.13 mL, 0.62 mmol, 1.05 eq.) in dry toluene (6 mL) and a solution of 283 (100 mg, 0.59 mmol, 
1 eq.) and dry Et3N (0.12 mL, 0.84 mmol, 1.4 eq.) in dry toluene (3 mL) and 2-fluorobenzylamine (0.14 
mL, 1.18 mmol, 2 eq.) were used following the representative procedure for compound 36. After work-
up and chromatography (hexanes-EtOAc, 5:1, Rf = 0.22), 160 mg of 36g was obtained. Next, 36g (160 
mg, 0.55 mmol, 1 eq.) in dry THF (2 mL) and potassium tert-butoxide (68 mg, 0.60 mmol, 1.1 eq.) 
were used following the representative procedure for compound 38. The crude product was 
recrystallized from MeOH to give the title compound 38g (115 mg, 75% over two steps) as white 
crystals.  
1
H NMR (400 MHz, DMSO-d6):  = 5.06 (s, 2H), 7.01-7.40 (m, 4H), 7.69 (s, 1H), 
8.52 (s, 1H), 11.05 (br. s, 1H). 
13
C NMR (100 MHz, DMSO-d6):  = 37.3 (d, J = 5.1 
Hz), 110.6, 115.6 (d, J = 21.1 Hz), 124.8 (d, J = 14.0 Hz), 124.9 (d, J = 3.2 Hz), 
125.4, 126.2, 128.5 (d, J = 4.1 Hz), 129.3 (d, J = 8.1 Hz), 145.3, 151.0, 158.9, 160.3 
(d, J = 244.4 Hz). 
19
F NMR (376 MHz, DMSO-d6):  = -118.3. IR: 1729, 1660, 1334, 1243, 1230, 753, 
718 cm
-1
. MS (ESI, 70 eV): m/z (%) = 261 (100) [M+H]
+
. HRMS: m/z [M + H]
+
 calcd for C13H9FN2O3: 
261.0670; found: 261.0665. Mp 244-245 °C (degrad.).  
3-(3-Fluorobenzyl)furo[3,4-d]pyrimidine-2,4(1H,3H)-dione (38h) 
DPPA (0.13 mL, 0.62 mmol, 1.05 eq.) in dry toluene (6 mL) and a solution of 283 (100 mg, 0.59 mmol, 
1 eq.) and dry Et3N (0.12 mL, 0.84 mmol, 1.4 eq.) in dry toluene (3 mL) and 3-fluorobenzylamine (0.14 
mL, 1.18 mmol, 2 eq.) were used following the representative procedure for compound 36. After work-
up and chromatography (hexanes-EtOAc, 5:1, Rf = 0.22), 149 mg of 36h was obtained. Next, 36h (149 
mg, 0.51 mmol, 1 eq.) in dry THF (2 mL) and potassium tert-butoxide (63 mg, 0.56 mmol, 1.1 eq.) 
were used following the representative procedure for compound 38. The crude product was 
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recrystallized from MeOH to give the title compound 38h (109 mg, 71% over two steps) as white 
crystals.  
1
H NMR (400 MHz, DMSO-d6):  = 5.01 (s, 2H), 7.04-7.15 (m, 3H), 7.31-7.40 (m, 
1H), 7.68 (d, J = 1.6 Hz, 1H), 8.51 (d, J = 1.6 Hz, 1H), 11.03 (br. s, 1H). 
13
C NMR 
(100 MHz, DMSO-d6):  = 42.8, 110.6, 114.3 (d, J = 20.8 Hz), 114.6 (d, J = 21.9 
Hz), 123.7 (d, J = 2.6 Hz), 125.4, 126.1, 130.8 (d, J = 8.5 Hz), 141.0 (d, J = 7.3 
Hz), 145.3, 151.1, 159.0, 162.6 (d, J = 243.5 Hz). 
19
F NMR (376 MHz, DMSO-d6):  = -113.0. IR: 
1724, 1652, 1336, 1275, 1237, 767, 739 cm
-1
. MS (ESI, 70 eV): m/z (%) = 259 (100) [M-H]
-
. HRMS: 
m/z [M + H]
+
 calcd for C13H9FN2O3: 261.0670; found: 261.0678. Mp 220-221 °C (degrad.).  
3-(3,4,5-Trimethoxybenzyl)furo[3,4-d]pyrimidine-2,4(1H,3H)-dione (38i) 
DPPA (0.13 mL, 0.62 mmol, 1.05 eq.) in dry toluene (6 mL) and a solution of 283 (100 mg, 0.59 mmol, 
1 eq.) and dry Et3N (0.12 mL, 0.84 mmol, 1.4 eq.) in dry toluene (3 mL) and 3,4,5-
trimethoxybenzylamine (0.20 mL, 1.18 mmol, 2 eq.) were used following the representative procedure 
for compound 36. After work-up and chromatography (hexanes-EtOAc, 2:1, Rf = 0.17), 197 mg of 36i 
was obtained. Next, 36i (197 mg, 0.54 mmol, 1 eq.) in dry THF (2 mL) and potassium tert-butoxide (67 
mg, 0.59 mmol, 1.1 eq.) were used following the representative procedure for compound 38. The 
crude product was recrystallized from MeOH to give the title compound 38i (158 mg, 81% over two 
steps) as white crystals. 
1
H NMR (400 MHz, DMSO-d6):  = 3.62 (s, 3H), 3.72 (s, 6H), 4.94 (s, 2H), 6.61 
(s, 2H), 7.67 (d, J = 1.6 Hz, 1H), 8.50 (d, J = 1.6 Hz, 1H), 10.99 (br. s, 1H). 
13
C 
NMR (100 MHz, DMSO-d6):  = 43.4, 56.3, 60.4, 105.6, 110.7, 125.4, 126.1, 
133.8, 137.1, 145.2, 151.2, 153.2, 159.0. IR: 1729, 1657, 1591, 1350, 1333, 
1236, 1114, 1011, 747, 704 cm
-1
. MS (ESI, 70 eV): m/z (%) = 333 (100) [M+H]
+
. HRMS: m/z [M + H]
+
 
calcd for C16H16N2O6: 333.1081; found: 333.1085. Mp 218-219 °C (degrad.).  
3-(2,3-Dimethoxybenzyl)furo[3,4-d]pyrimidine-2,4(1H,3H)-dione (38j) 
DPPA (0.13 mL, 0.62 mmol, 1.05 eq.) in dry toluene (6 mL) and a solution of 283 (100 mg, 0.59 mmol, 
1 eq.) and dry Et3N (0.12 mL, 0.84 mmol, 1.4 eq.) in dry toluene (3 mL) and 2,3-
dimethoxybenzylamine (0.18 mL, 1.18 mmol, 2 eq.) were used following the representative procedure 
for compound 36. After work-up and chromatography (hexanes-EtOAc, 2:1, Rf = 0.17), 185 mg of 36j 
was obtained. Next, 36j (185 mg, 0.55 mmol, 1 eq.) in dry THF (2 mL) and potassium tert-butoxide (68 
mg, 0.61 mmol, 1.1 eq.) were used following the representative procedure for compound 38. The 
crude product was recrystallized from MeOH to give the title compound 38j (137 mg, 77% over two 
steps) as white crystals. 
1
H NMR (400 MHz, DMSO-d6):  = 3.80 (s, 3H), 3.81 (s, 3H), 5.03 (s, 2H), 6.49 
(d, J = 6.6 Hz, 1H), 6.89-7.02 (m, 2H), 7.69 (s, 1H), 8.50 (s, 1H), 11.01 (br. s, 
1H). 
13
C NMR (100 MHz, DMSO-d6):  = 38.5, 56.1, 60.2, 110.7, 111.9, 118.3, 
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124.3, 125.4, 126.1, 131.4, 145.2, 146.4, 151.1, 152.8, 159.0. IR: 1732, 1660, 1334, 1234, 1221, 
1066, 758, 744 cm
-1
. MS (ESI, 70 eV): m/z (%) = 303 (100) [M+H]
+
. HRMS: m/z [M + H]
+
 calcd for 
C15H14N2O5: 303.09755; found: 303.0974. Mp 215-216 °C (degrad.).  
3-[4-(Trifluoromethoxy)benzyl]furo[3,4-d]pyrimidine-2,4(1H,3H)-dione (38k)  
DPPA (0.13 mL, 0.62 mmol, 1.05 eq.) in dry toluene (6 mL) and a solution of 283 (100 mg, 0.59 mmol, 
1 eq.) and dry Et3N (0.12 mL, 0.84 mmol, 1.4 eq.) in dry toluene (3 mL) and 4-
(trifluoromethoxy)benzylamine (0.18 mL, 1.18 mmol, 2 eq.) were used following the representative 
procedure for compound 36. After work-up and chromatography (hexanes-EtOAc, 4:1, Rf = 0.21), 206 
mg of 36k was obtained. Next, 36k (206 mg, 0.57 mmol, 1 eq.) in dry THF (2 mL) and potassium tert-
butoxide (71 mg, 0.63 mmol, 1.1 eq.) were used following the representative procedure for compound 
38. The crude product was recrystallized from MeOH to give the title compound 38k (157 mg, 82% 
over two steps) as white crystals.  
1
H NMR (400 MHz, DMSO-d6):  = 5.03 (s, 2H), 7.31 (d, J = 8.4 Hz, 2H), 7.42 
(d, J = 8.4 Hz, 2H), 7.68 (d, J = 1.6 Hz, 1H), 8.51 (d, J = 1.6 Hz, 1H), 11.04 (br. 
s, 1H). 
13
C NMR (100 MHz, DMSO-d6):  = 42.6, 110.6, 120.5 (q, J = 255.9 Hz), 
121.4, 125.4, 126.2, 129.8, 137.6, 145.3, 147.7, 151.1, 159.0. 
19
F NMR (376 
MHz, DMSO-d6):  = -56.4. IR: 1728, 1667, 1281, 1239, 1211, 1146, 1098, 706 cm
-1
. MS (ESI, 70 eV): 
m/z (%) = 325 (100) [M-H]
-
. HRMS: m/z [M - H]
-
 calcd for C14H9F3N2O4: 325.0442; found: 325.0453. 
Mp 203-204 °C (degrad.).  
3-(4-Phenoxybenzyl)furo[3,4-d]pyrimidine-2,4(1H,3H)-dione (38l) 
DPPA (0.13 mL, 0.62 mmol, 1.05 eq.) in dry toluene (6 mL) and a solution of 283 (100 mg, 0.59 mmol, 
1 eq.) and dry Et3N (0.12 mL, 0.84 mmol, 1.4 eq.) in dry toluene (3 mL) and 4-phenoxybenzylamine 
(0.21 mL, 1.18 mmol, 2 eq.) were used following the representative procedure for compound 36. After 
work-up and chromatography (hexanes-EtOAc, 4:1, Rf = 0.27), 205 mg of 36l was obtained. Next, 36l 
(205 mg, 0.56 mmol, 1 eq.) in dry THF (2 mL) and potassium tert-butoxide (69 mg, 0.62 mmol, 1.1 eq.) 
were used following the representative procedure for compound 38. The crude product was 
recrystallized from MeOH to give the title compound 38l (157 mg, 80% over two steps) as white 
crystals. 
1
H NMR (400 MHz, DMSO-d6):  = 4.99 (s, 2H), 6.80-7.50 (m, 9H), 7.67 (s, 
1H), 8.50 (s, 1H), 11.01 (br. s, 1H). 
13
C NMR (100 MHz, DMSO-d6):  = 42.6, 
110.7, 118.9, 119.0, 123.8, 125.3, 126.1, 129.9, 130.5, 133.3, 145.2, 151.2, 
156.1, 157.2, 158.9. IR: 1727, 1651, 1343, 1236, 752, 738, 690 cm
-1
. MS 
(ESI, 70 eV): m/z (%) = 335 (100) [M+H]
+
. HRMS: m/z [M + H]
+
 calcd for C19H14N2O4: 335.1026; found: 
335.1027. Mp 209-210 °C (degrad.).  
3-(4-Ethoxybenzyl)furo[3,4-d]pyrimidine-2,4(1H,3H)-dione (38m)  
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DPPA (0.13 mL, 0.62 mmol, 1.05 eq.) in dry toluene (6 mL) and a solution of 283 (100 mg, 0.59 mmol, 
1 eq.) and dry Et3N (0.12 mL, 0.84 mmol, 1.4 eq.) in dry toluene (3 mL) and 4-ethoxybenzylamine (178 
mg, 1.18 mmol, 2 eq.) were used following the representative procedure for compound 36. After work-
up and chromatography (hexanes-EtOAc, 4:1, Rf = 0.25), 167 mg of 36m was obtained. Next, 36m 
(167 mg, 0.52 mmol, 1 eq.) in dry THF (2 mL) and potassium tert-butoxide (65 mg, 0.58 mmol, 1.1 eq.) 
were used following the representative procedure for compound 38. The crude product was 
recrystallized from MeOH to give the title compound 38m (128 mg, 76% over two steps) as white 
crystals. 
1
H NMR (400 MHz, DMSO-d6):  = 1.30 (t, J = 6.9 Hz, 3H), 3.98 (q, J = 6.9 Hz, 
2H), 4.93 (s, 2H), 6.85 (d, J = 8.4 Hz, 2H), 7.23 (d, J = 8.4 Hz, 2H), 7.65 (s, 1H), 
8.48 (s, 1H), 10.97 (br. s, 1H). 
13
C NMR (100 MHz, DMSO-d6):  = 15.1, 42.6, 
63.4, 110.7, 114.6, 125.3, 126.0, 129.6, 130.0, 145.1, 151.2, 158.1, 158.9. IR: 
1729, 1659, 1250, 1236, 1220, 744, 681 cm
-1
. MS (ESI, 70 eV): m/z (%) = 287 (100) [M+H]
+
. HRMS: 
m/z [M + H]
+
 calcd for C15H14N2O4: 287.1026; found: 287.1033. Mp 209-210 °C (degrad.).  
3-[(6-Methoxypyridin-3-yl)methyl]furo[3,4-d]pyrimidine-2,4(1H,3H)-dione (38n)  
DPPA (0.13 mL, 0.62 mmol, 1.05 eq.) in dry toluene (6 mL) and a solution of 283 (100 mg, 0.59 mmol, 
1 eq.) and dry Et3N (0.12 mL, 0.84 mmol, 1.4 eq.) in dry toluene (3 mL) and 5-(aminomethyl)-2-
methoxypyridine (162 mg, 1.18 mmol, 2 eq.) were used following the representative procedure for 
compound 36. After work-up and chromatography (hexanes-EtOAc, 2:1, Rf = 0.19), 147 mg of 36n 
was obtained. Next, 36n (147 mg, 0.48 mmol, 1 eq.) in dry THF (2 mL) and potassium tert-butoxide 
(59 mg, 0.53 mmol, 1.1 eq.) were used following the representative procedure for compound 38. The 
crude product was recrystallized from MeOH to give the title compound 38n (111 mg, 69% over two 
steps) as white crystals. 
1
H NMR (400 MHz, DMSO-d6):  = 3.82 (s, 3H), 4.94 (s, 2H), 6.76 (d, J = 8.5 
Hz, 1H), 7.63-7.68 (m, 2H), 8.15 (d, J = 2.1 Hz, 1H), 8.49 (d, J = 1.6 Hz, 1H), 
11.01 (br. s, 1H). 
13
C NMR (100 MHz, DMSO-d6):  = 40.4, 53.6, 110.66, 
110.67, 125.3, 126.1, 126.85, 139.7, 145.2, 147.1, 151.1, 158.95, 163.3. IR: 
1720, 1673, 1499, 1394, 1330, 1293, 1243, 1028, 1017, 873, 760, 743, 688 cm
-1
. MS (ESI, 70 eV): 
m/z (%) = 274 (100) [M+H]
+
. HRMS: m/z [M + H]
+
 calcd for C13H11N3O4: 274.0822; found: 274.0828. 
Mp 211-212 °C (degrad.).  
3-(4-Cyanobenzyl)furo[3,4-d]pyrimidine-2,4(1H,3H)-dione (38o)  
DPPA (0.13 mL, 0.62 mmol, 1.05 eq.) in dry toluene (6 mL) and a solution of 283 (100 mg, 0.59 mmol, 
1 eq.) and dry Et3N (0.12 mL, 0.84 mmol, 1.4 eq.) in dry toluene (3 mL) and 4-cyanobenzylamine (155 
mg, 1.18 mmol, 2 eq.) were used following the representative procedure for compound 36. After work-
up and chromatography (hexanes-EtOAc, 2:1, Rf = 0.24), 162 mg of 36o was obtained. Next, 36o (162 
mg, 0.54 mmol, 1 eq.) in dry THF (2 mL) and potassium tert-butoxide (67 mg, 0.60 mmol, 1.1 eq.) 
were used following the representative procedure for compound 38. The crude product was 
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recrystallized from MeOH to give the title compound 38o (123 mg, 78% over two steps) as white 
crystals. 
1
H NMR (400 MHz, DMSO-d6):  = 5.08 (s, 2H), 7.46 (d, J = 8.0 Hz, 2H), 7.69 (s, 
1H), 7.78 (d, J = 8.0 Hz, 2H), 8.52 (s, 1H), 11.07 (br. s, 1H). 
13
C NMR (100 MHz, 
DMSO-d6):  = 43.2, 110.2, 110.6, 119.3, 125.4, 126.2, 128.5, 132.8, 143.9, 
145.3, 151.1, 159.0. IR: 2226, 1727, 1662, 1431, 1340, 1235, 760, 740, 712 cm
-1
. 
MS (ESI, 70 eV): m/z (%) = 266 (100) [M-H]
-
. HRMS: m/z [M - H]
-
 calcd for C14H9N3O3: 266.0571; 
found: 266.0573. Mp 250-251 °C (degrad.).  
Representative procedure for the synthesis of 285: 
1-Isopropyl-3-propylfuro[3,4-d]pyrimidine-2,4(1H,3H)-dione (285a) 
To a solution of 38a (500 mg, 2.57 mmol, 1 eq.) in dry DMF (20 mL), Cs2CO3 (2.52 g, 7.7 mmol, 3 eq.) 
and TBAI (2.85 g, 7.7 mmol, 3 eq.) were added under an inert atmosphere. After stirring the reaction 
for 30 minutes at room temperature, 2-bromopropane (0.73 ml, 7.7 mmol, 3 eq.) was added and 
stirring continued at room temperature for 24 hours. Water (50 mL) was added, and the reaction 
mixture was extracted with EtOAc (3x 50 mL). The combined organic layers were combined, washed 
with brine (50 mL), dried over MgSO4 and evaporated in vacuo. The crude product was purified by 
column chromatography over silica and subsequently recrystallized from EtOH to give the title 
compound 285a (335 mg, 55%) as white crystals.  
1
H NMR (300 MHz, DMSO-d6):  = 0.83 (t, J = 7.6 Hz, 3H, CH2CH3), 1.35 (d, J = 7.1 
Hz, 6H, CH(CH3)2), 1.51 (sextet, J = 7.6 Hz, 2H, CH2CH3), 3.76 (t, J = 7.6 Hz, 2H, 
NCH2), 4.75 (septet, J = 7.1 Hz, 1H, CH(CH3)2), 8.06 (d, J = 1.4 Hz, 1H, OCHCqN), 
8.51 (d, J = 1.4 Hz, 1H, OCHCqC(O)). 
13
C NMR (75 MHz, DMSO-d6):  = 11.7 
(CH2CH3), 18.8 (CH(CH3)2), 21.5 (CH2CH3), 42.5 (NCH2), 48.9 (CH(CH3)2), 111.5 (CqC(O)), 125.4 
(CqNC(O)), 126.9 (OCHCqN), 145.2 (OCHCqC(O)), 150.4 (NC(O)N), 158.2 (CqC(O)N). IR: 1701, 1660, 
1630, 1259, 1068, 870, 757, 748 cm
-1
. MS (ESI, 70 eV): m/z (%) = 237 (100) [M+H]
+
. HRMS: m/z [M + 
H]
+
 calcd for C12H16N2O3: 237.1239; found: 237.1232. Mp 55-56 °C; Rf = 0.15 (hexanes-EtOAc, 5:1).  
1-Benzyl-3-propylfuro[3,4-d]pyrimidine-2,4(1H,3H)-dione (285b) 
38a (500 mg, 2.57 mmol, 1 eq.) in dry DMF (20 mL), Cs2CO3 (2.52 g, 7.7 mmol, 3 eq.), TBAI (2.85 g, 
7.7 mmol, 3 eq.) and benzyl bromide (0.92 ml, 7.7 mmol, 3 eq.) were used following the representative 
procedure for compound 285. After work-up and chromatography over silica, the title compound 285b 
(731 mg, 99%) was obtained as a white solid.  
1
H NMR (300 MHz, CDCl3):  = 0.98 (t, J = 7.4 Hz, 3H), 1.70 (sextet, J = 7.4 Hz, 2H), 
3.99 (t, J = 7.4 Hz, 2H), 5.00 (s, 2H), 7.17 (d, J = 1.7 Hz, 1H), 7.25-7.39 (m, 5H), 8.02 
(d, J = 1.7 Hz, 1H). 
13
C NMR (75 MHz, CDCl3):  = 11.4, 21.5, 43.1, 49.5, 111.2, 125.1, 
127.6, 127.9, 128.15, 129.0, 135.3, 144.1, 151.4, 158.4. IR: 1709, 1662, 1638, 1392, 
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1334, 1251, 1035, 746, 711, 697 cm
-1
. MS (ESI, 70 eV): m/z (%) = 285 (100) [M+H]
+
. HRMS: m/z [M + 
H]
+
 calcd for C16H16N2O3: 285.1239; found: 285.1232. Mp 118-119 °C; Rf = 0.22 (hexanes-EtOAc, 5:1).  
1-Allyl-3-propylfuro[3,4-d]pyrimidine-2,4(1H,3H)-dione (285c) 
38a (500 mg, 2.57 mmol, 1 eq.) in dry DMF (20 mL), Cs2CO3 (2.52 g, 7.7 mmol, 3 eq.), TBAI (2.85 g, 
7.7 mmol, 3 eq.) and allyl bromide (0.67 ml, 7.7 mmol, 3 eq.) were used following the representative 
procedure for compound 285. After work-up, chromatography over silica and subsequent 
recrystallization from EtOH, the title compound 285c (307 mg, 51%) was obtained as white crystals.  
1
H NMR (300 MHz, DMSO-d6):  = 0.84 (t, J = 7.4 Hz, 3H), 1.53 (sextet, J = 7.4 Hz, 
2H), 3.79 (t, J = 7.4 Hz, 2H), 4.35 (d, J = 5.1 Hz, 2H), 5.13-5.30 (m, 2H), 5.75-5.90 (m, 
1H), 7.87 (d, J = 1.7 Hz, 1H), 8.51 (d, J = 1.7 Hz, 1H). 
13
C NMR (75 MHz, DMSO-d6): 
 = 11.7, 21.5, 42.6, 48.1, 111.0, 118.3, 126.7, 127.8, 131.8, 145.6, 150.6, 158.4. IR: 
1712, 1659, 1636, 1340, 1288, 1266, 764 cm
-1
. MS (ESI, 70 eV): m/z (%) = 235 (100) [M+H]
+
. HRMS: 
m/z [M + H]
+
 calcd for C12H14N2O3: 235.1083; found: 235.1081. Mp 77-78 °C; Rf = 0.22 (hexanes-
EtOAc, 5:1).  
3-Benzyl-1-isopropylfuro[3,4-d]pyrimidine-2,4(1H,3H)-dione (285d) 
38b (375 mg, 1.55 mmol, 1 eq.) in dry DMF (12 mL), Cs2CO3 (1.52 g, 4.65 mmol, 3 eq.), TBAI (1.72 g, 
4.65 mmol, 3 eq.) and 2-bromopropane (0.44 ml, 4.65 mmol, 3 eq.) were used following the 
representative procedure for compound 285. After work-up, chromatography over silica and 
subsequent recrystallization from EtOH, the title compound 285d (290 mg, 66%) was obtained as 
white crystals.  
1
H NMR (300 MHz, CDCl3):  = 1.43 (d, J = 6.8 Hz, 6H), 4.93 (septet, J = 6.8 Hz, 
1H), 5.16 (s, 2H), 7.21-7.36 (m, 3H), 7.39 (d, J = 1.7 Hz, 1H), 7.45-7.52 (m, 2H), 8.08 
(d, J = 1.7 Hz, 1H). 
13
C NMR (75 MHz, CDCl3):  = 18.8, 44.5, 48.8, 111.7, 125.0, 
125.25, 127.6, 128.5, 129.0, 137.45, 144.05, 150.7, 158.4. IR: 1704, 1660, 1627, 
1347, 1262, 708 cm
-1
. MS (ESI, 70 eV): m/z (%) = 285 (100) [M+H]
+
. HRMS: m/z [M + H]
+
 calcd for 
C16H16N2O3: 285.1239; found: 285.1235. Mp 100-101 °C; Rf = 0.24 (hexanes-EtOAc, 5:1).  
1,3-Dibenzylfuro[3,4-d]pyrimidine-2,4(1H,3H)-dione (285e) 
38b (120 mg, 0.50 mmol, 1 eq.) in dry DMF (5 mL), Cs2CO3 (0.49 g, 1.50 mmol, 3 eq.), TBAI (0.55 g, 
1.50 mmol, 3 eq.) and benzyl bromide (0.18 ml, 1.50 mmol, 3 eq.) were used following the 
representative procedure for compound 285. After work-up, chromatography over silica and 
subsequent recrystallization from EtOH, the title compound 285e (141 mg, 86%) was obtained as 
white crystals.  
1
H NMR (300 MHz, acetone-d6):  = 5.05 (s, 2H), 5.17 (s, 2H), 7.18-7.48 (m, 10H), 7.67 (s, 1H), 8.29 
(s, 1H). 
13
C NMR (75 MHz, acetone-d6):  = 44.0, 48.9, 111.2, 126.1, 127.2, 127.67, 127.73, 128.1, 
128.2, 128.3, 128.7, 136.15, 138.05, 144.8, 151.3, 158.0. IR: 1709, 1664, 1638, 1339, 1258, 714, 708 
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cm
-1
. MS (ESI, 70 eV): m/z (%) = 333 (100) [M+H]
+
. HRMS: m/z [M + H]
+
 calcd for 
C20H16N2O3: 333.1239; found: 333.1235. Mp 108-109 °C; Rf = 0.20 (hexanes-EtOAc, 
5:1).  
 
1-Allyl-3-benzylfuro[3,4-d]pyrimidine-2,4(1H,3H)-dione (285f) 
38b (500 mg, 2.06 mmol, 1 eq.) in dry DMF (20 mL), Cs2CO3 (2.0 g, 6.18 mmol, 3 eq.), TBAI (2.3 g, 
6.18 mmol, 3 eq.) and allyl bromide (0.54 ml, 6.18 mmol, 3 eq.) were used following the representative 
procedure for compound 285. After work-up and chromatography over silica, the title compound 285f 
(518 mg, 89%) was obtained as a white solid.  
1
H NMR (300 MHz, DMSO-d6):  = 4.37 (d, J = 4.5 Hz, 2H), 5.03 (s, 2H), 5.14-5.31 
(m, 2H), 5.75-5.91 (m, 1H), 7.17-7.36 (m, 5H), 7.91 (d, J = 1.7 Hz, 1H), 8.56 (d, J = 
1.7 Hz, 1H). 
13
C NMR (75 MHz, DMSO-d6):  = 44.2, 48.2, 110.95, 118.4, 127.0, 
127.6, 127.8, 127.9, 128.9, 131.7, 138.05, 145.9, 150.7, 158.5. IR: 1710, 1665, 
1638, 1390, 1342, 1305, 1263, 758, 708 cm
-1
. MS (ESI, 70 eV): m/z (%) = 283 (100) [M+H]
+
. HRMS: 
m/z [M + H]
+
 calcd for C16H14N2O3: 283.1083; found: 283.1076. Mp 101-102 °C; Rf = 0.20 (hexanes-
EtOAc, 5:1).  
1-Isopropyl-3-(pyridin-2-ylmethyl)furo[3,4-d]pyrimidine-2,4(1H,3H)-dione (285g) 
38c (500 mg, 2.06 mmol, 1 eq.) in dry DMF (20 mL), Cs2CO3 (2.0 g, 6.18 mmol, 3 eq.), TBAI (2.3 g, 
6.18 mmol, 3 eq.) and 2-bromopropane (0.58 ml, 6.18 mmol, 3 eq.) were used following the 
representative procedure for compound 285. After work-up, chromatography over silica and 
subsequent recrystallization from EtOH, the title compound 285g (159 mg, 35%) was obtained as off-
white crystals.  
1
H NMR (300 MHz, CDCl3):  = 1.45 (d, J = 7.1 Hz, 6H), 4.93 (septet, J = 7.1 Hz, 
1H), 5.31 (s, 2H), 7.13 (dd, J = 7.5 Hz, J = 5.0 Hz, 1H), 7.22 (d, J = 7.5 Hz, 1H), 7.43 
(d, J = 1.7 Hz, 1H), 7.62 (dt, J = 7.5 Hz, J = 1.9 Hz, 1H), 8.11 (d, J = 1.7 Hz, 1H), 
8.52 (dd, J = 5.0 Hz, J = 1.9 Hz, 1H). 
13
C NMR (75 MHz, CDCl3):  = 18.9, 45.9, 
48.8, 111.7, 121.25, 122.1, 125.1, 125.45, 136.5, 144.2, 149.6, 150.7, 156.55, 158.4. IR: 1711, 1670, 
1631, 1265, 760, 751 cm
-1
. MS (ESI, 70 eV): m/z (%) = 286 (100) [M+H]
+
. HRMS: m/z [M + H]
+
 calcd 
for C15H15N3O3: 286.1192; found: 286.1191. Mp 120-121 °C; Rf = 0.14 (hexanes-EtOAc, 1:1).  
1-Benzyl-3-(pyridin-2-ylmethyl)furo[3,4-d]pyrimidine-2,4(1H,3H)-dione (285h) 
38c (500 mg, 2.06 mmol, 1 eq.) in dry DMF (20 mL), Cs2CO3 (2.0 g, 6.18 mmol, 3 eq.), TBAI (2.3 g, 
6.18 mmol, 3 eq.) and benzyl bromide (0.74 ml, 6.18 mmol, 3 eq.) were used following the 
representative procedure for compound 285. After work-up, chromatography over silica and 
subsequent recrystallization from EtOH, the title compound 285h (570 mg, 83%) was obtained as off-
white crystals.  
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1
H NMR (300 MHz, CDCl3):  = 5.02 (s, 2H), 5.37 (s, 2H), 7.15 (dd, J = 7.7 Hz, J = 
5.0 Hz, 1H), 7.19 (d, J = 1.7 Hz, 1H), 7.26 (d, J = 7.7 Hz, 1H), 7.29-7.39 (m, 5H), 
7.63 (dt, J = 7.7 Hz, J = 1.7 Hz, 1H), 8.05 (d, J = 1.7 Hz, 1H), 8.53 (dd, J = 5.0 Hz, J 
= 1.7 Hz, 1H). 
13
C NMR (75 MHz, CDCl3):  = 45.9, 49.5, 111.1, 121.4, 122.2, 125.3, 
127.6, 127.9, 128.15, 129.0, 135.15, 136.6, 144.5, 149.6, 151.5, 156.3, 158.5. IR: 1719, 1672, 1639, 
758, 695 cm
-1
. MS (ESI, 70 eV): m/z (%) = 334 (100) [M+H]
+
. HRMS: m/z [M + H]
+
 calcd for 
C19H15N3O3: 334.1192; found: 334.1190. Mp 125-126 °C; Rf = 0.18 (hexanes-EtOAc, 1:1).  
1-Allyl-3-(pyridin-2-ylmethyl)furo[3,4-d]pyrimidine-2,4(1H,3H)-dione (285i) 
38c (500 mg, 2.06 mmol, 1 eq.) in dry DMF (20 mL), Cs2CO3 (2.0 g, 6.18 mmol, 3 eq.), TBAI (2.3 g, 
6.18 mmol, 3 eq.) and allyl bromide (0.54 ml, 6.18 mmol, 3 eq.) were used following the representative 
procedure for compound 285. After work-up, chromatography over silica and subsequent 
recrystallization from EtOH, the title compound 285i (402 mg, 69%) was obtained as off-white crystals.  
1
H NMR (300 MHz, DMSO-d6):  = 4.37 (d, J = 4.5 Hz, 2H), 5.15 (s, 2H), 5.15-5.33 
(m, 2H), 5.74-5.90 (m, 1H), 7.18-7.31 (m, 2H), 7.72 (t, J = 7.8 Hz, 1H), 7.94 (d, J = 
1.1 Hz, 1H), 8.42 (d, J = 4.8 Hz, 1H), 8.58 (d, J = 1.1 Hz, 1H). 
13
C NMR (75 MHz, 
DMSO-d6):  = 45.5, 48.1, 111.0, 118.3, 121.2, 122.7, 127.0, 127.9, 131.7, 137.2, 
145.9, 149.4, 150.7, 156.65, 158.5. IR: 1704, 1663, 1639, 1323, 759, 749 cm
-1
. MS (ESI, 70 eV): m/z 
(%) = 284 (100) [M+H]
+
. HRMS: m/z [M + H]
+
 calcd for C15H13N3O3: 284.1035; found: 284.1030. Mp 
113-114 °C; Rf = 0.25 (hexanes-EtOAc, 1:1).  
1-Isopropyl-3-(4-methoxybenzyl)furo[3,4-d]pyrimidine-2,4(1H,3H)-dione (285j) 
38d (500 mg, 1.84 mmol, 1 eq.) in dry DMF (20 mL), Cs2CO3 (1.8 g, 5.52 mmol, 3 eq.), TBAI (2.0 g, 
5.52 mmol, 3 eq.) and 2-bromopropane (0.52 ml, 5.52 mmol, 3 eq.) were used following the 
representative procedure for compound 285. In this case, the reaction mixture was stirred at room 
temperature for 48 hours. After work-up, chromatography over silica and subsequent recrystallization 
from EtOH, the title compound 285j (276 mg, 48%) was obtained as white crystals.  
1
H NMR (300 MHz, CDCl3):  = 1.42 (d, J = 6.8 Hz, 6H), 3.77 (s, 3H), 4.94 
(septet, J = 6.8 Hz, 1H), 5.10 (s, 2H), 6.83 (d, J = 8.6 Hz, 2H), 7.37 (s, 1H), 7.46 
(d, J = 8.6 Hz, 2H), 8.07 (s, 1H). 
13
C NMR (75 MHz, CDCl3):  = 18.85, 43.9, 
48.7, 55.3, 111.8, 113.8, 124.95, 125.2, 129.7, 130.7, 144.0, 150.7, 158.4, 
159.1. IR (ATR): 1703, 1656, 1631, 1265, 1241 cm
-1
. MS (ESI, 70 eV): m/z (%) = 315 (100) [M+H]
+
. 
HRMS: m/z [M + H]
+
 calcd for C17H18N2O4: 315.1345; found: 315.1341. Mp 109-110 °C; Rf = 0.26 
(hexanes-EtOAc, 5:1).  
1-Benzyl-3-(4-methoxybenzyl)furo[3,4-d]pyrimidine-2,4(1H,3H)-dione (285k) 
38d (500 mg, 1.84 mmol, 1 eq.) in dry DMF (20 mL), Cs2CO3 (1.8 g, 5.52 mmol, 3 eq.), TBAI (2.0 g, 
5.52 mmol, 3 eq.) and benzyl bromide (0.66 ml, 5.52 mmol, 3 eq.) were used following the 
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representative procedure for compound 285. After work-up, chromatography over silica and 
subsequent recrystallization from EtOH, the title compound 285k (464 mg, 70%) was obtained as a 
white solid.  
1
H NMR (300 MHz, CDCl3):  = 3.78 (s, 3H), 4.98 (s, 2H), 5.15 (s, 2H), 6.84 (d, J 
= 7.2 Hz, 2H), 7.14 (s, 1H), 7.24-7.40 (m, 5H), 7.47 (d, J = 7.2 Hz, 2H), 8.02 (s, 
1H). 
13
C NMR (75 MHz, CDCl3):  = 44.1, 49.6, 55.3, 111.2, 113.85, 125.2, 
127.6, 127.8, 128.2, 129.0, 129.6, 130.7, 135.15, 144.3, 151.4, 158.4, 159.15. 
IR: 1706, 1668, 1645, 1297, 1248, 1022, 738, 694 cm
-1
. MS (ESI, 70 eV): m/z (%) = 363 (100) [M+H]
+
. 
HRMS: m/z [M + H]
+
 calcd for C21H18N2O4: 363.1345; found: 363.1343. Mp 186-187 °C; Rf = 0.23 
(hexanes-EtOAc, 5:1).  
1-Allyl-3-(4-methoxybenzyl)furo[3,4-d]pyrimidine-2,4(1H,3H)-dione (285l) 
38d (500 mg, 1.84 mmol, 1 eq.) in dry DMF (20 mL), Cs2CO3 (1.8 g, 5.52 mmol, 3 eq.), TBAI (2.0 g, 
5.52 mmol, 3 eq.) and allyl bromide (0.48 ml, 5.52 mmol, 3 eq.) were used following the representative 
procedure for compound 285. After work-up, chromatography over silica and subsequent 
recrystallization from EtOH, the title compound 285l (485 mg, 84%) was obtained as white crystals.  
1
H NMR (300 MHz, DMSO-d6):  = 3.69 (s, 3H), 4.36 (d, J = 4.8 Hz, 2H), 4.96 
(s, 2H), 5.12-5.32 (m, 2H), 5.73-5.91 (m, 1H), 6.84 (d, J = 8.3 Hz, 2H), 7.23 (d, J 
= 8.3 Hz, 2H), 7.89 (s, 1H), 8.54 (s, 1H). 
13
C NMR (75 MHz, CDCl3):  = 43.6, 
48.2, 55.6, 111.0, 114.25, 118.5, 126.9, 127.7, 129.8, 130.1, 131.7, 145.85, 
150.7, 158.4, 159.0. IR: 1703, 1665, 1636, 1298, 1246, 1031, 933 cm
-1
. MS (ESI, 70 eV): m/z (%) = 
313 (100) [M+H]
+
. HRMS: m/z [M + H]
+
 calcd for C17H16N2O4: 313.1188; found: 313.1181. Mp 106-107 
°C; Rf = 0.23 (hexanes-EtOAc, 5:1).  
Methyl 4-[3-(4-methoxycarbonylfuran-3-yl)ureido]furan-3-carboxylate (286) 
DPPA (4.7 mL, 1.05 eq.) in dry toluene (100 mL) and a solution of 4-(methoxycarbonyl)furan-3-
carboxylic acid 283 (3.5 g, 20.6 mmol, 1 eq.) and dry Et3N (4.1 mL, 1.4 eq.) in dry toluene (50 mL) and 
were used following the representative procedure for compound 36. After stirring at 75 °C for three 
hours, the reaction is cooled down to room temperature, and 0.19 mL of water (0.5 eq.) is added 
dropwise to the reaction After stirring for ten minutes at room temperature, 0.03 mL of water (0.08 eq.) 
is added to the reaction, and stirring continued for twelve hours at room temperature. After evaporation 
of the solvent, the residue was taken up in EtOAc (200 mL) and was added in a separation funnel 
together with water (200 mL). While frequently shaking, the aqueous layer was neutralized with dilute 
HCl (3N). After separation, the aqueous layer was extracted again with EtOAc (100 mL). The 
combined organic extracts were washed with brine (100 mL), dried over magnesium sulfate and 
evaporated in vacuo. The product is triturated in 10 mL of methanol, filtered off and dried to afford 
2.137 g of a white solid (Y = 67%).  
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1
H NMR (400 MHz, DMSO-d6): δ = 3.83 (s, 6H, OCH3), 8.09 (d, J = 1.7 Hz, 2H, 
OCHCqN), 8.28 (d, J = 1.7 Hz, 2H, OCHCqC(O)), 9.35 (s, 2H, NH).
 13
C NMR (100 
MHz, DMSO-d6): δ = 51.5 (OCH3), 110.5 (CqC(O)OMe), 124.6 (CqNHC(O)), 132.1 
(OCHCqNH), 147.4 (OCHCqC(O)OMe), 152.1 (NHC(O)NH), 163.0 (C(O)OMe). IR: 
1703, 1668, 1547, 1526, 1314, 1258, 1152, 1103, 1030, 770, 571, 548 cm
–1
. MS (ESI, 70 eV): m/z (%) 
= 309.1 (100, [M + H]
+
). Mp 214-215 °C  
3-(4-Methoxycarbonylfuran-3-yl)furo[3,4-d]pyrimidine-2,4(1H,3H)-dione (288) 
132 mg of compound 286 (0.46 mmol; 1 eq.) is dissolved in 5 mL of dry DMF under an atmosphere of 
nitrogen. Then, 837 mg of cesium carbonate (6 eq.) and 949 mg of TBAI (6 eq.) are added. After 
stirring for thirty minutes at room temperature, 0.16 mL of iodomethane (6 eq.) is added. Stirring 
continued for eighteen hours at room temperature. The reaction mixture is poured in 50 mL of water 
and extracted with ethyl acetate (3 x 50 mL). The combined organic layers are washed with brine (50 
mL), dried over magnesium sulfate and the solvent is removed in vacuo. The crude product is 
triturated in 1 mL of ethyl acetate. After removal of the ethyl acetate by decantation, 51 mg of an off-
white solid is obtained (Y = 41%).  
1
H NMR (400 MHz, DMSO-d6): δ = 3.31 (s, 3H), 3.66 (s, 3H), 8.01 (d, J = 1.6 Hz, 1H), 
8.04 (d, J = 1.5 Hz, 1H), 8.51 (d, J = 1.6 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H).
 13
C NMR 
(100 MHz, DMSO-d6): δ = 32.3, 51.5, 110.2, 115.8, 120.9, 126.7, 128.5, 143.2, 146.1, 
149.0, 149.9, 157.5, 161.5. IR: 1682, 1645, 1377, 1167, 758, 596 cm
–1
. MS (ESI, 70 
eV): m/z (%) = 291.1 (100, [M + H]
+
). Mp 191-192 °C.  
3-Propyl-5,7-dihydrofuro[3,4-d]pyrimidine-2,4(1H,3H)-dione (298) 
MeOH (2 mL) was added to a mixture of 38a (75 mg, 0.39 mmol, 1 eq.) and Pd/C (10 wt. % Pd; 21 
mg, 5 mol%). The reaction mixture was stirred at room temperature under a H2 atmosphere (5 bar) for 
1 h, filtered over a pad of celite (1 cm) and rinsed with MeOH (2x 10 mL). The solvent was evaporated 
in vacuo, and the crude product was purified by column chromatography over silica and subsequently 
recrystallized from MeOH to give the title compound 298 (54 mg, 71%) as white crystals.  
1
H NMR (400 MHz, CDCl3):  = 0.96 (t, J = 7.5 Hz, 3H, CH3), 1.66 (sextet, J = 7.5 Hz, 
2H, CH2CH3), 3.89 (t, J = 7.5 Hz, 2H, NCH2), 4.90 (t, J = 3.6 Hz, 2H, OCH2CqC(O)), 
4.96 (t, J = 3.6 Hz, 2H, OCH2CqNH), 10.88 (br. s, 1H, NH). 
13
C NMR (100 MHz, 
CDCl3):  = 11.3 (CH3), 21.0 (CH2CH3), 42.3 (NCH2), 71.0 (OCH2CqC(O)), 72.2 
(OCH2CqNH), 108.6 (CqC(O)), 149.1 (CqNHC(O)), 154.0 (NHC(O)N, 158.8 (CqC(O)N). IR: 1713, 1670, 
1622, 1538, 1444, 1418, 1334, 1060, 760, 736 cm
-1
. MS (ESI, 70 eV): m/z (%) = 195 (100) [M - H]
-
. 
HRMS: m/z [M - H]
-
 calcd for C9H12N2O3: 195.0775; found: 195.0776. Mp 179-180 °C; Rf = 0.20 
(hexanes-EtOAc, 1:1).  
3-(4-Methoxybenzyl)-5,7-dihydrofuro[3,4-d]pyrimidine-2,4(1H,3H)-dione (300) 
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MeOH (1 mL) was added to a mixture of 38d (50 mg, 0.18 mmol, 1 eq.) and Pd/C (10 wt. % Pd; 10 
mg, 5 mol%). The reaction mixture was stirred at room temperature under a H2 atmosphere (5 bar) for 
1 h, filtered over a pad of celite (1 cm) and rinsed with MeOH (2x 10 mL). The solvent was evaporated 
in vacuo, and the crude product was purified by column chromatography over silica and subsequently 
recrystallized from MeOH to give the title compound 300 (33 mg, 66%) as white crystals 
1
H NMR (400 MHz, CDCl3):  = 3.77 (s, 3H), 4.85 (t, J = 3.6 Hz, 2H), 4.95 (t, J = 
3.6 Hz, 2H), 5.02 (s, 2H), 6.82 (d, J = 8.7 Hz, 2H), 7.39 (d, J = 8.7 Hz, 2H), 
10.75 (br. s, 1H). 
13
C NMR (100 MHz, CDCl3):  = 43.3, 55.3, 71.0, 72.2, 108.7, 
113.8, 128.7, 130.6, 149.2, 154.0, 158.6, 159.2. IR: 1709, 1633, 1514, 1246, 
1030, 666 cm
-1
. MS (ESI, 70 eV): m/z (%) = 273 (100) [M - H]
-
. HRMS: m/z [M - H]
-
 calcd for 
C14H14N2O4: 273.0881; found: 273.0892. Mp 227-228 °C; Rf = 0.19 (hexanes-EtOAc, 1:1).  
3-Propyltetrahydrofuro[3,4-d]pyrimidine-2,4(1H,3H)-dione (299) 
MeOH (40 mL) was added to a mixture of 38a (815 mg, 4.2 mmol, 1 eq.) and Rh/Al (5 wt. % Rh; 432 
mg, 5 mol%). The reaction mixture was stirred at room temperature under a H2 atmosphere (5 bar) for 
12 h, filtered over a pad of celite (1 cm) and rinsed with MeOH (2x 20 mL). The solvent was 
evaporated in vacuo, and the crude product was purified by column chromatography over silica and 
subsequently recrystallized from MeOH to give the title compound 299 (662 mg, 79%) as white 
crystals.  
1
H NMR (400 MHz, CDCl3):  = 0.91 (t, J = 7.4 Hz, 3H, CH3), 1.58 (sextet, J = 7.4 Hz, 
2H, CH2CH3), 3.24-3.32 (m, 1H, CHC(O)), 3.70-3.79 (m, 2H, NCH2), 3.84 (dd, J = 9.5 
Hz, J = 3.1 Hz, 1H, OCHaHbCHNH), 3.97 (dd, J = 9.5 Hz, J = 4.7 Hz, 1H, 
OCHaHbCHNH), 4.08-4.17 (m, 2H, OCHaHbCHC(O), CHNH), 4.24 (t, J = 8.8 Hz, 1H, 
OCHaHbCHC(O)), 5.96 (br. s, 1H, NH). 
13
C NMR (100 MHz, CDCl3):  = 11.2 (CH3), 21.6 (CH2CH3), 
42.0 (NCH2), 43.6 (CHC(O)), 50.7 (CHNH), 70.9 (OCH2CHC(O)), 75.0 (OCH2CHNH), 153.3 
(NHC(O)N), 168.8 (CHC(O)N)). IR : 1714, 1671, 1449, 1364, 1246, 1045, 765, 720 cm
-1
. MS (ESI, 70 
eV): m/z (%) = 197 (100) [M - H]
-
. HRMS: m/z [M - H]
-
 calcd for C9H14N2O3: 197.0932; found: 
197.0934. Mp 110-111 °C; Rf = 0.28 (EtOAc).  
3-(4-Methoxybenzyl)tetrahydrofuro[3,4-d]pyrimidine-2,4(1H,3H)-dione (301) 
MeOH (2 mL) was added to a mixture of 38d (50 mg, 0.18 mmol, 1 eq.) and Rh/Al (5 wt. % Rh; 19 mg, 
5 mol%). The reaction mixture was stirred at room temperature under a H2 atmosphere (5 bar) for 12 
h, filtered over a pad of celite (1 cm) and rinsed with MeOH (2x 20 mL). The solvent was evaporated in 
vacuo, and the crude product was purified by column chromatography over silica and subsequently 
recrystallized from MeOH to give the title compound 301 (36 mg, 71%) as white crystals.  
1
H NMR (400 MHz, CDCl3):  = 3.24-3.32 (m, 1H), 3.78 (s, 3H), 3.72-3.84 (m, 
1H), 3.94 (dd, J = 9.5 Hz, J = 4.8 Hz, 1H), 4.05-4.13 (m, 2H), 4.18-4.25 (m, 1H), 
4.90 (s, 2H), 6.19 (br. s, 1H), 6.82 (d, J = 8.7 Hz, 2H), 7.33 (d, J = 8.7 Hz, 2H). 
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13
C NMR (100 MHz, CDCl3):  = 43.0, 43.6, 50.7, 55.2, 70.7, 74.9, 113.8, 129.5, 130.2, 153.0, 159.0, 
168.6. IR: 1716, 1667, 1514, 1455, 1249, 1175, 1033, 768, 719 cm
-1
. MS (ESI, 70 eV): m/z (%) = 277 
(100) [M + H]
+
. HRMS: m/z [M + H]
+
 calcd for C14H16N2O4: 277.1183; found: 277.1171. Mp 141-142 °C; 
Rf = 0.14 (hexanes-EtOAc, 1:1).  
3-Benzyl-5,7-dihydrofuro[3,4-d]pyrimidine-2,4(1H,3H)-dione (302) 
MeOH (5 mL) was added to a mixture of 38b (100 mg, 0.41 mmol, 1 eq.) and Pd/C (10 wt. % Pd; 20 
mg, 5 mol%). The reaction mixture was stirred at room temperature under a H2 atmosphere (5 bar) for 
24 h, filtered over a pad of celite (1 cm) and rinsed with MeOH (2x 20 mL). The solvent was 
evaporated in vacuo, and the crude product was recrystallized from ethanol and subsequently 
recrystallized from acetonitrile to afford 37 mg of white crystals (Y = 36%).  
1
H NMR (400 MHz, DMSO-d6): δ = 4.78 (s, 4H), 4.95 (s, 2H), 7.18-7.35 (m, 5H), 
11.71 (s, 1H). 
13
C NMR (100 MHz, DMSO-d6): δ = 42.7, 70.5, 71.0, 105.7, 127.1, 
127.5, 128.3, 137.3, 151.1, 151.8, 158.7. IR: 1665, 1628, 1605, 1414, 698, 669 cm
-1
. 
MS (ESI, 70 eV): m/z (%) = 245.2 (100, [M + H]
+
). Mp 239-240 °C.  
3-Benzyl-1-(cyclohexylmethyl)tetrahydrofuro[3,4-d]pyrimidine-2,4(1H,3H)-dione (305) 
MeOH (5 mL) was added to a mixture of 285e (100 mg, 0.3 mmol, 1 eq.) and Rh/Al (5 wt. % Rh; 31 
mg, 5 mol%). The reaction mixture was stirred at room temperature under a H2 atmosphere (5 bar) for 
60 h, filtered over a pad of celite (1 cm) and rinsed with MeOH (2x 20 mL). The solvent was 
evaporated in vacuo, and the crude product was purified by preparative TLC (AcOEt/hexane (1:3); Rf 
= 0.2) and subsequently preparative HPLC (water/acetonitrile; gradient from 60% to 65% acetonitrile 
over 6 column volumes) to obtain 21 mg of a colourless oil (Y = 20%). The position of the hexyl ring 
and the benzene ring was elucidated by a combination of 
1
H-
1
H COSY, HSQC and HMBC NMR 
techniques.  
1
H NMR (400 MHz, CDCl3): δ = 0.85-1.08 (m, 2H), 1.10-1.30 (m, 3H), 1.57-1.80 (m, 
6H), 2.96 (dd, J = 7.1 Hz, J = 13.9 Hz, 1H), 3.23 (ddd, J = 3.0 Hz, J = 7.1 Hz, J = 8.4 
Hz, 1H), 3.47 (t, J = 8.4 Hz, 1H), 3.60 (dd, J = 7.1 Hz, J = 13.9 Hz, 1H), 3.93-4.01 
(m, 1H), 4.06 (dd, J = 6.9 Hz, J = 8.4 Hz, 1H), 4.12 (dd, J = 7.1 Hz, J = 9.1 Hz, 1H), 
4.40 (dd, J = 3.0 Hz, J = 9.1 Hz, 1H), 4.98 (d, J = 14.0 Hz, 1H), 5.05 (d, J = 14.0 Hz, 1H), 7.19-7.39 
(m, 5H).
 13
C NMR (100 MHz, CDCl3): δ = 25.7, 25.8, 26.4, 30.7, 31.0, 36.7, 42.9, 44.5, 54.6, 56.0, 
70.8, 71.5, 127.4, 128.5, 128.6, 137.7, 151.8, 169.0. IR: 2922, 2850, 1705, 1664, 1464, 1450, 1213, 
699 cm
–1
. MS (ESI, 70 eV): m/z (%) = 343.0 (100, [M + H]
+
). HRMS: m/z [M + H]
+
 calcd for 
C20H27N2O3: 343.2016; found: 343.2015. 
1-Allyl-3-propyltetrahydrofuro[3,4-d]pyrimidine-2,4(1H,3H)-dione (306) 
To a solution of 299 (200 mg, 1 mmol, 1 eq.) in dry DMF (10 mL), Cs2CO3 (986 mg, 3 eq.) and TBAI 
(1.12 g, 3 eq.) were added under an inert atmosphere. After stirring the reaction for 30 minutes at 
room temperature, allyl bromide (0.26 ml, 3 eq.) was added and stirring continued at room 
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temperature for 12 hours. Water (50 mL) was added, and the reaction mixture was extracted with 
EtOAc (3x 50 mL). The combined organic layers were combined, washed with brine (50 mL), dried 
over MgSO4 and evaporated in vacuo. The crude product was purified by column chromatography 
over silica (AcOEt/hexane (1:3)) to afford 144 mg of a yellow oil (Y = 60%).  
1
H NMR (400 MHz, CDCl3): δ = 0.84 (t, J = 7.5 Hz, 3H), 1.52 (sextet, J = 7.5 Hz, 2H), 
3.17 (dt, J = 3.5 Hz, J = 12.1 Hz, 1H), 3.45-3.52 (m, 1H), 3.65-3.80 (m, 2H), 3.87-4.03 
(m, 3H), 4.06 (dd, J = 7.3 Hz, J = 9.1 Hz, 1H), 4.12 (ddt, J = 1.3 Hz, J = 6.0 Hz, J = 
15.3 Hz, 1H), 4.27 (dd, J = 3.5 Hz, J = 9.1 Hz, 1H), 5.16-5.25 (m, 2H), 5.70-5.83 (m, 
1H).
 13
C NMR (100 MHz, CDCl3): δ = 11.2, 21.5, 42.8, 42.8, 50.6, 54.7, 70.8, 71.8, 118.7, 132.6, 
151.3, 168.8. IR: 2962, 1703, 1660, 1461, 1220, 1070, 928, 753 cm
–1
. MS (ESI, 70 eV): m/z (%) = 
239.1 (100, [M + H]
+
). HRMS: m/z [M + H]
+
 calcd for C12H19N2O3: 239.1390; found: 239.1397. 
1-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)furo[3,4-d]pyrimidine-
2,4(1H,3H)-dione (314) 
To a suspension of 6 (110 mg; 0.72 mmol; 1 eq.) in 7 mL of dry acetonitrile, 0.53 mL of N,O-
bis(trimethylsilyl)acetamide (3 eq.). was added dropwise The mixture was stirred for two hours at room 
temperature under an inert atmosphere. To the reaction mixture were successively added a solution of 
343 mg of ATBR (0.94 eq.) in 3 mL of acetonitrile, and 0.21 mL of TMSOTf (1.6 eq.). The reaction was 
heated at 85 °C for 45 minutes, cooled down to room temperature and the solvent was removed in 
vacuo. The residue was dissolved in 10 mL of dichloromethane, washed with 10 mL of sat. aqueous 
sodium bicarbonate and 10 mL of brine, dried over magnesium sulfate and the solvent was removed in 
vacuo. The crude product was purified by column chromatography over silica (AcOEt/hexane, gradient 
from 0% to 100% ethyl acetate over 15 column volumes; Rf = 0.64 (AcOEt/hexane (1:1))). The 
obtained product (300 mg) was dissolved in 10 mL of 7M ammonia in methanol solution and stirred at 
room temperature for 12 hours. The solvent was removed in vacuo, and the crude product was 
purified by column chromatography over silica (dichloromethane/methanol, gradient from 0% to 10% 
methanol over 15 column volumes; Rf = 0.19 (10% methanol in dichloromethane). Compound 314 was 
obtained as a white solid (114 mg, Y = 55%).  
1
H NMR (400 MHz, DMSO-d6): δ = 3.58-3.69 (m, 2H, CH2OH), 3.80-3.85 (m, 1H, 4’-H), 
4.00-4.07 (m, 1H, 3’-H), 4.27 (dd, J = 6.8 Hz, J = 13.3 Hz, 1H, 2’-H), 5.04 (d, J = 4.8 Hz, 
1H, 3’-OH), 5.17-5.24 (m, 2H, 2’-OH, 5’-OH), 6.00 (d, J = 6.8 Hz, 1H, 1’-H), 8.17 (d, J = 
1.6 Hz, 1H, CHCqN), 8.49 (d, J = 1.6 Hz, 1H, CHCqC(O)), 11.16 (br. s, 1H, NH).
 13
C 
NMR (100 MHz, DMSO-d6): δ = 61.4 (CH2OH), 68.6 (2’-C), 69.7 (3’-C), 85.5 (4’-C), 87.6 
(1’-C), 111.9 (CHCqC(O)), 124.8 (CHCqN), 128.9 (CHCqN), 144.5 (CHCqC(O)), 151.0 
(NC(O)NH), 158.6 (CqC(O)NH). IR: 3402, 3186, 3102, 1698, 1682, 1638, 1297, 1080, 1041, 1028 cm
–
1
. MS (ESI, 70 eV): m/z (%) = 283.0 (100, [M – H]
-
). HRMS: m/z [M – H]
-
 calcd for C11H11N2O7: 
283.0572; found: 283.0572. Mp 170-171 °C.  
1-((2-Acetoxyethoxy)methyl)furo[3,4-d]pyrimidine-2,4(1H,3H)-dione (315) 
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The synthesis of 2-(chloromethoxy)ethyl acetate was accomplished following the procedure of Manvar 
and Shah.
209
 All spectra were in accordance with the reported spectral data. 
To a stirred suspension of 6 (300 mg, 1.97 mmol, 1 eq.) in 24 mL of dry dichloromethane, 1.06 mL of 
N,O-BSA (2.2 eq.) was added dropwise at room temperature under an inert atmosphere. After stirring 
for an additional 30 minutes, 7.3 mg of TBAI (0.01 eq.) was added, the reaction mixture was cooled 
down to 0 °C and 451 mg of 2-(chloromethoxy)ethyl acetate (1.5 eq.) was added dropwise. Stirring 
was continued for 2 hours at 0 °C. The mixture was poured into ice cold sat. aqueous sodium 
bicarbonate (60 mL) and stirred at 0 °C for 30 minutes. The organic layer was separated and the 
aqueous layer was extracted with dichloromethane (2 x 60 mL). The combined organic layers were 
washed with brine (2 x 90 mL), dried over magnesium sulfate and the solvent was removed in vacuo. 
The crude product was purified by column chromatography over silica (dichloromethane/methanol, 
gradient from 0% methanol to 5% methanol over 15 column volumes; Rf = 0.4 (5% methanol in 
dichloromethane)). Compound 315 was obtained as a white solid (218 mg, Y = 41%).  
1
H NMR (400 MHz, CDCl3): δ = 2.03 (s, 3H), 3.77 (t, J = 4.6 Hz, 2H), 4.21 (t, J = 4.6 
Hz, 2H), 5.34 (s, 2H), 7.52 (d, J = 1.3 Hz, 1H), 7.95 (br. s, 1H), 8.09 (d, J = 1.3 Hz, 
1H).
 13
C NMR (100 MHz, CDCl3): δ = 20.8, 62.9, 66.9, 74.8, 111.0, 126.8, 127.5, 
144.2, 150.4, 157.6, 170.8. IR: 3060, 1728, 1681, 1638, 1291, 1255, 1235, 1128, 
1085, 1051, 1033, 712 cm
–1
. MS (ESI, 70 eV): m/z (%) = 267.0 (100, [M – H]
-
). HRMS: m/z [M – H]
-
 
calcd for C11H11N2O6: 267.0623; found: 267.0630. Mp 176-177 °C. 
1-((2-Hydroxyethoxy)methyl)furo[3,4-d]pyrimidine-2,4(1H,3H)-dione (316) 
A mixture of 56 mg of compound 315 (0.2 mmol) in 5 mL of a 7M ammonia in methanol solution was 
stirred at room temperature for 12 hours. The solvent was removed in vacuo and the crude product 
was purified by column chromatography over silica (dichloromethane/methanol, gradient from 0% 
methanol to 10% methanol over 15 column volumes; Rf = 0.48 (10% methanol in dichloromethane)). 
Compound 316 is obtained as a white solid (40 mg, Y = 85%).  
1
H NMR (400 MHz, MeOH-d4): δ = 3.59-3.68 (m, 4H, CH2CH2), 5.33 (s, 2H, NCH2O), 
7.74 (d, J = 1.6 Hz, 1H, CHCqN), 8.24 (d, J = 1.6 Hz, 1H, CHCqC(O)).
 13
C NMR (100 
MHz, MeOH-d4): δ = 61.9 (CH2OH), 71.5 (CH2CH2OH), 75.8 (NCH2O), 112.5 
(CqC(O)), 128.4 (CHCqN), 129.4 (CqNC(O)), 145.5 (CHCqC(O)), 152.7 (NC(O)NH), 
160.7 (CqC(O)NH). IR: 3439, 3030, 2860, 1678, 1634, 1292, 1069, 1015, 883, 723, 
584 cm
–1
. MS (ESI, 70 eV): m/z (%) = 226.7 (7, [M + H]
+
). HRMS: m/z [M + H]
+
 calcd for C9H11N2O5: 
227.0662; found: 227.0671. Mp 197-198 °C.  
1-(Ethoxymethyl)furo[3,4-d]pyrimidine-2,4(1H,3H)-dione (317) 
To a stirred suspension of 6 (100 mg, 0.66 mmol, 1 eq.) in 8 mL of dry dichloromethane, 0.354 mL of 
N,O-BSA (2.2 eq.) was added dropwise at room temperature under an inert atmosphere. After stirring 
for an additional 30 minutes at room temperature, 2.4 mg of TBAI (0.01 eq.) was added, the reaction 
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mixture was cooled down to 0 °C and 0.09 mL of chloromethyl ethyl ether (1.5 eq.) was added 
dropwise. Stirring was continued for 2 hours at 0 °C. The mixture was poured into ice cold sat. 
aqueous sodium bicarbonate (20 mL) and stirred at 0 °C for 30 minutes. The organic layer was 
separated and the aqueous layer was extracted with dichloromethane (2 x 20 mL). The combined 
organic layers were washed with brine (2 x 30 mL), dried over magnesium sulfate and the solvent was 
removed in vacuo. The crude product was recrystallized from methanol to obtain compound 317 as 
white crystals (115 mg, Y = 83%).  
1
H NMR (400 MHz, CDCl3): δ = 1.21 (t, J = 7.0 Hz, 3H), 3.61 (q, J = 7.0 Hz, 2H), 5.30 (s, 
2H), 7.52 (d, J = 1.2 Hz, 1H), 8.09 (d, J = 1.2 Hz, 1H), 8.01 (br. s, 1H).
 13
C NMR (100 
MHz, CDCl3): δ = 14.9, 64.6, 74.5, 111.0, 126.8, 127.6, 144.1, 150.5, 158.0. IR: 3083, 
1726, 1675, 1637, 1288, 1074, 764, 707 cm
–1
. MS (ESI, 70 eV): m/z (%) = 209.0 (100, 
[M – H]
-
). HRMS: m/z [M – H]
-
 calcd for C9H9N2O4: 209.0568; found: 209.0574. Mp 179-180 °C  
5,7-Dihydrofuro[3,4-d]pyrimidine-2,4(1H,3H)-dione (8) 
Compound 8 was synthesized following a literature procedure, and was obtained in 12% yield over 
two steps. All spectra were in accordance with the reported spectral data.
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1-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5,7-dihydrofuro[3,4-
d]pyrimidine-2,4(1H,3H)-dione (319) 
To a suspension of 200 mg of 8 (1.3 mmol, 1 eq.) in 14 mL of dry acetonitrile was added dropwise 
0.95 mL of N,O-BSA (3 eq.) and the reaction mixture was stirred for two hours at room temperature 
under an inert atmosphere. Then, a solution of 616 mg of ATBR (0.94 eq.) in 6 mL of dry acetonitrile 
was added to the reaction, followed by 0.38 mL of TMSOTf (1.6 eq.). The reaction mixture was stirred 
at 85 °C for 45 minutes, cooled down to room temperature and the solvent was removed in vacuo. The 
residue was dissolved in 20 mL of dichloromethane and washed with 20 mL of sat. aqueous sodium 
bicarbonate solution and 20 mL of brine. The organic layer was dried over magnesium sulfate and the 
solvent was evaporated in vacuo. The crude product was purified by column chromatography over 
silica (dichloromethane/methanol, gradient from 0% methanol to 5% methanol over 10 column 
volumes, Rf = 0.4 (diethyl ether/dichloromethane (1:3))) and subsequently by preparative HPLC 
(water/acetonitrile, gradient from 60% acetonitrile to 72.5% acetonitrile over 5 column volumes) to 
obtain compound 318 (159 mg). This compound was taken up in 20 mL of a 7M ammonia in methanol 
solution and was stirred at room temperature for two days. The solvent was removed in vacuo, and the 
crude product was purified by column chromatography over silica (ethyl acetate (A)/(ethyl 
acetate/methanol/water [30:10:5] (B)), gradient from 0% of B to 100% of B over 15 column volumes, Rf 
= 0.74 (B)) and subsequently recrystallized from absolute ethanol to obtain compound 319 as white 
crystals (27 mg, Y = 7% over two steps).  
1
H NMR (400 MHz, MeOH-d4): δ = 3.68 (dd, J = 4.9 Hz, J = 12.1 Hz, 1H, CHaHbOH), 3.78 (dd, J = 3.0 
Hz, J = 12.1 Hz, 1H, CHaHbOH), 3.89-3.95 (m, 1H, 4’-H), 4.20 (t, J = 5.5 Hz, 1H, 3’-H), 4.53 (t, J = 5.5 
Hz, 1H, 2’-H), 4.80-4.90 (m, 2H, OCH2CqN), 5.01-5.14 (m, 2H, OCH2CqC(O)), 5.35 (d, J = 5.5 Hz, 1H, 
138 
 
1’-H). 
13
C NMR (100 MHz, MeOH-d4): δ = 63.2 (CH2OH), 71.2 (3’-C), 72.2 (OCH2CqN), 
72.7 (OCH2CqC(O)), 73.2 (2’-C), 86.9 (4’-C), 94.1 (1’-C), 110.5 (CqC(O)), 153.0 
(NC(O)NH), 154.8 (OCH2CqN), 161.2(CqC(O)NH). IR: 3437, 3146, 3019, 2899, 2803, 
1665, 1508, 1128, 1074, 530 cm
–1
. MS (ESI, 70 eV): m/z (%) = 285 (100, [M – H]
-
). Mp 
177-178 °C.  
1-((2-Acetoxyethoxy)methyl)5,7-dihydrofuro[3,4-d]pyrimidine-2,4(1H,3H)-dione (320) 
The synthesis of 2-(acetoxyethoxy)methyl acetate was accomplished following the procedure of 
Boncel et al.
140
 All spectra were in accordance with the reported spectral data.  
To a stirred mixture of compound 8 (72 mg, 0.47 mmol, 1 eq.) in 6 mL of dry dichloromethane , 0.25 
mL of N,O-BSA (2.2 eq.) was added dropwise at room temperature under an inert atmosphere. After 
stirring at room temperature for three hours, 124 mg of 2-(acetoxyethoxy)methyl acetate (1.5 eq.) was 
added and the reaction mixture was cooled down to 0 °C. Then, 0.017 mL of TMSOTf (0.2 eq.) was 
added at 0 °C and the reaction mixture was stirred at room temperature for three days. The reaction 
was quenched by addition of 10 mL of sat. aqueous sodium bicarbonate and the layers were 
separated. The aqueous layer was extracted with dichloromethane (4 x 10 mL), the combined organic 
layers were washed with brine (20 mL), dried over magnesium sulfate and the solvent was removed in 
vacuo. The crude product was purified by column chromatography over silica 
(dichloromethane/methanol, gradient from 0% to 5% methanol over 15 column volumes, Rf = 0.48 (5% 
methanol in dichloromethane)) and subsequently purified by preparative HPLC (water/acetonitrile 
(9:1)). Compound 320 was obtained as a white solid (33 mg, Y = 26%).  
1
H NMR (400 MHz, CDCl3): δ = 2.08 (s, 3H), 3.76-3.84 (m, 2H), 4.17-4.25 (m, 2H), 
4.93-5.00 (m, 2H), 5.01-5.08 (m, 2H), 5.19 (s, 2H).
 13
C NMR (100 MHz, CDCl3): δ = 
20.8, 62.9, 67.7, 71.0, 71.9, 74.3, 110.0, 152.1, 153.0, 158.6, 170.8. MS (ESI, 70 
eV): m/z (%) = 271.0 (27, [M + H]
+
). HRMS: m/z [M + H]
+
 calcd for C11H15N2O6: 
271.0925; found: 271.0916. Mp 101-102 °C  
1-((2-Hydroxyethoxy)methyl)-5,7-dihydrofuro[3,4-d]pyrimidine-2,4(1H,3H)-dione (321) 
A mixture of compound 320 (18 mg, 0.07 mmol) and 2 mL of a 7M ammonia in methanol solution was 
stirred at room temperature for 12 hours. The solvent was removed in vacuo, and the crude product 
was recrystallized from methanol to afford compound 321 as white crystals (14 mg, Y = 92%).  
1
H NMR (400 MHz, MeOH-d4): δ = 3.59-3.67 (m, 4H, CH2CH2), 4.87 (t, J = 3.7 Hz, 
2H, OCH2CqN), 5.07 (t, J = 3.7 Hz, 2H, OCH2CqC(O)), 5.19 (s, 2H, NCH2O).
 13
C NMR 
(100 MHz, MeOH-d4): δ = 61.9 (CH2OH), 72.1 (CH2CH2OH), 72.1 (OCH2CqC(O)), 
72.5 (OCH2CqN), 75.6 (NCH2O), 110.1 (CqC(O)), 154.0 (NC(O)NH), 155.6 
(CqNC(O)), 161.4 (CqC(O)). IR: 3422, 3026, 1674, 1638, 1497, 1119, 1070, 1049, 895, 561 cm
–1
. MS 
(ESI, 70 eV): m/z (%) = 227.0 (100, [M – H]
-
). HRMS: m/z [M – H]
-
 calcd for C9H11N2O5: 227.0673; 
found: 227.0673. Mp 196-197 °C.  
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1-(Ethoxymethyl)-5,7-dihydrofuro[3,4-d]pyrimidine-2,4(1H,3H)-dione (322) 
To a stirred suspension of compound 8 (200 mg, 1.3 mmol, 1 eq.) in 16 mL of dry dichloromethane, 
0.7 mL of N,O-BSA (2.2 eq.) was added dropwise at room temperature under an inert atmosphere. 
After stirring for an additional 30 minutes, 4.8 mg of TBAI (0.01 eq.) was added, the reaction mixture 
was cooled down to 0 °C and 0.18 mL of chloromethyl ethyl ether (1.5 eq.) was added dropwise. 
Stirring was continued for two hours at 0 °C. The mixture was poured into ice cold sat. aqueous 
sodium bicarbonate (40 mL) and stirred at 0 °C for 30 minutes. The organic layer was separated and 
the aqueous layer was extracted with dichloromethane (2 x 20 mL). The combined organic layers were 
washed with brine (2 x 30 mL), dried over magnesium sulfate and the solvent was removed in vacuo. 
The crude product was recrystallized from methanol to obtain compound 322 as white crystals (135 
mg, Y = 49%).  
1
H NMR (400 MHz, DMSO-d6): δ = 1.10 (t, J = 7.0 Hz, 3H), 3.50 (q, J = 7.0 Hz, 2H), 4.77 
(t, J = 3.7 Hz, 2H), 4.96 (t, J = 3.7 Hz, 2H), 5.06 (s, 2H), 11.38 (br. s, 1H). 
13
C NMR (100 
MHz, DMSO-d6): δ = 14.8, 63.9, 70.5, 71.0, 73.5, 108.1, 152.0, 153.0, 158.8. IR: 3048, 
1686, 1649, 1491, 1051 cm
–1
. MS (ESI, 70 eV): m/z (%) = 211.1 (100, [M – H]
–
). HRMS: 
m/z [M – H]
–
 calcd for C9H11N2O4: 211.0724; found: 211.0731. Mp 149-150 °C.  
Tetrahydrofuro[3,4-d]pyrimidine-2,4(1H,3H)-dione (323) 
A suspension of 500 mg of 6 (3.3 mmol; 1 eq.) and 338 mg of 5 wt% rhodium on alumina (5 mol%) in 
50 mL of a methanol/water mixture (4:1) was stirred for 28 hours at room temperature under a 
hydrogen atmosphere of 5 bar. The reaction mixture was filtered over a pad of celite and rinsed with 
hot water (40~50 °C, 2 x 20 mL). The solvent was evaporated in vacuo, and the residue was 
recrystallized from methanol to obtain compound 323 (mixture of cis-isomers) as off-white crystals 
(267 mg, Y = 52%).  
1
H NMR (400 MHz, DMSO-d6): δ = 3.12-3.20 (m, 1H, CHC(O)), 3.63 (dd, J = 3.5 Hz, J = 
9.0 Hz, 1H, OCHaHbCHNH), 3.76 (dd, J = 5.1 Hz, J = 9.0 Hz, 1H, OCHaHbCHNH), 3.88 
(dd, J = 6.2 Hz, J = 8.5 Hz, 1H, OCHaHbCHC(O)), 4.00 (t, J = 8.5 Hz, 1H, 
OCHaHbCHC(O)), 4.02-4.08 (m, 1H, CHNH), 7.63 (s, 1H, CHNH), 10.23 (s, 1H, 
C(O)NHC(O)). 
13
C NMR (100 MHz, DMSO-d6): δ = 42.1 (CHC(O)), 51.2 (CHNH), 69.7 
(OCH2CHC(O)), 73.9 (OCH2CHNH), 152.1 (NHC(O)NH), 170.5 (CHC(O)). IR: 3188, 3090, 1680, 
1261, 760, 557, 500, 449 cm
–1
. MS (ESI, 70 eV): m/z (%) = 155.1 (100, [M – H]
-
). HRMS: m/z [M – H]
-
 
calcd for C6H7N2O3: 155.0462; found: 155.0460. Mp 213-214 °C.  
1-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)tetrahydrofuro[3,4-
d]pyrimidine-2,4(1H,3H)-dione (325) 
A suspension of 61 mg of 314 (0.215 mmol, 1 eq.) and 22 mg of 5 wt% rhodium on alumina (5 mol%) 
in 2 mL of methanol was stirred for two days in a sealed flask equipped with a balloon filled with 
hydrogen gas. The reaction mixture was filtered over a pad of celite, rinsed with 5 mL of methanol and 
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the solvent was removed in vacuo. The crude product was purified by preparative HPLC 
(water/acetonitrile (97:3)) to obtain compound 325 as two separate diastereomers (13 mg DIA1, 13 mg 
DIA2, combined Y = 42%).  
 
Spectral data for DIA1 (325a or 325b): 
1
H NMR (400 MHz, DMSO-d6): δ = 3.13-3.21 (m, 1H, CHC(O)), 3.32-3.4 (t, J = 8.4 Hz, 1H, 
OCHaHbCHN), 3.43-3.55 (m, 2H, CH2OH), 3.68-3.74 (m, 1H, 4’-H), 3.75-3.83 (m, 2H, 2’-H, 
OCHaHbCHC(O)), 3.88 (dd, J = 2.3 Hz, J = 5.2 Hz, 1H, 3’-H), 3.97 (t, J = 8.4 Hz, 1H, OCHaHbCHN), 
4.22 (dd, J = 0.8 Hz, J = 8.6 Hz, 1H, OCHaHbCHC(O)), 4.44 (q, J = 8.4 Hz, 1H, CHN), 4.70-5.39 (m, 
3H, OH), 5.73 (d, J = 7.4 Hz, 1H, 1’-H), 10.6 (br. s, 1H, NH). 
13
C NMR (100 MHz, DMSO-d6): δ = 42.1 
(CHC(O)), 50.0 (CHN), 61.7 (CH2OH), 68.8 (OCH2CHC(O)), 70.4 (3’-C), 71.0 (OCH2CHN), 71.3 (2’-C), 
83.9 (4’-C), 86.2 (1’-C), 152.0 (NC(O)NH), 170.5 (CHC(O)). IR: 1676, 1462, 1252, 1217, 1049, 1012, 
405 cm
–1
. MS (ESI, 70 eV): m/z (%) = 286.9 (100, [M – H]
-
). HRMS: m/z [M – H]
-
 calcd for C11H15N2O7: 
287.0885; found: 287.0896. Colourless oil.  
Spectral data for DIA2 (325a or 325b): 
1
H NMR (400 MHz, DMSO-d6): δ = 3.15-3.25 (m, 2H, CHC(O), OCHaHbCHN), 3.41-3.53 (m, 2H, 
CH2OH), 3.67 (q, J = 3.8 Hz, 1H, 4’-H), 3.80-3.90 (m, 2H, 3’-H, OCHaHbCHC(O)), 3.98-4.08 (m, 2H, 2’-
H, OCHaHbCHN), 4.13 (dd, J = 1.4 Hz, J = 8.6 Hz, 1H, OCHaHbCHC(O)), 4.21 (q, J = 8.1 Hz, 1H, 
CHN), 4.60-5.50 (m, 3H, OH), 5.74 (d, J = 6.4 Hz, 1H, 1’-H), 10.6 (br. s, 1H, NH). 
13
C NMR (100 MHz, 
DMSO-d6): δ = 42.4 (CHC(O)), 51.0 (CHN), 61.5 (CH2OH), 68.9 (OCH2CHC(O)), 70.3 (2’-C, 3’-C), 
71.7 (OCH2CHN), 83.7 (4’-C), 87.4 (1’-C), 152.0 (NC(O)NH), 170.8 (CHC(O)). IR: 1674, 1244, 1223, 
1051, 1013, 403 cm
–1
. MS (ESI, 70 eV): m/z (%) = 287.0 (100, [M – H]
-
). HRMS: m/z [M – H]
-
 calcd for 
C11H15N2O7: 287.0885; found: 287.0898. Colourless oil. 
1-((2-Acetoxyethoxy)methyl)tetrahydrofuro[3,4-d]pyrimidine-2,4(1H,3H)-dione (326) 
A suspension of 100 mg of 315 (0.37 mmol; 1 eq.) and 38 mg of 5 wt% rhodium on alumina (5 mol%) 
in 3 mL of dry methanol was stirred for one day in a sealed flask equipped with a balloon filled with 
hydrogen gas. The reaction mixture was filtered over a pad of celite, rinsed with 5 mL of methanol and 
the solvent was removed in vacuo. The residue was purified by column chromatography over silica 
(dichloromethane/methanol, gradient from 0% methanol to 10% methanol over 20 column volumes) to 
obtain compound 326 (mixture of cis-isomers) as a colourless oil (90 mg, Y = 89%).  
1
H NMR (400 MHz, MeOH-d4): δ = 2.05 (s, 3H), 3.32-3.40 (m, 1H), 3.64 (dd, J = 7.4 
Hz, J = 9.0 Hz, 1H), 3.67-3.78 (m, 2H), 4.06 (dd, J = 7.1 Hz, J = 8.9 Hz, 1H), 4.11 
(dd, J = 7.4 Hz, J = 9.0 Hz, 1H), 4.14-4.34 (m, 4H), 4.78 (d, J = 10.6 Hz, 1H), 5.19 
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(d, J = 10.6 Hz, 1H).
 13
C NMR (100 MHz, MeOH-d4): δ = 20.8, 43.8, 57.6, 64.5, 67.8, 70.9, 73.1, 77.9, 
153.6, 172.3, 172.7. IR: 1694, 1472, 1246, 1094, 1043 cm
–1
. MS (ESI, 70 eV): m/z (%) = 271.0 (100, 
[M – H]
-
).  
1-((2-Hydroxyethoxy)methyl)tetrahydrofuro[3,4-d]pyrimidine-2,4(1H,3H)-dione (327) 
A solution of 90 mg of 326 (0.33 mmol; 1 eq.) in 10 mL of 7 M ammonia in methanol 
was stirred for 12 hours at room temperature. The solvent was evaporated, and the 
residue was purified by column chromatography over silica 
(dichloromethane/methanol, gradient from 0% to 10% methanol over 20 column 
volumes). The obtained product still contained acetamide, and was recrystallized 
from chloroform-diethyl ether to afford compound 327 (mixture of cis-isomers) as white crystals (25 
mg, 33%).  
1
H NMR (400 MHz, DMSO-d6): δ = 3.30-3.34 (m, 1H, CHC(O)), 3.40-3.54 (m, 5H, CH2CH2, 
OCHaHbCHN), 3.90-3.97 (m, 1H, OCHaHbCHC(O)), 3.97-4.04 (m, 1H, OCHaHbCHN), 4.05-4.11 (m, 
1H, OCHaHbCHC(O)), 4.17-4.26 (m, 1H, CHN), 4.58-4.66 (m, 1H, OH), 4.75 (d, J = 10.4 Hz, 1H, 
NCHaHbO), 4.99 (d, J = 10.4 Hz, 1H, NCHaHbO), 10.60 (br. s, 1H, NH). 
13
C NMR (100 MHz, DMSO-
d6): δ = 43.8 (CHC(O)), 57.3 (CHN), 62.1 (CH2OH), 70.9 (OCH2CHC(O)), 71.3 (CH2CH2OH), 73.0 
(OCH2CHN), 77.8 (NCH2O), 153.7 (NC(O)NH), 172.3 (CHC(O)). IR: 3526, 3429, 3073, 2959, 2868, 
1697, 1043, 411 cm
–1
. MS (ESI, 70 eV): m/z (%) = 229.0 (100, [M – H]
-
). Mp 100-101 °C. 
1-(Ethoxymethyl)tetrahydrofuro[3,4-d]pyrimidine-2,4(1H,3H)-dione (328) 
To a solution of 100 mg of 323 (0.64 mmol; 1 eq.) in 2 mL of dry DMF was added 29 mg of sodium 
hydride (60% dispersion in mineral oil, 1.1 eq.) and the reaction mixture was stirred for fifteen minutes 
at room temperature. Then, 67 mg of chloromethyl ethyl ether was added (1.1 eq.) and the reaction 
mixture was stirred for one day at room temperature. The solvent was removed in vacuo, the residue 
was taken up in 20 mL of sat. aqueous ammonium chloride solution and extracted with 
dichloromethane (2 x 20 mL) and ethyl acetate (2 x 20 mL). The combined organic layers were dried 
over magnesium sulfate and the solvent was evaporated in vacuo. The crude product was purified by 
column chromatography over silica (dichloromethane/methanol, gradient from 0% methanol to 10% 
methanol over 15 column volumes) and preparative HPLC (water/acetonitrile (89:11)) to obtain 
compound 328 (mixture of cis-isomers) as a white solid (15 mg, Y = 11%).  
1
H NMR (400 MHz, DMSO-d6): δ = 1.01-1.11 (m, 3H), 3.28-3.40 (m, 1H), 3.41-3.53 (m, 
2H), 3.64-3.72 (m, 1H), 3.72-3.81 (m, 1H), 3.84-3.95 (m, 1H), 4.00-4.12 (m, 2H), 5.00-
5.12 (m, 2H), 7.97 (s, 1H). 
13
C NMR (100 MHz, DMSO-d6): δ = 15.1, 42.8, 49.8, 63.9, 
68.5, 69.8, 73.9, 151.7, 169.7. IR: 3200, 3092, 2976, 2938, 2872, 1674, 1452, 1254, 
1063, 561 cm
–1
. MS (ESI, 70 eV): m/z (%) = 213.2 (100, [M – H]
-
). Mp 99-100 °C.  
2.2 Oxazolo[5,4-d]pyrimidine and oxazolo[4,5-d]pyrimidine derivatives 
5-Ethyl 4-methyl oxazole-4,5-dicarboxylate (340a) 
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To a solution of 1.36 g of imidazole (20 mmol, 1 eq.) in 30 mL of dry tetrahydrofuran was added 8 mL 
of dry triethylamine (55 mmol, 2.75 eq.). The mixture was cooled down to 0 °C and a solution of 2.24 
mL of ethyl 2-chloro-2-oxoacetate (20 mmol, 1 eq.) in 20 mL of dry tetrahydrofuran was added 
dropwise. After an additional 30 minutes of stirring at 0 °C, 1.82 mL of methyl 2-isocyanoacetate (20 
mmol, 1 eq.) was added in one portion. The reaction mixture was stirred at 0 °C for one hour and then 
at reflux temperature for twelve hours. The solvent was removed in vacuo, and the crude product was 
purified by column chromatography over silica (ethyl acetate/hexane (1:4)) to obtain compound 340a 
as a pale yellow oil (3.143 g, Y = 79%).  
1
H NMR (400 MHz, CDCl3): δ = 1.42 (t, J = 7.1 Hz, 3H, CH2CH3), 3.98 (s, 3H, OCH3), 
4.45 (q, J = 7.1 Hz, 2H, CH2), 7.98 (s, 1H, CH). 
13
C NMR (100 MHz, CDCl3): δ = 14.0 
(CH2CH3), 52.9 (OCH3), 62.5 (CH2CH3), 135.2 (NCq), 143.2 (OCq), 151.3 (CH), 156.6 
(C(O)OEt), 160.6 (C(O)OMe). IR: 1728, 1499, 1338, 1303, 1282, 1148, 1052, 762, 626 
cm
–1
. MS (ESI, 70 eV): m/z (%) = 200.0 (100, [M + H]
+
). HRMS: m/z [M + H]
+
 calcd for C8H10NO5: 
200.0553; found: 200.0558. 
Isopropyl 2-chloro-2-oxoacetate (339b) 
Isopropanol (3.83 mL, 0.05 mol, 1 eq.) was added dropwise to oxalyl chloride (9.5 mL, 0.1 mol, 2 eq.) 
at 0 °C. After addition, the mixture was allowed to warm up to room temperature, and stirring was 
continued for two hours. Excess oxalyl chloride was removed by distillation (1 atm, fraction with boiling 
point 60-80 °C). Further vacuum distillation (58 mbar, fraction with boiling point 64-66 °C) afforded 
compound 339b as a colourless liquid (5.27 g, Y = 70%). All spectra were in accordance with reported 
spectral data.
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5-Isopropyl 4-methyl oxazole-4,5-dicarboxylate (340b) 
To a solution of 1 g of imidazole (14.69 mmol, 1 eq.) in 20 mL of dry tetrahydrofuran was added 5.7 
mL of dry triethylamine (2.75 eq.). The mixture was cooled down to 0 °C and a solution of 2.212 g of 
339b (1 eq.) in 15 mL of dry tetrahydrofuran was added dropwise. After an additional 30 minutes of 
stirring at 0 °C, 1.34 mL of methyl 2-isocyanoacetate (1 eq.) was added in one portion. The reaction 
mixture was stirred at 0 °C for one hour and then at reflux temperature for twelve hours. The solvent 
was removed in vacuo and the residue was dissolved in 25 mL of ethyl acetate and washed with 25 
mL of water and 25 mL of brine. The organic layer was dried over magnesium sulfate and the solvent 
was removed in vacuo. The crude product was purified by column chromatography over silica (ethyl 
acetate/hexane (1:4), Rf = 0.275) to obtain compound 340b as a pale yellow oil (2.889 g, Y = 92%).  
1
H NMR (400 MHz, CDCl3): δ = 1.40 (d, J = 6.3 Hz, 6H), 3.97 (s, 3H), 5.30 (septet, J = 
6.3 Hz, 1H), 7.98 (s, 1H). 
13
C NMR (100 MHz, CDCl3): δ = 21.7, 52.8, 70.7, 135.0, 143.4, 
151.2, 156.2, 160.6. IR: 2985, 1725, 1589, 1370, 1307, 1283, 1158, 1101, 1050, 935, 
844, 797, 763 cm
–1
. MS (ESI, 70 eV): m/z (%) = 214.0 (23, [M + H]
+
). HRMS: m/z [M – H]
-
 
calcd for C9H10NO5: 212.0564; found: 212.0573.  
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5-(tert-Butyl) 4-methyl oxazole-4,5-dicarboxylate (340c) 
tert-Butyl 2-chloro-2-oxoacetate (339c) was synthesized following a literature procedure, and was 
obtained as a colourless liquid in 50% yield.
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To a solution of 6.205 g of imidazole (0.09 mol, 1 eq.) in 130 mL of dry tetrahydrofuran was added 35 
mL of dry triethylamine (2.75 eq.). The mixture was cooled down to 0 °C and a solution of 15 g of 339c 
(1 eq.) in 90 mL of dry tetrahydrofuran was added dropwise. After an additional 30 minutes of stirring 
at 0 °C, 8.29 mL of methyl 2-isocyanoacetate (1 eq.) was added dropwise. The reaction mixture was 
stirred at 0 °C for one hour and then at reflux temperature for twelve hours. The solvent was removed 
in vacuo and the residue was dissolved in 100 mL of ethyl acetate and washed with 100 mL of water 
and 100 mL of brine. The organic layer was dried over magnesium sulfate and the solvent was 
removed in vacuo. The crude product was purified by column chromatography over silica (ethyl 
acetate/hexane (1:5), Rf = 0.3) to obtain compound 340c as a pale yellow oil (19.68 g, Y = 95%).  
1
H NMR (400 MHz, CDCl3): δ = 1.60 (s, 9H), 3.96 (s, 3H), 7.96 (s, 1H). 
13
C NMR (100 
MHz, CDCl3): δ = 28.0, 52.8, 84.5, 134.4, 144.0, 150.9, 155.7, 160.8. IR: 2982, 1725, 
1590, 1356, 1307, 1142, 1053, 765 cm
–1
. MS (ESI, 70 eV): m/z (%) = 250 (7, [M + Na]
+
). 
HRMS: m/z [M – H]
-
 calcd for C10H12NO5: 226.0721; found: 226.0720.  
4-(tert-Butyl) 5-methyl oxazole-4,5-dicarboxylate (340d) 
To a solution of 468 mg of imidazole (6.9 mmol, 1 eq.) in 15 mL of dry tetrahydrofuran was added 2.64 
mL of dry triethylamine (2.75 eq.). The mixture was cooled down to 0 °C and a solution of 842 mg of 
methyl 2-chloro-2-oxoacetate (1 eq.) in 10 mL of dry tetrahydrofuran was added dropwise. After an 
additional 30 minutes of stirring at 0 °C, 1 mL of tert-butyl 2-isocyanoacetate (1 eq.) was added 
dropwise. The reaction mixture was stirred at 0 °C for one hour and then at reflux temperature for 
twelve hours. The solvent was removed in vacuo and the residue was dissolved in 100 mL of ethyl 
acetate and washed with 100 mL of water and 100 mL of brine. The organic layer was dried over 
magnesium sulfate and the solvent was removed in vacuo. The crude product was purified by column 
chromatography over silica (ethyl acetate/hexane (1:5), Rf = 0.32) to obtain compound 340d as a pale 
yellow oil (1.354 g, Y = 87%).  
1
H NMR (400 MHz, CDCl3): δ = 1.50-1.58 (m, 9H, C(CH3)3), 3.87-3.93 (m, 3H, OCH3), 
7.93 (s, 1H, CH). 
13
C NMR (100 MHz, CDCl3): δ = 27.9 (C(CH3)3), 52.8 (OCH3), 83.5 
(C(CH3)3), 137.0 (NCq), 141.7 (OCq), 151.4 (CH), 157.1 (C(O)OMe), 159.4 (C(O)Ot-Bu). 
IR: 2530, 1714, 1580, 1429, 1306, 1159, 746 cm
–1
. MS (ESI, 70 eV): m/z (%) = 250 (9, 
[M + Na]
+
). HRMS: m/z [M – H]
-
 calcd for C10H12NO5: 226.0721; found: 226.0730. 
5-(Methoxycarbonyl)oxazole-4-carboxylic acid (341) 
To a solution of 340d (2.525 g, 11.1 mmol, 1 eq.) in 23 mL of dry dichloromethane were added 4.44 
mL of triethylsilane (2.5 eq.) and 11 mL of trifluoroacetic acid (13 eq.). After one hour of stirring at 
room temperature, the solvent was removed in vacuo, the residue was triturated in 6.5 mL of dry 
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diethyl ether and filtered over a glass sintered filter. The filter cake was washed with 6.5 mL of dry 
diethyl ether and dried to obtain compound 341 as a white solid (1.787 g, Y = 94%).  
1
H NMR (400 MHz, DMSO-d6): δ = 3.88 (s, 3H, OCH3), 8.69 (s, 1H, CH), 13.79 (br. s, 1H, 
OH). 
13
C NMR (100 MHz, DMSO-d6): δ = 53.3 (OCH3), 137.0 (NCq), 141.0 (OCq), 154.1 
(CH), 157.4 (C(O)OMe), 162.2 (C(O)OH). IR: 3118, 2971, 1731, 1607, 1281, 1129, 1051, 
732, 716 cm
–1
. MS (ESI, 70 eV): m/z (%) = 172.0 (100, [M + H]
+
). HRMS: m/z [M + H]
+
 
calcd for C6H6NO5: 172.0240; found: 172.0238. Mp 136-137 °C.  
4-(Methoxycarbonyl)oxazole-5-carboxylic acid (342) 
To a solution of 340c (19.68 g, 86.6 mmol, 1 eq.) in 178 mL of dry dichloromethane were added 34.6 
mL of triethylsilane (2.5 eq.) and 86.2 mL of trifluoroacetic acid (13 eq.). After one hour of stirring at 
room temperature, the solvent was removed in vacuo, the residue was triturated in 50 mL of dry 
diethyl ether and filtered over a glass sintered filter. The filter cake was washed with 50 mL of dry 
diethyl ether and dried to obtain compound 342 as a white solid (14.52 g, Y = 98%).  
1
H NMR (400 MHz, DMSO-d6): δ = 3.86 (s, 3H, OCH3), 8.69 (d, J = 1.5 Hz, 1H, CH). 
13
C 
NMR (100 MHz, DMSO-d6): δ = 53.2 (OCH3), 134.8 (NCq), 143.2 (OCq), 153.9 (CH), 158.0 
(C(O)OH), 161.7 (C(O)OMe). IR: 2530, 1714, 1580, 1429, 1306, 1159, 746 cm
–1
. MS (ESI, 
70 eV): m/z (%) = 172.0 (87, [M + H]
+
). HRMS: m/z [M + H]
+
 calcd for C6H6NO5: 172.0240; 
found: 172.0242. Mp 150-151 °C.  
Lithium 5-(tert-butoxycarbonyl)oxazole-4-carboxylate (343) 
To a stirred solution of 400 mg of 340c (1.76 mmol, 1 eq.) in 25 mL of THF, a solution of 
74 mg of LiOH monohydrate (1.76 mmol, 1 eq.) in 13 mL of water was added dropwise. 
The mixture was stirred at room temperature for one hour. THF was removed by rotary 
evaporation, and the remaining aqueous solution was washed two times with 10 mL of 
diethyl ether. After evaporation of the water phase and drying under high vacuum, compound 343 was 
obtained as a white, hygroscopic solid (333 mg, 86%). The purity of the compound was assessed by 
LCMS and NMR, but characterization of the compound was not performed.  
Lithium 5-(isopropoxycarbonyl)oxazole-4-carboxylate (345) 
To a stirred solution of 506 mg of 340b (2.37 mmol, 1 eq.) in 25 mL of THF, a solution of 
99.6 mg of LiOH monohydrate in 13 mL of water was added dropwise at 0 °C. The 
mixture was stirred at 0 °C for one hour and at room temperature for one more hour. The 
reaction was worked up according to the procedure for compound 343, and resulted in a 
pale yellow oil (440 mg, 90%). Characterization of the compound was not performed.  
Methyl 5-carbamoyloxazole-4-carboxylate (351) 
To a suspension of 2.054 g of 342 (12 mmol, 1 eq.) in 80 mL of dry dichloromethane were added 1.22 
mL of oxalyl chloride (1.2 eq.) and five drops of DMF. The reaction was stirred at room temperature for 
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one hour and the solvent was removed in vacuo. The crude acyl chloride was taken up in 30 mL of dry 
dichloromethane and was added to a solution of 7.65 mL of hexamethyldisilazane (3 eq.) in 90 mL of 
dichloromethane at 0 °C. The reaction mixture was stirred at room temperature for twelve hours and 
the solvent was removed in vacuo. The crude product was dissolved in 30 mL of dry dichloromethane 
and 20 mL of trifluoroacetic acid (22 eq.) was added. After stirring at room temperature for one hour, 
the solvent was removed in vacuo and the crude product was suspended in 200 mL of sat. aqueous 
sodium bicarbonate solution. The suspension was extracted with ethyl acetate (3 x 200 mL). The 
combined organic layers were dried over magnesium sulfate and evaporated in vacuo. The crude 
product was triturated in 10 mL of acetone, triturated in 10 mL of hexane and dried to obtain product 
351 as a white solid (1.79 g, Y = 88%).  
1
H NMR (400 MHz, DMSO-d6): δ = 3.88 (s, 3H, OCH3), 8.21 (br. s, 1H, NHaHb), 8.59 (br. s, 
1H, NHaHb), 8.65 (s, 1H, CH). 
13
C NMR (100 MHz, DMSO-d6): δ = 53.3 (OCH3), 130.4 
(NCq), 148.3 (OCq), 152.6 (CH), 157.3 (C(O)NH2), 162.7 (C(O)OMe). IR: 3333, 3183, 
1708, 1682, 1318, 1300, 1170, 1055, 648 cm
–1
. MS (ESI, 70 eV): m/z (%) = 171.0 (100, [M 
+ H]
+
). HRMS: m/z [M + H]
+
 calcd for C6H7N2O4: 171.0400; found: 171.0400. Mp 184-185 °C (degrad.).  
Methyl 4-(tritylcarbamoyl)oxazole-5-carboxylate (356) 
To a suspension of 341 (100 mg, 0.58 mmol, 1 eq.) in 2 mL of dry dichloromethane was added 0.12 
mL of oxalyl chloride (2.5 eq.) and one drop of DMF at 0 °C. After stirring for 15 minutes at 0 °C and 
two hours at room temperature, the solvent was removed in vacuo and the crude acyl chloride was 
taken up in 5 mL of dry dichloromethane and cooled down to 0 °C. Then, 0.41 mL of dry triethylamine 
(5 eq.) was added, followed by 152 mg of tritylamine (1 eq.). After stirring at room temperature for 
twelve hours, the solvent was removed in vacuo and the crude product was purified by column 
chromatography over silica (ethyl acetate/hexane (1:1), Rf = 0.4) to obtain compound 356 as a white 
solid (190 mg, Y = 79%).  
1
H NMR (400 MHz, CDCl3): δ = 3.93 (s, 3H), 7.20-7.35 (m, 15H), 7.94 (s, 1H), 9.47 (br. 
s, 1H). 
13
C NMR (100 MHz, CDCl3): δ = 53.4, 71.2, 127.0, 127.9, 128.8, 139.9, 140.1, 
144.3, 151.1, 157.3, 158.9. MS (ESI, 70 eV): m/z (%) = 411.1 (100, [M – H]
-
). HRMS: 
m/z [M – H]
-
 calcd for C25H19N2O4: 411.1350; found: 411.1361. mp 81-82 °C.  
Methyl 4-carbamoyloxazole-5-carboxylate (357) 
To a solution of 27 mg of 356 (0.065 mmol, 1 eq.) in 2 mL of dry dichloromethane was added 19 mg of 
triethylsilane (2.5 eq.) and 2 mL of trifluoroacetic acid. After stirring at room temperature for one hour, 
the solvent was removed in vacuo and the crude product was recrystallized from 
dichloromethane/hexane to obtain compound 357 as off-white crystals (9 mg, Y = 81%).  
1
H NMR (400 MHz, DMSO-d6): δ = 3.87 (s, 3H, OCH3), 7.83 (br. s, 1H, NHaHb), 8.08 (br. 
s, 1H, NHaHb), 8.67 (s, 1H, CH). 
13
C NMR (100 MHz, DMSO-d6): δ = 53.2 (OCH3), 139.1 
(OCq), 140.1 (NCq), 153.9 (CH), 158.2 (C(O)OMe), 161.6 (C(O)NH2). IR: 3325, 1674, 
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1632, 1531, 1493, 1449, 1306, 1202, 1051, 698, 910 cm
–1
. MS (ESI, 70 eV): m/z (%) = 171.0 (100, [M 
+ H]
+
). HRMS: m/z [M + H]
+
 calcd for C6H7N2O4: 171.0400; found: 171.0402. Mp 168-169 °C.  
Representative procedure for compounds 350a-c,e-g: 
Methyl 5-(3-propylureido)oxazole-4-carboxylate (350a) 
To a suspension of 200 mg of 351 (1.2 mmol, 1 eq.) in 10 mL of dry dichloromethane was added 
1.136 g of PhI(OAc)2 (3 eq.) and the reaction mixture was stirred at room temperature for two hours. 
Then, 417 mg of n-propylamine (6 eq.) was added, and the reaction mixture was stirred at room 
temperature for twelve hours. The reaction mixture was poured into a separation funnel, 10 mL of 
dichloromethane was added and the organic layer was washed with 15 mL of sat. aqueous ammonium 
chloride solution. The aqueous layer was extracted with dichloromethane (2 x 20 mL), the combined 
organic layers were dried over magnesium sulfate and the solvent was removed in vacuo. The crude 
product was purified by column chromatography over silica (dichloromethane/methanol, gradient from 
0% methanol to 5% methanol over 10 column volumes, Rf = 0.43 (5% methanol in dichloromethane)) 
to afford a pale yellow product. After trituration in 1 mL of diethyl ether, compound 350a was obtained 
as a white solid (156 mg, Y = 58%).  
1
H NMR (400 MHz, CDCl3): δ = 0.98 (t, J = 7.2 Hz, 3H, CH2CH3), 1.62 (sextet, J = 7.2 
Hz, 2H, CH2CH3), 3.31 (dt, J = 5.9 Hz, J = 7.2 Hz, 2H, NCH2), 3.91 (s, 3H, OCH3), 5.87 
(br. s, 1H, NHCH2), 7.51 (s, 1H, CH), 8.47 (br. s, 1H, CqNHC(O)). 
13
C NMR (100 MHz, 
CDCl3): δ = 11.3 (CH2CH3), 23.0 (CH2CH3), 42.5 (NCH2), 52.1 (OCH3), 108.5 (NCq), 
142.1 (CH), 151.1 (NHC(O)NH), 152.2 (OCq), 163.3 (C(O)OMe). IR: 3333, 2972, 1697, 1638, 1450, 
1310, 1061, 785, 631 cm
–1
. MS (ESI, 70 eV): m/z (%) = 225.9 (100, [M – H]
-
). HRMS: m/z [M - H]
-
 
calcd for C9H12N3O4: 226.0833; found: 226.0838. Mp 167-168 °C.  
Methyl 5-(3-butylureido)oxazole-4-carboxylate (350b) 
Compound 350b was synthesized and purified following the representative procedure, using 200 mg 
of 351, 1.136 g of PhI(OAc)2 and 516 mg of n-butylamine. Rf = 0.41 (5% methanol in 
dichloromethane). Compound 350b was obtained as a white solid (159 mg, Y = 56%).  
1
H NMR (400 MHz, CDCl3): δ = 0.95 (t, J = 7.4 Hz, 3H), 1.40 (sextet, J = 7.4 Hz, 2H), 
1.58 (pentet, J = 7.4 Hz, 2H), 3.30-3.38 (m, 2H), 3.90 (s, 3H), 5.90 (br. s, 1H), 7.51 
(s, 1H), 8.51 (br. s, 1H). 
13
C NMR (100 MHz, CDCl3): δ = 13.7, 20.0, 31.8, 40.5, 52.0, 
108.5, 142.1, 151.2, 152.2, 163.3. IR: 3316, 1667, 1636, 1450, 1215, 1084, 1053, 
642 cm
–1
. MS (ESI, 70 eV): m/z (%) = 239.6 (100, [M – H]
-
). HRMS: m/z [M + H]
+
 calcd for C10H16N3O4: 
242.1135; found: 242.1133. Mp 145-146 °C.  
Methyl 5-(3-isopropylureido)oxazole-4-carboxylate (350c) 
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Compound 350c was synthesized and purified following the representative procedure, using 200 mg 
of 351, 1.136 g of PhI(OAc)2 and 418 mg of isopropylamine. Rf = 0.39 (5% methanol in 
dichloromethane). Compound 350c was obtained as a white solid (173 mg, Y = 65%).  
1
H NMR (400 MHz, CDCl3): δ = 1.25 (d, J = 6.4 Hz, 6H), 3.90 (s, 3H), 4.04 (octet, J = 6.4 
Hz, 1H), 5.69 (d, J = 6.4 Hz, 1H), 7.51 (s, 1H), 8.47 (br. s, 1H). 
13
C NMR (100 MHz, 
CDCl3): δ = 22.9, 43.0, 52.0, 108.6, 142.2, 150.3, 152.3, 163.3. IR: 3327, 1707, 1634, 
1499, 1314, 1090, 629 cm
–1
. MS (ESI, 70 eV): m/z (%) = 250.2 (73, [M + Na]
+
). HRMS: 
m/z [M + H]
+
 calcd for C9H14N3O4: 228.0979; found: 228.0973. Mp 177-178 °C.  
Methyl 5-(3-benzylureido)oxazole-4-carboxylate (350d) 
To a suspension of 200 mg of 351 (1.2 mmol, 1 eq.) in 30 mL of dry dichloromethane was added 
2.272 g of PhI(OAc)2 (6 eq.) and the reaction mixture was stirred at reflux temperature for two and a 
half hours. The reaction was cooled down to 0 °C, 0.771 mL of benzylamine (6 eq.) was added, the 
reaction mixture was allowed to warm up to room temperature and stirred for twelve more hours. The 
reaction mixture was poured into a separation funnel and the organic layer was washed with 20 mL of 
sat. aqueous ammonium chloride solution. The aqueous layer was extracted with dichloromethane (2 
x 20 mL), the combined organic layers were dried over magnesium sulfate and the solvent was 
removed in vacuo. The crude product was purified by column chromatography over silica 
(dichloromethane/methanol, gradient from 0% methanol to 5% methanol over 10 column volumes) to 
afford a pale yellow product. After trituration in 1 mL of diethyl ether and subsequent recrystallization 
from methanol, compound 350d was obtained as white crystals (49 mg, Y = 15%).  
1
H NMR (400 MHz, DMSO-d6): δ = 3.78 (s, 3H), 4.31 (d, J = 5.4 Hz, 2H), 7.22-7.41 
(m, 5H), 7.69-7.78 (m, 1H), 8.13 (s, 1H), 9.23 (br. s, 1H). 
13
C NMR (100 MHz, DMSO-
d6): δ = 43.5, 51.8, 111.8, 127.5, 127.7, 128.9, 139.8, 145.8, 152.1, 152.5, 162.5. IR: 
3262, 1626, 1537, 1206, 1036, 669 cm
–1
. MS (ESI, 70 eV): m/z (%) = 274.0 (100, [M 
– H]
-
). HRMS: m/z [M + H]
+
 calcd for C13H14N3O4: 276.0979; found: 276.0979. Mp 176-177 °C.  
Methyl 5-(3-isobutylureido)oxazole-4-carboxylate (350e) 
Compound 350e was synthesized and purified following the representative procedure, using 200 mg 
of 351, 1.136 g of PhI(OAc)2 and 516 mg of isobutylamine. Rf = 0.4 (5% methanol in dichloromethane). 
Compound 350e was obtained as a white solid (144 mg, Y = 51%).  
1
H NMR (400 MHz, CDCl3): δ = 0.97 (d, J = 6.7 Hz, 6H), 1.86 (nonet, J = 6.7 Hz, 1H), 
3.14-3.20 (m, 2H), 3.91 (s, 3H), 5.93 (br. s, 1H), 7.51 (s, 1H), 8.51 (br. s, 1H). 
13
C NMR 
(100 MHz, CDCl3): δ = 20.0, 28.6, 48.1, 52.0, 108.5, 142.1, 151.2, 152.2, 163.3. IR: 
3331, 2965, 1697, 1636, 1568, 1206, 1081, 627 cm
–1
. MS (ESI, 70 eV): m/z (%) = 
240.3 (100, [M – H]
-
). HRMS: m/z [M + H]
+
 calcd for C10H16N3O4: 242.1135; found: 242.1137. Mp 151-
152 °C.  
Methyl 5-(3-cyclohexylureido)oxazole-4-carboxylate (350f) 
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Compound 350f was synthesized and purified following the representative procedure, using 200 mg of 
351, 1.136 g of PhI(OAc)2 and 700 mg of cyclohexylamine. Rf = 0.55 (5% methanol in 
dichloromethane). Compound 350f was obtained as a white solid (199 mg, Y = 63%).  
1
H NMR (400 MHz, CDCl3): δ = 1.14-1.30 (m, 3H), 1.32-1.48 (m, 2H), 1.56-1.69 (m, 
1H), 1.69-1.80 (m, 2H), 1.95-2.07 (m, 2H), 3.64-3.80 (m, 1H), 3.91 (s, 3H), 5.63 (br. s, 
1H), 7.51 (s, 1H), 8.40 (br. s, 1H). 
13
C NMR (100 MHz, CDCl3): δ = 24.7, 25.4, 33.2, 
49.7, 52.1, 108.3, 142.0, 150.1, 152.2, 163.3. IR: 3296, 1661, 1634, 1449, 1209, 1084, 
1053, 637 cm
–1
. MS (ESI, 70 eV): m/z (%) = 268.1 (100, [M + H]
+
). HRMS: m/z [M + H]
+
 calcd for 
C12H18N3O4: 268.1292; found: 268.1290. Mp 192-193 °C.  
Methyl 5-(3-cyclopropylureido)oxazole-4-carboxylate (350g) 
Compound 350g was synthesized and purified following the representative procedure, using 200 mg 
of 351, 1.136 g of PhI(OAc)2 and 403 mg of cyclopropylamine. Rf = 0.4 (5% methanol in 
dichloromethane). After trituration in diethyl ether, the obtained product was purified by reversed 
phase column chromatography on C18 silica (water/acetonitrile, gradient from 0% acetonitrile to 100% 
acetonitrile over 20 column volumes) and subsequent recrystallization from acetonitrile to obtain 
compound 350g as white crystals (50 mg, Y = 19%).  
1
H NMR (400 MHz, CDCl3): δ = 0.60-0.83 (m, 2H), 0.84-1.08 (m, 2H), 2.65-2.76 (m, 1H), 
3.93 (s, 3H), 5.68 (br. s, 1H), 7.55 (s, 1H), 9.37 (br. s, 1H). 
13
C NMR (100 MHz, DMSO-
d6): δ = 6.2, 22.4, 51.4, 111.0, 145.2, 151.7, 152.6, 162.1. MS (ESI, 70 eV): m/z (%) = 
226.1 (100, [M + H]
+
). HRMS: m/z [M + H]
+
 calcd for C9H12N3O4: 226.0822; found: 
226.0822. Mp 171-172 °C.  
Methyl 5-(3-tritylureido)oxazole-4-carboxylate (350h) 
To a suspension of 200 mg of 351 (1.2 mmol, 1 eq.) in 25 mL of dry dichloromethane was added 
2.272 g of PhI(OAc)2 (6 eq.) and the reaction mixture was stirred at reflux temperature for two and a 
half hours. The reaction was cooled down to 0 °C, 1.829 g of tritylamine (6 eq.) was added and the 
reaction mixture was stirred at 0 °C for 30 minutes. The reaction was quenched by addition of 20 mL 
of a sat. sodium thiosulfate solution and stirred at 0 °C for 30 minutes. The reaction mixture was 
poured into a separation funnel and the organic layer was separated. The aqueous layer was 
extracted with dichloromethane (2 x 20 mL), the combined organic layers were dried over magnesium 
sulfate and the solvent was removed in vacuo. The crude product was purified by column 
chromatography over silica (dichloromethane/methanol, gradient from 0% methanol to 5% methanol 
over 10 column volumes, Rf = 0.5 (5% methanol in dichloromethane)) to afford a white solid. After 
trituration in 1 mL of diethyl ether, compound 350h was obtained as a white solid (155 mg, Y = 31%).  
1
H NMR (400 MHz, DMSO-d6): δ = 3.78 (s, 3H), 7.05-7.45 (m, 15H), 8.01 (s, 1H), 8.47 
(s, 1H), 9.70 (s, 1H). 
13
C NMR (100 MHz, DMSO-d6): δ = 51.8, 69.7, 111.2, 127.1, 
128.2, 128.9, 145.2, 145.4, 151.1, 152.1, 162.6. IR: 1632, 1533, 1306, 1202, 1051, 698 
149 
 
cm
–1
. MS (ESI, 70 eV): m/z (%) = 426.0 (100, [M – H]
-
). HRMS: m/z [M + H]
+
 calcd for C25H22N3O4: 
428.1605; found: 428.1585. Mp 238-239 °C.  
Methyl 5-ureidooxazole-4-carboxylate (350i) 
To a solution of 543 mg of 350h (1.27 mmol, 1 eq.) in 10 mL of dry dichloromethane were 
added 369 mg of triethylsilane (2.5 eq.) and 1.26 mL of trifluoroacetic acid (13 eq.). After 
stirring at room temperature for one hour, the solvent was evaporated in vacuo and an off-
white solid was obtained. The crude material was suspended in 5 mL of dichloromethane 
and triturated. Then, 15 mL of hexane was added and the solvent was decanted. Next, the 
solids were suspended in 5 mL of acetone and triturated. Then, 15 mL of hexane was added and the 
solvent was decanted. After drying under high vacuum, compound 350i was obtained as a white solid 
(193 mg, 82%).  
1
H NMR (400 MHz, DMSO-d6): δ = 3.78 (s, 3H, OCH3), 6.71 (s, 2H, NH2), 8.10 (s, 1H, CH), 9.07 (br. s, 
1H, NH). 
13
C NMR (100 MHz, DMSO-d6): δ = 51.4 (OCH3), 111.3 (CqC(O)OMe), 145.3 (CH), 151.8 
(CqNHC(O)), 152.7 (NHC(O)NH2), 162.1 (C(O)OMe). IR: 3345, 3184, 3142, 1730, 1672, 1611, 1327, 
1063, 635, 610 cm
–1
. MS (ESI, 70 eV): m/z (%) = 184.1 (87, [M – H]
-
). Mp 213-214 °C (degrad.).  
Representative procedure for the synthesis of compounds 337a-d: 
6-Propyloxazolo[5,4-d]pyrimidine-5,7(4H,6H)-dione (337a) 
To a suspension of 50 mg of 350a (0.22 mmol, 1 eq.) in 0.8 mL of dry methanol was added 35 mg of 
sodium methoxide (2.9 eq.). The reaction mixture was stirred at room temperature for 27 days. The 
solvent was removed in vacuo, and the residue was dissolved in 0.5 mL of ice cold water. The solution 
was acidified to pH = 5~6 by dropwise addition of 1N aqueous sulfuric acid solution at 0 °C. The 
precipitate was filtered off and washed with 1 mL of ice cold water and dried under high vacuum to 
obtain compound 337a as an off-white solid (20 mg, Y = 46%).  
1
H NMR (400 MHz, DMSO-d6): δ = 0.86 (t, J = 7.5 Hz, 3H, CH3), 1.54 (pentet, J = 7.5 
Hz, 2H, CH2CH3), 3.74-3.81 (m, 2H, NCH2), 8.31 (s, 1H, CH), 13.30 (br. s, 1H, NH). 
13
C 
NMR (100 MHz, DMSO-d6): δ = 11.6 (CH3), 21.1 (CH2CH3), 42.3 (NCH2), 110.3 (NCq), 
147.1 (CH), 150.3 (NHC(O)N), 155.0 (OCq), 157.2 (CqC(O)). IR: 1722, 1643, 1555, 
1055, 1011 cm
–1
. MS (ESI, 70 eV): m/z (%) = 196.0 (100, [M + H]
+
). HRMS: m/z [M – H]
-
 calcd for 
C8H8N3O3: 194.0571; found: 194.0566. Mp 170-171 °C (degrad.).  
6-Butyloxazolo[5,4-d]pyrimidine-5,7(4H,6H)-dione (337b) 
Compound 337b was synthesized following the representative procedure, using 70 mg of 350b (0.29 
mmol) and 46 mg of sodium methoxide, and was obtained as an off-white solid (31 mg, Y = 51%).  
1
H NMR (400 MHz, DMSO-d6): δ = 0.89 (t, J = 7.4 Hz, 3H), 1.28 (sextet, J = 7.4 Hz, 2H), 1.49 (pentet, 
J = 7.4 Hz, 2H), 3.79 (t, J = 7.4 Hz, 2H), 8.19 (s, 1H). 
13
C NMR (100 MHz, DMSO-d6): δ = 13.7, 19.6, 
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29.6, 40.2, 109.2, 146.1, 151.1, 156.6, 157.1. IR: 3136, 3082, 2963, 2870, 1643, 
1555, 1013, 752, 621, 525, 492 cm
–1
. MS (ESI, 70 eV): m/z (%) = 210.1 (100, [M + 
H]
+
). Mp 169-170 °C (degrad.).  
6-Isobutyloxazolo[5,4-d]pyrimidine-5,7(4H,6H)-dione (337c) 
Compound 337c was synthesized following the representative procedure, using 28.5 mg of 350c (0.12 
mmol) and 18.5 mg of sodium methoxide, and was obtained as an off-white solid (13 mg, Y = 53%).  
1
H NMR (400 MHz, DMSO-d6): δ = 0.78-0.92 (m, 6H), 1.93-2.10 (m, 1H), 3.60-3.72 (m, 
2H), 8.31 (s, 1H), 13.29 (br. s, 1H). 
13
C NMR (100 MHz, DMSO-d6): δ = 19.9, 26.6, 
47.0, 109.8, 146.6, 150.0, 154.4, 157.0. IR: 3134, 3084, 3053, 2963, 1726, 1653, 1555, 
754, 623, 540 cm
–1
. MS (ESI, 70 eV): m/z (%) = 210.1 (100, [M + H]
+
). Mp 170-171 °C 
(degrad.).  
6-Benzyloxazolo[5,4-d]pyrimidine-5,7(4H,6H)-dione (337d) 
Compound 337d was synthesized following the representative procedure, using 31 mg of 350d (0.11 
mmol) and 18 mg of sodium methoxide, and was obtained as an off-white solid (9 mg, Y = 33%).  
1
H NMR (400 MHz, DMSO-d6): δ = 5.01 (s, 2H), 7.15-7.35 (m, 5H), 8.31 (s, 1H), 13.4 
(br. s, 1H). MS (ESI, 70 eV): m/z (%) = 242.2 (100, [M - H]
-
).  
 
Oxazolo[5,4-d]pyrimidine-5,7(4H,6H)-dione (337e) 
To a suspension of 50 mg of 350i (0.27 mmol, 1 eq.) in 1.8 mL of dry methanol was added 
42 mg of sodium methoxide (2.9 eq.). The reaction mixture was stirred at room 
temperature for 15 days. The solvent was removed in vacuo, and the residue was taken 
up in 2 mL of ice cold water. The suspension was acidified to pH = 5~6 by dropwise 
addition of 2N aqueous HCl solution at 0 °C. The precipitate was filtered off and washed with 1 mL of 
ice cold water and dried under high vacuum to obtain compound 337e as an off-white solid (20 mg, Y 
= 48%).  
1
H NMR (400 MHz, DMSO-d6): δ = 8.07 (s, 1H, CH), 10.49 (br. s, 1H, NH). 
13
C NMR (100 MHz, 
DMSO-d6): δ = 109.2 (NCqC(O)), 145.6 (CH), 153.2 (NHC(O)NH), 158.0 (OCqNH), 160.9 (NCqC(O)). 
IR: 1682, 1630, 1609, 1281, 758, 625, 525, 482 cm
–1
. MS (ESI, 70 eV): m/z (%) = 152.1 (100, [M – H]
-
). Mp 249-250 °C (degrad.). 
Methyl 5-((tert-butoxycarbonyl)amino)oxazole-4-carboxylate (369) 
To a solution of 100 mg of 350a (0.44 mmol, 1 eq.) in 5 mL of dry THF were added 0.08 mL of 
triethylamine (1.3 eq.) and 27 mg of 4-(dimethylamino)pyridine (0.5 eq.) under an inert atmosphere. 
The mixture was cooled down to 0 °C and a solution of 125 mg of di-tert-butyl dicarbonate (1.3 eq.) in 
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1 mL of dry THF was added dropwise to the reaction. The reaction mixture was warmed up to room 
temperature and stirred for two hours. Then, 10 mL of water was added and the mixture was extracted 
with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine (10 mL), dried 
over magnesium sulfate and evaporated in vacuo. The crude product was purified by column 
chromatography over silica (ethyl acetate/hexane (1:3), Rf = 0.31) to obtain compound 369 as white 
crystals (86 mg, Y = 81%).  
1
H NMR (400 MHz, CDCl3): δ = 1.54 (s, 9H), 3.93 (s, 3H), 7.54 (s, 1H), 8.44 (br. s, 1H). 
13
C NMR (100 MHz, CDCl3): δ = 28.0, 52.1, 83.3, 110.1, 143.4, 149.3, 151.9, 163.5. IR: 
3121, 1705, 1626, 1312, 1148, 642 cm
–1
. MS (ESI, 70 eV): m/z (%) = 240.9 (100, [M – H]
-
). HRMS: m/z [M – H]
-
 calcd for C10H13N2O5: 241.0830; found: 241.0830. White crystals, 
mp 81-82 °C.  
Methyl 4-(3-propylureido)oxazole-5-carboxylate (370a) 
Compound 370a was synthesized and purified following the representative procedure for compounds 
350a-c,e-g, using 100 mg of 357, 568 mg of PhI(OAc)2 and 209 mg of n-propylamine. Rf = 0.43 (ethyl 
acetate/hexane (1:1)). Compound 370a was obtained as a colourless oil (82 mg, Y = 61%).  
1
H NMR (400 MHz, MeOH-d4): δ = 0.90-1.02 (m, 3H, CH2CH3), 1.53-1.66 (m, 2H, 
CH2CH3), 3.21-3.30 (m, 2H, NCH2), 3.93 (s, 3H, OCH3), 8.30 (s, 1H, CH). 
13
C NMR 
(100 MHz, MeOH-d4): δ = 11.7 (CH2CH3), 24.0 (CH2CH3), 42.9 (NHCH2), 52.5 (OCH3), 
124.2 (NCq), 146.1 (OCq), 154.0 (CH), 155.5 (NHC(O)NH), 160.2 (C(O)OMe). IR: 
3345, 3094, 2961, 2874, 1678, 1624, 1549, 1447, 1246, 1148 cm
–1
. MS (ESI, 70 eV): 
m/z (%) = 226.2 (100, [M – H]
-
).  
Methyl 4-(3-(3-methoxybenzyl)ureido)oxazole-5-carboxylate (370c) 
To a suspension of 300 mg of 341 (1.75 mmol, 1 eq.) in 5 mL of dry dichloromethane were added 0.18 
mL of oxalyl chloride and one drop of DMF at room temperature. The reaction was stirred for one and 
a half hours at room temperature, and the solvent was removed in vacuo. The crude acyl chloride was 
dissolved in 5 mL of dry acetone and a solution of 171 mg of sodium azide (1.5 eq.) in 1 mL of water 
was added dropwise to the reaction mixture at 0 °C. After stirring for one hour at 0 °C, 10 mL of water 
was added and the mixture was extracted with ethyl acetate (2 x 10 mL). The combined organic layers 
were dried over magnesium sulfate and evaporated in vacuo at low temperature (20 to 25 °C) to afford 
the pure acyl azide 372 (316 mg, Y = 92%). A solution of 116 mg of 372 (0.51 mmol, 1 eq.) in 5 mL of 
toluene was heated at 70 °C for one hour and fifteen minutes, cooled down to room temperature and 
163 mg of 3-methoxybenzylamine was added to the reaction mixture (2 eq.). After stirring for twelve 
hours at room temperature, the solvent was evaporated in vacuo and the crude product was purified 
by column chromatography over silica (ethyl acetate/hexane (1:1), Rf = 0.27) to obtain compound 
370c as a colourless oil (63 mg, Y = 35%).  
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1
H NMR (400 MHz, MeOH-d4): δ = 3.76 (s, 3H), 3.90 (s, 3H), 4.44 (s, 2H), 6.76-
6.83 (m, 1H), 6.87-6.97 (m, 2H), 7.18-7.25 (m, 1H), 8.22 (s, 1H). 
13
C NMR (100 
MHz, MeOH-d4): δ = 44.8, 52.5, 55.6, 113.7, 114.0, 120.6, 124.5, 130.7, 141.6, 
145.9, 154.0, 155.5, 160.2, 161.4. IR: 3329, 2955, 1678, 1624, 1445, 1240, 
1144, 1045, 758, 610 cm
–1
. MS (ESI, 70 eV): m/z (%) = 304.2 (100, [M – H]
-
).  
Oxazolo[4,5-d]pyrimidine-5,7(4H,6H)-dione (333a) 
A suspension of 100 mg of 372 (0.51 mmol, 1 eq.) and 67 mg of 1H-benzotriazole (1.1 eq.) in 3 mL of 
dry toluene was heated at 70 °C for 1.5 hours. After a few minutes, the suspension turned into a clear 
solution, and after 1.5 hours, a white precipitate is observed in the reaction. The solvent was 
evaporated, and an off-white solid was obtained. The solid was taken up in 5 mL of a 7M solution of 
ammonia in methanol, and stirred at room temperature for fifteen minutes. The solvent was removed 
in vacuo, and the residue was triturated in 5 mL of diethyl ether and decanted. This washing process 
was repeated two more times, and the product was dried under high vacuum. 50 mg of an off-white 
powder was obtained. This product still contained residual 1H-benzotriazole and a small amount of 
side products. A small sample was recrystallized from absolute ethanol for characterization purposes 
(370b, vide infra).  
43 mg of crude 370b was suspended in 1.2 mL of absolute ethanol, and 0.23 mL of a 1M aq. NaOH 
solution was added (1 eq.). The reaction mixture was heated at 80 °C for two hours. After cooling 
down to room temperature, the solvent was removed in vacuo. The residue was taken up in 1 mL of 
ice cold water and acidified to pH 5~6 with 1M aqueous H2SO4. The water layer was extracted with 
ethyl acetate (3x 5mL). The organic layers were combined, washed with 5 mL of brine, dried over 
magnesium sulfate and evaporated in vacuo. The crude product was purified by preparative HPLC 
(isocratic eluent mixture of acetonitrile/water 3:97). Compound 333a was obtained as a white powder 
(4 mg, 6% yield from 372 to 333a).  
1
H NMR (400 MHz, DMSO-d6): δ = 8.45 (s, 1H, CH), 10.17 (br. s, 1H, NH). IR: 1688, 1582, 
1335, 1132, 775, 754, 598, 561, 528, 480 cm
–1
. MS (ESI, 70 eV): m/z (%) = 152.1 (100, [M 
– H]
-
). 
 
Methyl 4-ureidooxazole-5-carboxylate (370b) 
White crystals from absolute ethanol (see procedure for 333a).  
1
H NMR (400 MHz, DMSO-d6): δ = 3.83 (s, 3H, OCH3), 6.92 (br. s, 2H, NH2), 8.12 (br. s, 
1H, NH), 8.56 (s, 1H, CH). 
13
C NMR (100 MHz, DMSO-d6): δ = 51.8 (OCH3), 123.4 
(NCqNHC(O)), 144.4 (OCqC(O)), 153.3 (CH), 153.3 (NHC(O)NH), 158.3 (OCqC(O)). IR: 
3404, 3377, 3217, 3115, 1719, 1688, 1632, 1609, 1315, 1288, 1142, 754, 610, 484, 463 
cm
–1
. MS (ESI, 70 eV): m/z (%) = 186.0 (100, [M + H]
+
).  
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2-(3,3-Dimethyl-2-oxobutyl)malononitrile (382) 
Chloropinacolone (5 g, 37 mmol, 1 eq.) was dissolved in 25 mL of methanol and a mixture of 
malononitrile (2.60 g, 1.06 eq.) and triethylamine (5.18 mL, 1 eq.) in 25 mL of methanol was added 
dropwise to the reaction mixture under an inert atmosphere at such a rate as to maintain the reaction 
temperature below 40 °C. The reaction mixture was stirred at room temperature for two hours and the 
solvent was evaporated in vacuo. The residue was taken up into 20 mL of dichloromethane, washed 
with 20 mL of brine, dried over magnesium sulfate, filtered over a plug of silica and evaporated to 
dryness to obtain compound 382 as pale brown crystals (5.223 g, Y = 86%).  
1
H NMR (400 MHz, CDCl3): δ = 1.22 (s, 9H, C(CH3)3), 3.28 (d, J = 6.9 Hz, 2H, CH2), 4.22 
(t, J = 6.9 Hz, 1H, CH).  
 
2-Amino-5-(tert-butyl)furan-3-carbonitrile (376) 
A solution of 500 mg of 382 (3 mmol, 1 eq.) in 3 mL of dry tetrahydrofuran and 1 mL of triethylamine 
was heated at 90 °C for one hour under an inert atmosphere in a microwave reactor. The solvent was 
evaporated in vacuo and the residue was dissolved in 10 mL of dichloromethane and washed with 10 
mL of brine. The aqueous layer was extracted again with 10 mL of dichloromethane. The combined 
organic layers were dried over magnesium sulfate, filtered over a plug of silica and evaporated to 
dryness. The crude product was recrystallized from hexane to obtain compound 376 as pale brown 
crystals (425 mg, Y = 85%).  
1
H NMR (400 MHz, CDCl3): δ = 1.20 (s, 9H, C(CH3)3), 4.57 (br. s, 2H, NH2), 5.83 (s, 1H, 
CH).  
 
2-Amino-5-(tert-butyl)furan-3-carboxamide (375) 
To 5.7 mL of concentrated sulfuric acid was added 1.49 g of 376 (9 mmol, 1 eq.) and the mixture was 
heated at 60 °C for 30 minutes. The reaction mixture was cooled down to 0 °C and 20 g of crushed ice 
was added to the reaction. The pH of the mixture was adjusted to pH = 9 by dropwise addition of a 
28% ammonia in water solution. The formed precipitate was filtered off, washed with 10 mL of water 
and dried under high vacuum to obtain compound 375 as a dark purple powder (1.276 g, Y = 77%).  
1
H NMR (400 MHz, CDCl3): δ = 1.22 (s, 9H, C(CH3)3), 5.20 (br. s, 2H, NH2), 5.46 (br. s, 
2H, NH2), 5.76 (s, 1H, CH). 
13
C NMR (100 MHz, CDCl3): δ = 28.8 (C(CH3)3), 32.2 
(C(CH3)3), 90.6 (CqCONH2), 99.5 (CH), 154.1 (CqNH2), 160.4 (CqC(CH3)3), 167.4 
(C(O)NH2).  
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3 Biological screenings 
3.1 NPP1 
The inhibition of NPP1 was screened in collaboration with Prof. Müller, Pharmaceutical Institute, 
Pharmaceutical Chemistry I, University of Bonn, Germany. This protocol has been described in the 
work of Koen Muylaert.
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3.1.1 Materials 
2-(N-cyclohexylamino)ethanesulfonic acid (CHES) and tris(hydroxymethyl)aminomethane (Tris) were 
purchased from Applichem (Darmstadt, Germany). Disodium hydrogen phosphate was obtained from 
Carl Roth (Karlsruhe, Germany). ATP, calcium chloride, dimethyl sulfoxide, magnesium chloride, p-
nitrophenyl 5’-thymidine monophosphate (p-Nph-5’-TMP), sodium chloride and sodium hydroxide were 
purchased from Sigma (Steinheim, Germany). Human recombinant soluble NPP1, expressed in NS0 
cells from murine myeloma, was obtained from R&D Systems GmbH (Wiesbaden, Germany). Human 
recombinant soluble NPP1, expressed in Sf9 insect cells, was prepared in-house.  
3.1.2 First screening 
The first screening of the compounds for inhibition of human NPP1 was performed using a colorimetric 
assay with the artificial substrate p-nitrophenyl 5’-thymidine monophosphate (p-Nph-5’-TMP).
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The assays were carried out at 37 °C in a total volume of 100 µL in a clear 96-well microplate. The 
reaction mixture contained 1 mM CaCl2, 200 µM ZnCl2, 50 mM Tris, pH 9.0, 400 µM p-Nph-5’-TMP 
and 10 µM of test compound. The enzymatic reactions were initiated by the addition of 20 ng of 
human NPP1 (commercial, Km = 8.17 µM), then incubated at 37 °C for 15 minutes, and subsequently 
terminated by the addition of 20 µL of 1.0 N NaOH. The liberated amount of p-nitrophenolate was 
measured at 400 nm. All experiments were performed two times in triplicate. The % inhibition of test 
compounds was determined and the blank experiment (without test compound) was set as 100% of 
enzyme activity.  
3.2 Antibacterial activity I 
The first antibacterial activity assessment was performed at the Laboratory for Microbiology (Ghent 
University, Belgium). A two-step procedure was proposed. In a first screening step, a large panel of 
compounds with unknown antimicrobial activity can be tested in a single ‘high’ concentration against a 
test panel of four bacterial test- and control strains. This screening will allow to objectively select those 
compounds that exhibit potential antimicrobial activity for a second series of tests in which the minimal 
inhibitory concentration (MIC) of the compounds can be individually determined for each compound-
test strain combination. 
3.2.1 Test organisms 
Initially, a panel of 4 internationally used test- and control strains for antimicrobial bioassays will be 
used in the assays. These strains have been chosen based on the clinical relevance of the 
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represented species as indicated in similar studies in literature. If required, additional strains can be 
added to the panel at later stages. 
Gram-positive bacteria: 
Bacillus subtilis LMG 13579 (28 °C) 
Staphylococcus aureus LMG 8064 (37 °C) 
Gram-negative bacteria: 
Escherichia coli LMG 8063 (37 °C) 
Klebsiella pneumoniae LMG 2095 (37 °C) 
3.2.2 Protocol outlines 
Initial screening for antimicrobial activity: 
Stock solutions of test compounds are prepared in DMSO by dissolving 1-10 mg in 200 L DMSO and 
adding 800 L Mueller-Hinton (MH) culture broth. Bacterial inocula of the four test strains are prepared 
from overnight cultures using the growth media as specified in the BCCM/LMG strain catalogue. 
Inocula are prepared in MH broth until a density of 10
5
 CFU/mL (or a McFarland turbidity standard 
equivalent) is reached. The bioassay is carried out in sterile 96-well microtiter plates. Per plate, the 
antimicrobial potency of max. 45 different compounds can be tested in duplicate against a single test 
strain. The remaining 6 wells are duplicates of positive, negative and sterility controls, respectively. To 
each well, 170 L of sterile MH broth is added. Next, depending on the type of well, additional 
reagents are added. In each pair of test wells, 10 L of a specific test compound stock solution is 
added. Test wells A1 and A2 thus contain 10 L of compound 1, test wells A3 and A4 contain 10 L of 
compound 2, etc. In the two positive control wells, 10 L gentamicin sulfate solution (in a 
concentration similar to the compound concentration) is added. In the two negative control wells, 10 
L of sterile 0.85% saline is added. Finally, in all wells, 20 L of bacterial inoculum is added. In the two 
sterility control wells, 20 L sterile MH broth is added. 
This way, final concentrations of 1% (v/v) DMSO, 0.05-0.5 mg/mL test compound and 10
4
 CFU/mL 
test bacteria are obtained in a test volume of 200 L. Depending on the test strain, plates are 
incubated at the respective temperatures (28 or 37 °C) for 24h under aerobic conditions.  
Bacterial growth will be assessed in each well by spectrophotometric turbidity measurement at 590 
nm. Turbidity levels comparable to those in the positive control wells will be regarded as positive for 
antimicrobial activity of the compound in question. Turbidity levels comparable to those in the negative 
control wells will be considered as negative for antimicrobial activity. In addition, wells will also be 
scored visually to potentially differentiate between bactericidal (low turbidity of supernatant without cell 
pellet formation) and bacteriostatic (low turbidity of supernatant with cell pellet formation) actions of the 
test compounds. 
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Determination of minimal inhibitory concentration (MIC): 
The methodological setup is highly comparable to the initial screening, with the crucial difference that 
for MIC determinations compounds will now be tested in a range of different concentrations. 
 
The MICs are determined by the liquid dilution method. For each of the selected test compounds 
exhibiting potential antimicrobial activity in the initial screening, stock solutions in a range of 
concentrations (e.g. 2.5, 5, 10, 20, 50 and 100 g/mL) are prepared in DMSO. For comparison of MIC 
results, also solutions of gentamicin sulfate are prepared in the same concentration range. 
For each MIC dilution series in increasing order of concentration, the first well showing lack of visible 
growth (i.e. exhibiting a turbidity comparable to the positive control wells) will be considered as the 
MIC (g/mL) for that specific compound-test strain combination. 
3.3 Antibacterial activity II 
A second antibacterial activity screening was performed at the Laboratory of Pharmaceutical 
Microbiology (Ghent University, Belgium). This protocol has been described in the work of Elisabeth 
Delbeke.
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The antibacterial activity against Escherichia coli LMG 8063, Klebsiella pneumoniae LMG 2095, 
Pseudomonas aeruginosa PAO1, Staphylococcus aureus ATCC 6538 and Staphylococcus aureus 
Mu50 was assessed by a broth dilution method (CLSI, Performance Standards for Antimicrobial 
Susceptibility Testing. Twentieth second Informational Supplement M100-S22. Wayne, PA, USA, 
2012). Strains with LMG designation were obtained from the BCCM/LMG Bacteria Collection (Ghent, 
Belgium) while strain ATCC 6538 was obtained from the American Type Culture Collection 
(Manassas, VA). Staphylococcus aureus Mu50 was a kind gift of P. Vandamme (Ghent, Belgium). All 
strains were grown aerobically at 37 °C on Mueller Hinton agar (LabM, Heywood, UK). The minimal 
inhibitory concentration that inhibited growth by at least 50% compared to the untreated control 
(MIC1/2), the minimal inhibitory concentration that inhibited growth completely (MIC) and the minimal 
bactericidal concentration at which no more cell viability of the test organism can be observed (MBC) 
were used as a measure of activity. MIC1/2, MIC and MBC values were determined using flat-bottomed 
96-well microtiter plates (TPP, Trasadingen, Switzerland). Concentrations of test compounds ranged 
from 0.48 to 2500 µg/mL in Mueller Hinton broth (LabM). The inoculum was standardized at 
approximately 5 x 10
5
 colony forming units/mL. The plates were incubated at 37 °C for 24 h and the 
optical density was determined at 590 nm using a multilabel microtiter plate reader (Envision Xcite, 
PerkinElmer LAS, Waltham, MA).  
3.4 Antiviral activity I 
Inhibition of feline parvovirus (FPV) was performed in collaboration with Okapi Sciences, Leuven, 
Belgium. This protocol has been described in the work of Koen Muylaert.
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To CrFK cells (cat kidney cells), a 1:5 serial dilution of test compounds (50, 10, 2, 0.4 µM) and a FPV 
concentration (high enough to obtain a complete cytopathogenic effect in the infected cells) are added. 
These with FPV-infected and with test compound treated CrFK cells are incubated for three to four 
days at 37 °C and 5% CO2. After this incubation period, the cytopathogenic effect is measured.  
3.5 Antiviral activity II 
A broad spectrum antiviral evaluation was performed in collaboration with Prof. Naesens (Rega 
Institute for Medical Research, KU Leuven, Belgium).  
The compounds were evaluated against a broad and diverse panel of DNA- and RNA-viruses, using 
cell culture-based cytopathic effect (CPE) reduction and cell viability assays. The following viruses 
were tested on human embryonic lung (HEL) fibroblast cells: herpes simplex virus type 1 (HSV-1); a 
thymidine kinase-deficient (TK
-
) HSV-1 strain resistant to acyclovir; herpes simplex virus type 2 (HSV-
2); vaccinia virus; human adenovirus type 2 (Ad2); and human coronavirus (strain 229E). The viruses 
monitored on human cervix carcinoma HeLa cells were: vesicular stomatitis virus (VSV); Coxsackie B4 
virus; and respiratory syncytial virus (RSV). African Green Monkey Vero cells were used to determine 
the antiviral effect on parainfluenza-3 virus; reovirus-1; Sindbis virus; Coxsackie B4 virus, Punta Toro 
virus, yellow fever virus and Zika virus. Human influenza A/H1N1, A/H3N2 and B viruses were 
examined on Madin-Darby canine kidney (MDCK) cells. Finally, the activity against human 
immunodeficiency virus type 1 and type 2 was assessed in human MT-4 lymphoblast cells. 
Semiconfluent cell cultures in multiwell plates were infected with virus at a multiplicity of infection of 
100 CCID50 (50% cell culture infective dose) per well. Together with the virus, the test and reference 
compounds were added at serial dilutions. Two parallel plate sets were prepared: one plate set 
receiving compounds and virus, and one plate set receiving compounds but no virus. The plates were 
incubated at 37 °C (or 35 °C in the case of corona- and influenza viruses) until clear CPE was 
reached, i.e. during 3 to 6 days, except for Ad2 which required 10 days incubation. 
In the first basic screening, the compounds’ activity and cytotoxicity were measured by MTS cell 
viability assay. The MTS reagent (CellTiter 96
®
 AQueous MTS Reagent from Promega) was added, and 
4 h later, absorbance at 490 nm was recorded in a plate reader. The EC50 (50% effective 
concentration) and CC50 (50% cytotoxic concentration) values were calculated by interpolation using 
semi-log dose response. The % protection against virus was defined as: [(ODCpd)virus - (ODContr)virus)] 
/ [(ODContr)mock - (ODContr)virus] x 100, where (ODCpd)virus is the OD for a given concentration of the 
compound in virus-infected cells; (ODContr)virus is the OD for the untreated virus control; and 
(ODContr)mock is the OD for the untreated mock-infected control. The % cytotoxicity was defined as: [1 
- (ODCpd)mock / [(ODContr)mock] x 100, where (ODCpd)mock is the OD for a given concentration of the 
compound in mock-infected wells. 
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Summary 
The pharmaceutical industry has already made large contributions to human healthcare and the 
quality of life, by providing medicines to treat a broad variety of medical conditions. However, the long 
list of incurable diseases and problems such as the development of resistance by pathogens against 
existing medicines illustrates the need for new medicines. Unfortunately, the pharmaceutical industry 
struggles to find new medicines for these diseases, and despite increased expenditures, the amount 
of new molecular entities remains relatively constant. One of the explanations for this problem is the 
fact that the large compound libraries, which are used in high-throughput screening, are suffering from 
poor chemical diversity.  
To address this problem, synthetic efforts should focus on creating new scaffolds rather than changing 
the decoration pattern of already extensively investigated scaffolds. In addition to that, the use of 
smaller fragments should increase the hit rates in biological screenings. The fragment hits are 
expected to have lower activities compared to the hits of larger molecules, but their small size allows 
for modifications in order to increase the activity. Another important aspect is that the new scaffolds 
should be drug-like. It is useless to create new molecules which are expected to have poor 
pharmacokinetic properties.  
In this PhD thesis, novel drug-like scaffolds were synthesized in order to increase the chemical 
diversity or ‘chemical space’. The scaffolds were selected from the class of privileged scaffolds, which 
are characterized by their ability to bind to different, unrelated biological targets. This way, the newly 
synthesized molecules could be screened for biological activity across a broad range of therapeutic 
areas.  
The proposed scaffolds, furo[3,4-d]pyrimidine and oxazolo[4,5-d]pyrimidine, have only been reported 
in the literature to a very limited extent, and a new synthetic route towards these novel, drug-like 
scaffolds was envisioned in this PhD research.  
Starting from commercially available dimethyl furan-3,4-dicarboxylate I, a partial hydrolysis afforded 
the monocarboxylic acid II in excellent yield (Scheme I). This carboxylic acid was converted via a 
Curtius rearrangement reaction to the ureid III in very good yield. Ring closure of the ureid afforded the 
furo[3,4-d]pyrimidine-2,4-dione scaffold IV in good yield.  
 
Scheme I. Three-step synthesis towards furo[3,4-d]pyrimidine-2,4-dione IV 
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Unfortunately, all attempts to convert the furo[3,4-d]pyrimidine-2,4-dione scaffold IV to the 2,4-
dichloropyrimidine V were unsuccessful, blocking the synthetic route towards the envisioned furo[3,4-
d]pyrimidines VI (Scheme II).  
 
Scheme II. Conversion of furo[3,4-d]pyrimidine-2,4-dione IV to the 2,4-dichloropyrimidine V was not successful 
By using an appropriate amine in the Curtius rearrangement reaction, the ureids VII and subsequent 
N-3 functionalized furo[3,4-d]pyrimidine-2,4-diones VIII could be obtained in good yields (Scheme III).  
 
Scheme III. Straightforward synthesis of N-3 functionalized furo[3,4-d]pyrimidine-2,4-diones 
These compounds could be further functionalized by a cesium carbonate mediated alkylation of N(1) 
to afford the N(1)-/N(3)-functionalized structures IX (Scheme IV).  
 
Scheme IV. Synthesis of N-1/N-3-functionalized furo[3,4-d]pyrimidine-2,4-diones 
The transformation of the furan ring could be accomplished by heterogeneous catalytic hydrogenation. 
The use of palladium on carbon allowed the synthesis of 5,7-dihydrofuro[3,4-d]pyrimidine-2,4-diones 
X, while the use of rhodium on alumina afforded the tetrahydrofuro[3,4-d]pyrimidine-2,4-diones XI 
(Scheme V).  
 
Scheme V. Hydrogenation towards 5,7-dihydrofuro[3,4-d]pyrimidine-2,4-diones X and tetrahydrofuro[3,4-d]pyrimidine-2,4-diones 
XI 
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With the three scaffolds IV, XII and XIII in hand, a series of nucleoside analogues XIV-XVI was 
synthesized in varying yields (Scheme VI). In general, the yields of the N-1 functionalization reaction 
decreased upon increasing saturation of the furan ring.  
 
Scheme VI. Synthesis of N-1 functionalized furo[3,4-d]pyrimidine-2,4-diones 
In order to gain synthetic access to the oxazolo[4,5-d]pyrimidine and oxazolo[5,4-d]pyrimidine 
scaffolds, the esters XIX were constructed in good yields by reaction of 2-chloro-2-oxoacetate XVIII 
with isocyanide XVII (Scheme VII). The esters XIX could be transformed into the carboxylic acids XX 
and XXII in excellent yields, by a chemoselective trifluoroacetic acid-mediated cleavage of the tert-
butyl ester groups. These carboxylic acids were used as precursors for the Curtius rearrangement, 
and they were also further transformed into the primary carboxamides XXI and XXIII, which were used 
as precursors for the Hofmann rearrangement.  
 
Scheme VII. Synthesis of the precursors for the Curtius and Hofmann rearrangement 
The Curtius rearrangement of carboxylic acid XX was not successful, and a hypervalent iodine 
induced Hofmann rearrangement was used to convert the primary carboxamide XXI into the ureids 
XXIV in low to moderate yields (Scheme VIII). The use of oxidation-sensitive amines such as 
(activated) benzylamines proved to be problematic, limiting the scope of this reaction. The ureids were 
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ring-closed by sodium methoxide in methanol to afford the oxazolo[5,4-d]pyrimidine-5,7-diones XXV in 
low to moderate yields. This ring closure was characterized by very long reaction times.  
 
Scheme VIII. Synthesis of the ureids XXIV via a Hofmann rearrangement, and ring closure towards oxazolo[5,4-d]pyrimidine-
5,7-diones XXV 
The ureids XXVI could be obtained via the Curtius or Hofmann reaction (Scheme IX). The Hofmann 
reaction resulted in a much better yield, but did not allow the use of oxidation-sensitive amines. Ring 
closure of ureid XXVI afforded oxazolo[4,5-d]pyrimidine-5,7-dione XXVII in very low yield.  
 
Scheme IX. Synthesis of the ureids XXVI via the Curtius and Hofmann rearrangement reaction, and ring closure towards 
oxazolo[4,5-d]pyrimidine-5,7-dione XXVII 
The library of new molecules that resulted from this PhD research was screened for biological activity 
across different therapeutic areas: inhibition of NPP1, broad antibacterial activity and broad antiviral 
activity screening. No significant hits were detected during these biological screenings.  
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Samenvatting 
De farmaceutische industrie heeft reeds belangrijke bijdragen geleverd aan de gezondheidszorg en de 
levenskwaliteit, door medicijnen te ontwikkelen tegen een grote variëteit aan medische aandoeningen. 
Er zijn echter nog heel wat ongeneeslijke ziekten waarvoor geen effectief geneesmiddel ter 
beschikking is, en er zijn ook problemen zoals de ontwikkeling van resistentie door pathogenen tegen 
de huidige medicijnen. Dit illustreert de nood aan de ontwikkeling van nieuwe geneesmiddelen. De 
farmaceutische industrie heeft echter moeilijkheden om nieuwe medicijnen tegen deze aandoeningen 
te ontwikkelen, en ondanks een toename in de uitgaven voor onderzoek en ontwikkeling, resulteert dit 
niet in een toename van het aantal goedgekeurde nieuwe medicijnen. Een van de oorzaken van dit 
probleem is de lage chemische diversiteit in de molecuulbibliotheken die gebruikt worden in de 
zoektocht naar nieuwe actieve stoffen.  
Om dit probleem aan te pakken moet er gefocust worden op de synthese van nieuwe basisstructuren, 
in plaats van oppervlakkige wijzigingen aan te brengen aan basisstructuren die reeds uitvoerig 
onderzocht zijn. Daarbovenop zullen er ook kleinere fragmenten aangemaakt worden, omdat dit meer 
kans geeft op het ontdekken van biologische activiteit. De activiteit zal naar verwachting wel minder 
sterk zijn dan voor grotere moleculen, maar door hun lage molecuulmassa is er nog mogelijkheid om 
structurele aanpassingen te maken om zo de activiteit te verhogen. Een ander belangrijk aspect is dat 
deze nieuwe basisstructuren medicinaal interessant moeten zijn. Het heeft geen zin om nieuwe 
moleculen te maken als er verwacht wordt dat deze slechte farmacokinetische eigenschappen zullen 
bezitten.  
In dit doctoraatsonderzoek werden nieuwe, medicinaal interessante basisstructuren ontwikkeld om zo 
de chemische diversiteit te vergroten en onbekende ‘chemische ruimte’ te betreden. De 
basisstructuren werden geselecteerd uit de klasse van de geprivilegieerde structuren, welke 
gekenmerkt worden door hun activiteit tegenover diverse, niet aan elkaar verwante biologische 
doelwitten. Op deze manier zouden de nieuwe structuren onderzocht kunnen worden op biologische 
activiteit in diverse therapeutische domeinen.  
De vooropgestelde basisstructuren, furo[3,4-d]pyrimidine en oxazolo[4,5-d]pyrimidine, zijn slechts zeer 
schaars onderzocht geweest op zowel synthetisch als biologisch vlak, en een nieuwe syntheseroute 
om deze medicinaal interessante structuren aan te maken en te kunnen onderzoeken werd dan ook 
beoogd in dit doctoraatsonderzoek.  
Uitgaande van het commercieel beschikbare dimethyl furan-3,4-dicarboxylaat I werd een partiële 
hydrolyse uitgevoerd naar het enkelvoudig carbonzuur II (Schema I). Dit carbonzuur werd verder 
omgezet via een Curtius omleggingsreactie tot het ureïde III, dat met een heel goed rendement 
bekomen werd. De daaropvolgende ringsluiting van het ureïde leverde de furo[3,4-d]pyrimidine-2,4-
dion basisstructuur IV op met een goed rendement.  
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Schema I. Synthese in drie stappen naar furo[3,4-d]pyrimidine-2,4-dion IV 
Jammer genoeg mislukten alle pogingen om het furo[3,4-d]pyrimidine-2,4-dion IV verder om te zetten 
naar het 2,4-dichloorpyrimidine V (Schema II). Hierdoor was de syntheseroute naar de beoogde 
furo[3,4-d]pyrimidines VI geblokkeerd.  
 
Schema II. De omzetting van furo[3,4-d]pyrimidine-2,4-dion IV naar het 2,4-dichloorpyrimidine V was niet succesvol 
Door een geschikt amine te gebruiken in de Curtius omleggingsreactie konden de ureïden VII en de 
daar uit voortvloeiende N-3 gefunctionaliseerde furo[3,4-d]pyrimidine-2,4-dionen VIII bekomen worden 
met goede rendementen (Schema III).  
 
Schema III. De efficiënte synthese van N-3 gefunctionaliseerde furo[3,4-d]pyrimidine-2,4-dionen 
Deze moleculen werden verder gefunctionaliseerd door een alkylering uit te voeren op het N-1 
stikstofatoom. Deze transformatie werd bewerkstelligd door het gebruik van cesium carbonaat, en 
leverde de N-1/N-3-gefunctionaliseerde structuren IX op (Schema IV).  
 
Schema IV. De synthese van N-1/N-3-gefunctionaliseerde furo[3,4-d]pyrimidine-2,4-dionen 
De furan ring kon getransformeerd worden door middel van een heterogene katalytische 
hydrogenatie. Het gebruik van palladium op koolstof gaf aanleiding tot de vorming van de 5,7-
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dihydrofuro[3,4-d]pyrimidine-2,4-dionen X, terwijl het gebruik van rhodium op alumina de 
tetrahydrofuro[3,4-d]pyrimidine-2,4-dionen XI opleverde (Schema V).  
 
Schema V. De synthese van 5,7-dihydrofuro[3,4-d]pyrimidine-2,4-dionen X en tetrahydrofuro[3,4-d]pyrimidine-2,4-dionen XI 
Met de basisstructuren IV, XII en XIII ter beschikking kon een serie van nucleoside analogen XIV-XVI 
aangemaakt worden (Schema VI). Het rendement van deze reacties vertoonde een algemene 
dalende trend naarmate de verzadiging van de furan ring toenam.  
 
Schema VI. De synthese van N-1 gefunctionaliseerde furo[3,4-d]pyrimidine-2,4-dionen 
Om toegang te krijgen tot de oxazolo[4,5-d]pyrimidine en oxazolo[5,4-d]pyrimidine basisstructuren, 
werden de esters XIX aangemaakt met goede rendementen door een reactie tussen het 2-chloor-2-
oxoacetaat XVIII en het isocyanide XVII te bewerkstelligen (Schema VII). Deze esters konden verder 
getransformeerd worden naar de carbonzuren XX en XXII met uitstekende rendementen, dankzij een 
chemoselectieve afsplitsing van de tertiair-butyl ester groep door middel van trifluorazijnzuur. Deze 
carbonzuren werden gebruikt in de Curtius omleggingsreactie, en deze werden ook verder omgezet 
naar de primaire amiden XXI en XXIII, welke gebruikt werden in de Hofmann omleggingsreactie.  
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Schema VII. De synthese van de precursoren voor de Curtius en Hofmann omleggingsreactie 
Aangezien de Curtius omleggingsreactie niet bleek te werken met het carbonzuur XX, werd een 
Hofmann omleggingsreactie uitgevoerd op het primaire amide XXI om zo de ureïden XXIV te bekomen 
met lage tot matige rendementen (Schema VIII). Deze Hofmann omleggingsreactie werd 
bewerkstelligd door het gebruik van een hypervalent jood-reagens. Het gebruik van amines die 
gevoelig zijn voor oxidatie bleek echter problematisch te zijn, wat het toepassingsbereik van deze 
reactie inperkte. De ureïden werden ringgesloten door middel van natriummethoxide in methanol tot 
de oxazolo[5,4-d]pyrimidine-5,7-dionen XXV die met lage tot matige rendementen bekomen werden. 
Deze ringsluitingsreactie werd gekenmerkt door erg lange reactietijden.  
 
Schema VIII. De synthese van de ureïden XXIV via een Hofmann omleggingsreactie, en ringsluiting tot de oxazolo[5,4-
d]pyrimidine-5,7-dionen XXV 
De ureïden XXVI konden bekomen worden door zowel een Curtius als een Hofmann 
omleggingsreactie (Schema IX). De Hofmann reactie gaf wel een beter rendement, maar liet het 
gebruik van oxidatiegevoelige amines niet toe. Ringsluiting van ureïde XXVI leverde oxazolo[4,5-
d]pyrimidine-5,7-dion XXVII op met een zeer laag rendement.  
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Schema IX. De synthese van de ureïden XXVI via de Curtius en Hofmann omleggingsreactie, en de ringsluitingsreactie naar 
oxazolo[4,5-d]pyrimidine-5,7-dion XXVII 
De bibliotheek aan nieuwe moleculen die in dit doctoraatsonderzoek werd gesynthetiseerd, werd 
onderzocht op biologische activiteit in verschillende therapeutische domeinen: inhibitie van NPP1, 
brede antibacteriële activiteit en brede antivirale activiteit. Er werden echter geen significante 
activiteiten waargenomen tijdens deze biologische onderzoeken.  
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